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IN-QUEST OF BIOMARKERS FOR ALZHEIMER’S DISEASE AND
PHARMACOKINETIC PROFILE OF ANTICANCER AGENTS USING LC-MS IN
HUMAN PLASMA

CHANDANA MANNEM
ABSTRACT

In this dissertation work, a semi-quantitative assay using a lipidomics approach and an

absolute quantitative assay using liquid chromatography-mass spectrometry techniques
were developed (LC-MS).

In the lipidomics approach, ultra-high pressure liquid

chromatography in tandem with quadrupole time of flight (UHPLC-QTOF) mass

spectrometry was used to profile, compare and quantitate the human plasma lipids in
Alzheimer’s disease subjects (AD) and normal cognitive controls (NCCs). The purpose of

this study is to identify potential plasma lipid markers of AD and to explore the

relationships between AD and lipid pathways in humans by using bioinformatic tools. The
plasma samples of study subjects were first spiked with a mix of 12 synthetic-lipid internal
standards, then total lipids were extracted using a modified Blight-Dyer method and
fractionated into phospholipids (PL) and neutral lipids (NL) using the aminopropyl

cartridge. The UHPLC-QTOF-MS/MS data were processed and analyzed with corrections

of retention time and mass shifts.

Molecular features were extracted for lipid

identifications based on mass-to-charge ratios, isotopic patterns, adducts, and charge states.
Venn diagrams were plotted to group the common and the unique features of lipids between

AD patients and NCCs. The common significant molecular features between these two
study groups were analyzed using principal component analysis (PCA), partial least

vii

squares-discriminant analysis (PLS-DA), and non-parametric Wilcoxon rank-sum t-test
with false discovery rate calculated p-values. Quantitative lipidomics was performed on

the twenty-eight identified significant common lipids. Our results indicate these significant

common lipids between AD patients and NCCs were belong to glycerophospholipids,

glycerolipids, and sphingolipids. Gene-lipid centric pathway analysis was performed on
these significant lipids to obtain the implicated pathways in AD and to understand it’s
relation to AD.

In absolute quantitation work, an assay using a liquid chromatography system in tandem

with triple quadrupole mass spectrometry (LC-QqQ) was developed and validated to

measure the O6Benzylguanine (O6BG) and its metabolite, 8-oxo-O6Benzylguanine (8-oxo-

O6BG) in human plasma. O6BG and 8-oxo-O6BG along with the analog internal standard,
pCl-O6BG, were extracted from alkalinized human plasma by liquid-liquid extraction
(LLE) using ethyl acetate, dried under nitrogen and reconstituted in the mobile phase.

Reverse-phase chromatographic separation was achieved using isocratic elution with a

mobile phase containing 80% acetonitrile and 0.05% formic acid in water at a flow rate of

0.600 mL/min. Quantification was performed using multiple-reaction-monitoring (MRM)

mode with positive ion-spray ionization. The linear calibration ranges of the method for
O6BG and 8-oxo-O6BG were 1.25 to 250 ng/mL and 5.00 to 1.00 x 103 ng/mL respectively

with acceptable assay accuracy, precision, recovery and matrix factor. The method was
validated as per the Food and Drug Administration (FDA) guidelines and was applied to

the measurement of O6BG and 8-oxo-O6BG in patient plasma samples from the prior phase

I clinical trial.
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CHAPTER I
APPLICATION OF LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY IN
HUMAN PHARMACOKINETIC AND BIOMARKER ANALYSIS

1.1.

Pharmacokinetic (PK) analysis of drugs using mass spectrometry

1.1.1. Introduction

Pharmacokinetics (PK) is the study of absorption, distribution, metabolism, and

excretion (ADME) of drugs which is of fundamental importance in determining the drug’s
effect on the biological system and the response incurred by the drug administration [1-3].

With the advances in the drug development and the regulatory requirements surrounding
this space has increased the need of reliable analytical techniques as well as methodologies.

Mass spectrometry has played a central role in the pharmacokinetic studies to gain the
drug’s quantitative information thus able to estimate the drug distribution, metabolism,

excretion and half-life of the drug [4-7]. Pharmacodynamics (PD) deals with the study of
the relationships between the concentration of the drug at the effective site such as receptor

and the extent of the pharmacological effect evident. The primary goal of PD is to establish
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the dose-response profile of the drug in the biological system and is often carried out in
parallel to PK study [8-10].

Liquid chromatography coupled with the soft ionization techniques like
electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI) with
triple quadrupole mass spectrometry is the most common type of analytical methodology
applied for the pharmacokinetic studies of the drugs. The major reason being the capability

of Liquid Chromatography-Mass Spectrometry (LC-MS/MS) to simultaneously get the
structural as well as quantitative information of the drug in its various stages of metabolism.
With the advent of more potent drugs, the administration dose levels have significantly

reduced which in turn circumvents the need for more reliable, accurate and sensitive

quantitative methods in complex biomatrices like plasma, serum, urine and tissue which
can be easily achieved by LC-MS/MS [11-13]. This is carried out in three distinct phases

i.e., bioanalytical method development, validation and sample analysis.

1.1.2. Workflow of bioanalytical method development
The bioanalytical method development comprises of two key aspects, sample
extraction/preparation and instrumentation.

1.1.3. Biological sample extraction
With the advancements of the drug modalities, the potency of the drug has

increased which requires a sensitive quantitative method for the analysis of the drug.
Quantitative bioanalytical methods are focused to meet the requirements of detecting the
trace quantities of drugs or endogenous compounds in complex biomatrices like urine,
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plasma, serum, saliva and tissues. To achieve this goal, the major challenge is encountered

from the interfering compounds present in these matrices such as proteins, lipids,
metabolites, salts and endogenous compounds. Essentially the success of the quantitative

method is dependent on the selective extraction of the analytes of interest form the other

endogenous components of the matrix. The community has been employing some common
extraction methods to meet these requirements such as protein precipitation (PPT), liquid

liquid extraction (LLE), solid phase extraction (SPE), solid-liquid extraction (SLE) [14

16]. This work used the sample preparation techniques of liquid-liquid extraction (LLE),
which along with other extraction techniques will be discussed in brief.

1.1.3.1. Protein precipitation (PPT)

This is the most common method of extraction for the sample clean-up of analytes

form the blood products such as whole blood, plasma, serum. It is usually applied to the
various species such as dogs, rats, mice and human universally in spite of the matrices
differences. PPT usually allows the disruption of drug binding to the proteins by either

acidifying or basifying the protein precipitation solvents, which basically denatures the
protein and inhibits the drug binding capacity depending on the binding mechanism.
Usually the organic solvents like methanol, acetonitrile or a combination of organic

solvents and organic salts are used for the precipitation of the samples. This step is

followed by the centrifugation step which settles down the precipitated protein as sediment
and the supernatant can be isolated and used for the analysis.

A protein in solution is acted upon by the attractive forces form the induced

dipoles, and repulsive forces resulting from the hydration layer around protein. The
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balance between these forces is responsible for the non-aggregation of protein in the

solution. The principle of protein precipitation is based on disrupting the balance between
the attractive and repulsive forces on the protein in the aqueous solution, and this is

achieved by the organic solvents by reducing the hydration layer around protein leading to
the aggregation and precipitation of the protein. Though this sample preparation technique
is quite efficient in extracting the analyte of interest, the major limitation of this is its

inability to remove salts form the sample [17-21].

1.1.3.2. Liquid-Liquid extraction (LLE)

The physical and chemical properties of the components in the matrix are
different, and these differences determine the differential solubility of these components.

LLE exploits the differential solubility of different matrix components and selectively
extracts the analytes of interest. This extraction is based on the principle that the separation

is based in the differences in the distribution of the analyte in the water-immiscible organic
phase. The aqueous mixture of the matrix along with the analyte is mixed with the water

immiscible organic solvents and agitated, so that two distinct layers of immiscible layers
are formed, and the analytes of interest are partitioned between these layers depending on

the properties of the components. The hydrophilicity and the hydrophobicity drive this
partitioning. This partitioning is complete at a state of equilibrium when the ratio of the

concentrations in the two solvents no longer change. This is represented by the distribution
constant (KD) with the following equation
KD = Co/Caq (Equation 1.1)

where Co = concentration of the analyte in the organic phase
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Caq = concentration of the analyte in the aqueous phase.
The partitioning of the compound is dependent on the KD value. Higher being the
indication of better partitioning between the phases and lower being the prerequisite for

repeated extraction. KD can be increased by altering the strength of the organic solvent.
Hydrophobic molecules can be dissolved by adding a much non-polar solvents such as
hexane, carbon tetrachloride, whereas the polar molecules can be extracted using polar

solvents such as ethyl acetate and chloroform.

Alternative strategy to decrease the

solubility of the molecule in the aqueous phase is ‘salting out’. This is achieved by
suppressing the ionic nature of the molecule by changing the pH that can bring about the
change in the solubility of the molecule in that phase [22-24].

The primary advantage of using LLE over protein precipitation is the ability of
LLE to remove the salts and other interfering components of the matrix. However, on the
down side LLE required significant amount of organic solvents and sometimes time

consuming. There has also been reports of the emulsion formation when LLE is performed.

1.1.3.3. Solid-Phase extraction (SPE)

Solid-Phase extraction is the most intensive and efficient sample preparation
technique for the bioanalytical assays. This offers higher degree of selectivity, cleaner

sample extracts and ability to automate. This technique uses a sorbent bed where the

analytes are retained on the bed, and the bed is washed to remove the interfering
components and finally the analytes are eluted using the elution solvents. The choice of
the SPE system is dependent on the nature of the analyte and the type of the interactions

possible with the sorbent bed. The most common type of interactions involved in this type

5

of extraction are Vander Waals forces, hydrogen bonding, dipole-dipole interactions and
cation-anion interactions. Most commonly used SPE sorbent is reverse phase which is
employed when a nonpolar analyte is present in a polar matrix. Reverse phase SPE

cartridges uses the alkyl- or aryl-bonded silicas (C-18, C-8, C-4) reverse phases. Normal
phase is less common and used when a polar analyte is present in the non-polar to mid

polar matrix.

The typical media used for the normal phase cartridges are polar

functionalized bonded silica like LC-CN, LC-NH2, and LC-Diol.

Ion exchange

chromatography is used for the analytes which are ionized in the solution. Cationic
(positive) compounds are separated using the silica with sulphonic acid groups whereas the
anionic negative) charged analytes are separated using aliphatic quaternary amine group
bonded to silica surface [25-28].

The major advantage of this technique is the efficient removal of the interfering

components of the matrix and relatively higher recoveries. It must be noted that this is also
a complicated process and need careful optimization of the conditions and elution

parameters. Careful evaluation of the interactions between the chromatographic bed and
the analyte must be made before choosing the SPE variant. This offers the flexibility of

automation [29,30].

1.1.4. Liquid chromatography- mass spectrometry (LC-MS)
LC-MS has gained significance as the primary technique of choice for the

quantitative and qualitative analytical workflow. This has gained an important position in
the drug research and development. The basic components of LC-MS are represented in

Fig. 1.1.
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Figure 1.1. Basic components of LC-MS instrument [103].
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1.1.4.1. Liquid chromatography (LC)
Liquid chromatography is a separation technique to separate the analytes of
interest from the complex mixtures and biological matrices. It comprises of the mobile

phase, pumping mechanism, an autosampler, and an analytical column, which is connected
to the detector. Mobile phase constitutes the liquid component whose constant flow is
maintained by the binary pumps, autosampler is for the injection of the sample and an

analytical column for the actual separation of analytes from the complex mixtures.
Sometimes the guard column is used optionally to protect the analytical column.

The most commonly used modes of LC are reverse-phase chromatography RPC),
normal-phase chromatography (NPC), hydrophilic interaction chromatography (HILIC),

and ion-pair chromatography (IPC). Based on the nature of the analyte, different modes of
LC separation are employed [31,32]. As mentioned, this work used the RPC, which will

be further discussed.
Reverse-phase chromatography (RPC) consists of a C-8 or C-18 non-polar alkyl

hydrocarbons that are bonded to silica support as stationary phase and mobile phases are
RPC is based on the principle of analyte

mixture of aqueous and organic solvents.

partitioning between the mobile phase and the stationary phase. The retention of the

analyte in this is dependent on the pH, polarity and the organic content in the mobile phase.

These factors contribute to the selectivity to the separation. When compared to the other

separation techniques like NPC and IEC which need the use of nonvolatile salts like
phosphates or additives like ion pairing reagents, RPLC is more compatible with MS with

respect to the composition of mobile phase [33,34].
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1.1.4.2. Mass spectrometry
Mass spectrometry (MS) is the detection technique which identifies the molecules

based on their mass to charge (m/z) ratio. In recent times, this technique has gained

significance in the pharmacokinetic research. Mass spectrometry hyphenated with liquid
chromatography is used for the structure elucidation, accurate quantification of the

metabolites in the biological systems. The working of the mass spectrometry is a combined
events of sample ionization and vaporization in the ion source followed by the separation

of the produced ions in the mass analyzer based on the respective m/z ratio. The ions
produced are finally detected by the detector which is read out as mass spectrum.
Nature of the analyte and the complexity of the matrix dictates the type of the ion

source employed for the LC-MS analysis. The most commonly used ion sources are
electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI). In this

work, we used the ESI ion source where the sample passes through the charged needle to
produce a spray of droplets at the atmospheric pressure. The droplets are either charged
positive or negative in the solvent, and the heated nebulization gases aids in the evaporation

of the solvents. The produced ions travel the mass analyzers.
Mass analyzers help in the separation of ions based on the mass-to-charge (m/z)

ratios in presence of electric and magnetic field. The common mass analyzers used are

quadrupole MS, ion trap MS, and time-of-flight (TOF) MS. This work used the triple
quadrupole (QqQ) analyzer for the quantification of drug in the biomatrix (Fig.1.2). QqQ
analyzer mainly consists of three quadrupoles in which Q1 and Q3 are the mass filters

whereas Q2 acts as the collision cell which is the non-mass resolving quadrupole.
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Figure 1.2. Components of a triple quadrupole mass spectrometer [103].
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Each set of the quadrupole rods in Q1 and Q3 are applied with DC voltage and
radiofrequency. This voltage imparts the electromagnetic field between the electrodes.
This electromagnetic filed acts as the filter for the ions of particular m/z. Q2 is the collision

cells where the ions are fragmented via collision induced dissociation (CID). Essentially,
Q1 selects the parent or precursor ions, Q2 fragments them and passes them to Q3, and

finally Q3 filters the daughter ions to reach the detector [35-37].

1.1.5. Bioanalytical method development and validation

Method development and validation are the key aspects of a successful analysis of
the study samples. The method that is developed for the quantitative determination of the

analytes of interest has to be validated for its accuracy and reproducibility before the
application of the developed method for the analysis of the incurred samples [38-40].

1.1.5.1. Method development

During the method development, the major focus is the optimization of the mass
spectrometer parameters, LC and sample preparation.

The first step of the method

development is the tuning of mass spectrometer by direct infusion or by LC flow-injection
of the analytes in mobile phases to determine the mass spectrometric variables. Full MS

scans are performed to identify the molecular and adduct ions which is followed by the

fragmentation of these ions to determine the fragmentation pattern of the analyte. To
enhance the specificity, multiple reaction monitoring (MRM) are used based on the

fragmentation of the analyte. Thus, specific MRM transitions are selected for the analyte

and its respective internal standard.
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LC optimization includes selection of the mobile phase, type of column, flow rate,

pH, elution profile, etc. The main aim is to achieve baseline separation of the analytes
from the matrix interfering components. The peak shape and consistency are determined
to ensure the method accuracy and reproducibility [38,39,41,42].
The most important aspect of the method development is the sample extraction.

Sample extraction is designed to selectively extract the analyte of interest and its
corresponding internal standard from complex matrices such as blood, plasma, serum,
tissues, etc. Recovery and matrix effect evaluations determine the quality of the developed

sample extraction method. Based on the analyte’s polarity and chemical properties, the

extraction method is optimized for the best signal-to-noise ratio.

Sometimes, a

combination of sample extraction techniques may be required to obtain the optimized

signal-to-noise-ratio. Finally, the developed method is subjected to method validation
based on the FDA-ICH guidelines for industrial bioanalytical method validation.

1.1.5.2. Method validation

The U.S Food and Drug administration (FDA) has formulated the guidelines for
the validation of quantitative bioanalytical methods developed for the small molecules
before their application to the preclinical and clinical studies. These guidelines constitute

the standard procedures along with the acceptance criteria for the development of accurate

and reliable bioanalytical methods for the small molecules in biomatrices.

These

guidelines consist of selectivity, sensitivity, linearity of the calibration curve, matrix effect,
recovery, accuracy, precision, and stability studies.

The following is the brief discussion on the guidelines used for this work.
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I.

Selectivity

Selectivity is described as the ability of an analytical method to differentiate and
quantify the analyte in the presence of other components in the sample. To ensure the

selectivity of the assay the following tests are performed.

a.

Blank matrices from 6 individual sources are used and the mass

chromatograms at m/z of analyte and m/z of internal standard (IS) is evaluated in 5
replicates.

b.

In case of the interference in the blank matrix at the same retention time (tR)

of the analyte and IS, their mean peak area must be < 20% of the mean peak area of the

analyte at lower limit of quantitation (LLOQ), and < 5% of the IS.

c.

Sensitivity of the method is a measure of LLOQ. It is the lowest amount

that can be quantified with acceptable accuracy and precision using the method developed.

d.

LLOQ must be determined by evaluating at least 5 replicates of the sample

e.

LLOQ concentration on at least one of the validation days. The acceptance

at the

criteria for this is the intra-run precision (%CV) and accuracy (%RE) should be <± 20%.
f.

Apart from the above condition, the LLOQ is also evaluated in 6 sources of

g.

matrix with 5 replicated of each sample. The acceptance criteria being

blank

the %CV and %RE <± 20%.

II.

Calibration standards

The calibration standards constitute the calibration curve which includes.
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a.

Matrix blank: matrix sample without IS, also known as the double blank.

b.

Zero standard: matrix sample with IS, also known as blank.

c.

6 to 8 non-zero standards, which are calibrators.

d.

The acceptance criteria for considering the calibration curve are at least 75%

of standards/calibrators should meet the criteria; LLOQ < 20% and all other calibrators <

15%.

III.

Upper limit of quantitation (ULOQ)
This is not a mandatory test that must be included in the validation. However, this

is included to demonstrate the ruggedness of the developed method. The accuracy and
precision may be determined in a similar manner as LLOQ but %CV and %RE should be

< 15%.

IV.

Validation batches

The validation batches are analyzed at least 3 batches (i.e., calibration curves),

typically 5 for accuracy (%RE) and precision (%CV). These are performed in two types,
intra-day (compared within the same day) and inter-day (compared on different days).

V.

QC samples

The QC samples are analyzed to evaluate the calibration curve performance in
measuring the unknown samples.
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a.

QCs are analyzed in three different concentrations (low, mid, and high) with

either 6 or a minimum of 5% of the total number of unknown samples in each analytical

batch.
b.

The acceptance criteria for the QCs is at least 67% (4 out of 6) of the QC

samples should meet the acceptance criteria i.e., LLOQ < 20%, all others < 15%. It is also
important to note that 33% of the QC samples which cannot be all the replicates at the same
concentration, can be outside the acceptance criteria.

c.

If more than 2 QC samples at a concentration fail to meet the criteria, then

50% of QC samples at each concentration should meet the acceptance criteria.

VI.

Preparation of calibration standards and QC samples

Calibration standards and QC samples must be prepared from different spiking
stock solutions. A single source of matrix may also be used if selectivity has been verified.

VII.

Positional differences
While performing a validation batch, the calibrators and the quality controls are

analyzed in a predefined sequence
a.

One set of calibrators is place at the beginning of the run (front curve).

b.

The quality controls and other validation related samples are arranged after

the first calibration curve. The validation samples and the quality controls are randomized

in positions.
c.

Another set of calibrators is analyzed at the end of the run (back curve).

This makes it a dual curve.
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d.

To assess the carryover effect, a blank matrix sample or zero standard is

placed after the high concentration sample (ULOQ).

VIII.

Placement of samples

The calibrators, blanks, QCs and the unknown study samples are arranged in an
appropriate sequence based on the needs of the study. Usually it is recommended to
randomly spread the unknown study samples among the QCs for a better estimate of the

method performance.

IX.

Recovery

The recovery of an analyte in an assay is the detector response obtained from an
amount of the analyte added to and extracted from the biological matrix, compared to the
detector response obtained for the true concentration the pure authentic standard. Recovery

gives an estimate of the extraction efficiency of an analytical method within the limits of
variability. Recovery of the analyte in a bioanalytical method is not expected to be 100%

however the recovery of an analyte and of the internal standard should be consistent,

precise and reproducible. The following are the criteria for the recovery
a.

The recovery of the analyte and IS must be reproducible and consistent.

b.

The samples included in this test are blank matrix spiked with analyte and

IS; extracted blank matrix spiked with analyte and IS.

c.

These samples are prepared at all the three QC concentrations and analyzed

in the replicates of 5.
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d.

Peak areas (PA) of analyte and IS are calculated/obtained from the

chromatograms and recovery is calculated using the following equations
Recoveryanalyte = [(PA of analyte in matrix)/(PA of analyte in extracted matrix)] X 100%
RecoveryIS = [(PA of IS in matrix)/(PA of IS in extracted matrix)] X 100%

IS normalized recovery or Recoverynormalized = (Recovery of analyte)/(Recovery of IS)

X.

Matrix effect
Matrix factor, also termed as matrix effect is a measure of the suppression or

enhancement of ionization by co-eluting compounds, which is common in ESI source. This
parameter provides the information on the interference of endogenous compounds in the
matrix on the quantitation of the analyte of interest.

a.

It is ideal to have an absolute MF or IS-normalized MF of about 1 for the

assay to be reliable and reproducible. However, it is not a requirement. If IS is a heavy

isotope labeled compound, IS normalized MF is expected to be close to 1.
b.

It is a requirement to determine absolute MF (or IS-normalized MF) in 6

individual matrix lots and %CV should be less than 15%. If a stable isotope labeled IS is
employed, this requirement does not apply.

c.

The samples included in this test are spiked with analyte and IS in the

extracted blank matrix and the solvent.
d.

These samples are prepared at all the three QC concentrations and analyzed

in the replicates of 5.

e.

Peak areas (PA) of analyte and IS are obtained from the chromatograms and

matrix factor (MF) is calculated using the following equations
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MFanalyte = [(PA of analyte in extracted matrix)/(PA of analyte in solvent)]
MFIS = [(PA of IS in extracted matrix)/(PA of IS in solvent)]
IS normalized MF or MFnormalized= (MFanalyte)/(MFIS)

XI.

Accuracy and precision

The accuracy of an analytical method is defined by the closeness of the mean test

results obtained by the method to the true value (concentration) of the analyte. Accuracy
is determined by the replicate analysis of the samples containing known amounts of the

analyte. The precision of an analytical method id defined by the closeness of individual
measures of an analyte when the procedure is applied repeatedly to multiple aliquots of a
single homogenous volume of the biological matrix.

a.

Three level concentration QC samples (low, mid, and high) plus dilution

QC are included in this test.

b.

Low QC is the concentration level near the LLOQ (up to 3 x LLOQ).

c.

Mid QC is the concentration level which is middle of the calibration range

(at about the geometric mean of low and high QC concentration)
d.

High QC is the concentration range which is close to the high end of the

calibration range, about 70% to 85% of ULOQ.

e.

Dilution QC is the concentration level which covers the highest anticipated

dilution.
f.

Intra-run accuracy and precision is performed at least 5 replicates at each

concentration and the mean, SD, %CV, and %RE are determined. The criteria for

acceptance are %CV and %RE < 15%.
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g.

Inter-run accuracy and precision is performed at least 5 parallels at each

concentration and the mean, SD, %CV, and %RE are determined.

The criteria for

acceptance are %CV and %RE < 15%.

XII.

Stability

The stability of the analytes in the biological fluid is a function of the

storage/shipping conditions, the chemical properties of the analytes, the matrix, and the
container system. Stability testing must evaluate the stability of the analytes during sample

collection and handling, after long-term (frozen at the intended storage temperature) and
short-term (bench top at room temperature and auto-sampler) storage. The conditions for
the stability testing must be designed in such a way that they are as close as possible to that
are encountered during actual sample handling and analysis. The best possible scientific

rationale must be applied while choosing the test conditions. In general, the following tests
are included in the stability evaluation.

a.

The stability of the stock solution is determined at a minimum of 6 h at room

temperature.

b.

Post-preparative (extracted samples/autosampler tray) stability test is

performed to cover the longest duration from the sample preparation through sample

analysis. In this test, the stability samples are assessed against fresh standards, except for
autosampler re-injection reproducibility, in which the re-injected batch is compared to the

previous acquired data from the same batch.
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c.

Benchtop stability of analyte in matrix is assessed at ambient temperature

(or the conditions used for the sample preparation) to cover the duration of time taken to
accomplish the sample preparation typically ranging from 4-24 h.
d.

Freeze-thaw cycle evaluation is performed using QC samples at minimum

of 2 concentrations (low, high) which undergo at least 3 freeze-thaw cycles.

The

temperature used in this test is the sample storage temperature with at least 12 h between

each freeze-thaw cycle with an exception of first freeze-thaw of 24 h post QC preparation.

e.

Long-term stability is performed in such a way that it covers longest time

from collection to final analysis for any sample in study. In this test, 3 aliquots at low and
high concentrations (LQC, HQC) are analyzed with fresh prepared calibration curve.

Long-term stability can be completed post validation.

XIII.

Replicate analysis
Replicate analysis is not required if the method developed has acceptable variability

according to the criteria. It becomes a requirement when the developed method suffers

from the irreproducibility and difficult to achieve acceptable accuracy and precision.

XIV.

Multiple analytes in a run

This tells us about the acceptance criteria for the samples which involves multiple

analytes in a run. In case of multiple analytes in a run, the run cannot be rejected on the
basis of one analyte failing the criteria. The failed analyte can be reevaluated in such case.

This tells us about the acceptance criteria for the samples which involves multiple analytes

in a run.
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XIV.

Rejected run

It is not a requirement to document the data from the rejected runs, however the
rejection and the reason for rejection must be documented and reported.

Scientific

rationale must be used before a batch can be reinjected to avoid duplication of the sample
analysis data.

1.2.

Lipidomics

1.2.1. Introduction

LIPIDOMICS is an emerging field of biomedical research which primarily deals
with the complex lipidome analysis especially the cellular lipids based on analytical

chemistry principles and technological tools, mass spectrometry in particular. Lipidome is
defined as the comprehensive and quantitative description of the lipids present in an

organism. Lipidomics deals with identification and quantitation of system-level pathways,

intricate networks of cellular lipids and their interactions with other lipids, proteins and
other in vivo entities thus finding its application in health and disease. Lipidomics emerged

in 2003 and has greatly advanced in recent years, largely due to the development of mass
spectrometry [43-48]. It is considered as the subgroup of metabolomics and is subdivided

into membrane-lipidomics and mediator-lipidomics (Fig. 1.3).
1. Membrane-lipidomics: Aims to study the comprehensive and quantitative

description of membrane lipid constituents.

2. Mediator-lipidomics: Aims to study the structural characterization and
quantification of low abundant bioactive lipid species.
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Lipids are basically hydrophobic or amphipathic small molecules which constitute

monoglycerides, diglycerides, fats, waxes, phospholipids, sterols, and fat-soluble vitamins
such as vitamins A, D, E and K.

Lipoproteins are crucial components of cellular

membranes and play essential roles in cellular functions, including cellular barriers,
membrane matrices, signaling, and energy depots. Cellular lipids are highly complex; that
is, there are tens to hundreds of thousands molecular species at concentrations ranging from

pmol to nmol/mg protein [49-51]. Cellular lipids are dynamic in nature which change
constantly with physiological, pathological, and environmental conditions [52,53].

1.2.2. Goals
The primary goal of lipidomics to determine the lipid composition and the changes

occurring in the biological system in response to the physical and chemical changes. This
is majorly achieved by the profiling experiments performed on the biological systems in

various stages.

An extension of this primary goal is the identification of metabolic

pathways that play a major role in the pathophysiological changes occurring in the
biological system. Fulfillment of these goals will help us to identify and utilize the
biomarkers for the early diagnosis and screening. In this work, we profiled the lipids in
Alzheimer’s patient plasma samples, semi-quantitated and build the prediction models with

the quest for identifying the probable biomarkers for the early diagnosis of AD. The

probable biomarkers identified will need to be validated with a much defined and larger

dataset.
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Figure 1.3. Role of lipids in biological systems [104].
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1.2.3. Lipid nomenclature

Lipids are abbreviated as follows: sterol lipids - cholesteryl ester (CE), oxidised
cholesteryl ester (oxCE); sphingolipids - ceramide (Cer), dihydroceramide (DHCer),

ganglioside GM3 (GM3), hexa-ceramides with differing glycan chains (Hex1Cer,

Hex2Cer, Hex3Cer), sphingomyelin (SM); glycerolipids - diacylglyceride (DG),
triacylglyceride

(TG);

glycerophospholipids

-

phosphatidylcholine

(PC),

phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI),

phosphatidylserine (PS) and the lyso (L) species (LPC and LPE). Alkyl ether and

plasmalogen linkages are denoted by O- and P- respectively.
Lipids are named according to the LIPID MAPS classification system

‘Headgroup(sn1/sn2)’, where sn refers to the radyl side-chains [54,55]. The side-chain
structures are denoted as carbon chain length:number of double bonds and are provided for
each chain where they could be determined, or as a total number of all carbons and double

bonds where individual chains could not be determined. If the position of the individual
fatty acid side chain on glycerol backbone could not be determined by the technique, the it

is represented as ‘Headgroup(sn1_sn2)’.

1.2.4. Workflow of Lipidomics

The typical workflow of lipidomics includes the sample preparation, lipid analysis

which includes data acquisition, and finally data processing (Fig. 1.4). Recent advances in
lipidomics have greatly enhanced the novel applications of lipidomics in the field of
biomedical research [56].
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1.2.5. Sample preparation

The sample preparation for the lipidomic analysis involves the lipid extraction
followed by either the total lipid analysis, or fractionation of the extracted lipids into

various fractions.

We will briefly discuss the lipid extraction techniques and the

fractionation procedures in this work.

1.2.5.1. Lipid extraction
Lipid extraction is an important step in the sample preparation as it eliminates

most of the interfering components from the matrix, making our extracts rich in lipids.
During lipid extraction, the choice and addition of appropriate internal standards is critical

to the accurate quantitation of lipids extracted. The internal standards are used for the
normalization of the lipid signal in the extracted matrix and are added by normalization of

the total protein, wet/dry tissue, or fluid volume for lipid quantitation. Unbiased recovery

of lipid species is another critical aspect of the lipid quantitation. The most commonly
used extraction methods in lipidomics are modified Bligh and Dyer method, modified

Folch method, methyl tert-butyl ether (MTBE method), butanol/methanol (BUME

method). In this work we used the modified Bligh and Dyer method, however all the

extractions are discussed in brief below [57,58].
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Figure 1.4. General workflow of lipidomics [104].
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1.2.5.1.1. Modified Bligh and Dyer method

This extraction method uses chloroform/methanol/water (1: 1: 0.9, v/v/v) for the
extraction of total lipids from the biological samples. After phase separation, the total
lipids are present in the chloroform phase which is transferred to a separate tube for the
downstream process. This extraction is well-established standard method and is most

commonly used. The major drawbacks of this extraction are the use of the hazardous
chloroform, and the practical challenge of collecting the bottom chloroform layer which

may cause the carry-over of the water-soluble impurities. These aspects pose challenges

in the automation of this extraction procedure [59-61].

1.2.5.1.2. Modified Folch method

This extraction method uses chloroform/methanol (2: 1, v/v) for the extraction
of the total lipids from the biological samples. This method uses the water or 0.9% NaCl
to wash the solvent extract. This has similar advantages and disadvantages as the modified

Bligh and Dyer method [59,62-64].

1.2.5.1.3. MTBE method

This extraction method uses MTBE/methanol/water (5: 1.5: 1.45, v/v/v) for the

extraction of total lipids form the biological samples. This method helps to overcome the
challenges posed by the chloroform extraction as MTBS is present in the top layer after
phase separation, thus making it more feasible for high throughput and automation. The
drawback of this method is the presence of water-soluble impurities as MTBE has a
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significant amount of aqueous component that carryover the water-soluble contaminants
[65-67].

1.2.5.1.4. BUME method

This extraction method uses the addition of butanol/methanol (3: 1, v/v) to a
small amount of aqueous phase followed by the addition of the equal volume of
heptane/ethyl acetate (3: 1, v/v). Finally, 1% acetic acid is added in equal amounts of
BUMS to induce phase separation. This method offers the advantage of less water-soluble

contaminants in the extracted organic phase. The only drawback of this method is the
difficulty/longer drying time of butanol component in the organic phase.

After the extraction of the total lipids, some additional steps may be applied to

simplify the complexity of the extracts depending on the choice of mass spectrometry

analysis. This additional clean up step is importantly especially for the shotgun lipidomics
approach which do not employ any chromatographic separation/enrichment prior to MS

analysis. This additional clean-up process can be done either by physical processes like
liquid/liquid partitioning, solid phase extraction to separate polar vs. non-polar lipids or by

chemical approaches like base hydrolysis for the enrichment of low-abundance
phospholipids and/or glycerolipids [68-70]. For the lipids which lack the inherent charged

moieties and prevent efficient ionization, derivatization is the most commonly used

approach. In this work, we used the fractionation of lipids by solid-phase extraction to

isolate different classes of lipids.
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1.2.5.2. Fractionation of lipids

Followed by the extraction of total lipids, the next step involved the fractionation
of the complex mixture into various classes of lipids. This allows the isolation of each
lipid component that can be used for individual analysis. This technique allows most
comprehensive and accurate profiling and quantitation of unknown lipids. Thus, this
fractionation procedure can be adopted depending on the aim of the study. The neutral

lipids can be separated from the polar lipids. And it is also common to separate the complex

lipid mixtures into phospholipid and glycolipid fractions [71-75].
Solid phase extraction (SPE) is the most common sample preparation technique
used for the fractionation of lipids. Due to the ease of use, cost effectiveness and the

decreased requirements of the solvent usage, SPE has rapidly replaced the other
conventional methods like liquid-liquid extraction, liquid-solid column chromatography

and thin later chromatography that were used for the fractionation of lipids in the past. The

application of SPE for the lipid analysis commonly uses silica bonded aminopropyl and C18 reverse phase columns, alumina, microporous carbon and ion-exchange phases. There
are also availability of the mixed mode separation mechanisms and a large amount of

proprietary stationary phases in the market which are designed for specific applications
[76,77]. This work used the bonded aminopropyl sorbent-based fractionation of lipids,

which is discussed in brief.

1.2.5.2.1. Bonded aminopropyl sorbents

The bonded phases are formed by the treatment of the surface silanol groups of

silica with the siloxane derivatives. Commercially numerous bonded phases are available
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and classified as nonpolar (reverse phase), polar (normal phase), or ion exchange.
Depending on the number of layers of the bonding reagent the bonded phases are either
monomeric or polymeric phases and the choice is dictated by the specific application.

Aminopropyl bonded phase are polar and are classified as the normal-phase
sorbents. Lipids with polar functional groups have stronger interaction with the primary

amine through hydrogen bonding. The amino group present also offers the advantage of
ion exchange chromatography as it can impart the weak anion exchange properties. Owing

to the polarity of these phases, they have acquired a common usage for the fractionation of
lipids. Methodology for the rapid separation of the total lipids into the neutral and polar

lipids was developed in late 1900s and the modifications of this method was widely applied

based on the specific needs of the analysis. The neutral lipids can be separated and further
fractionated by gradual increase of the polarity of the elution solvents. Free fatty acids and
the phospholipids are bound to the column by ionic interactions, which can be disrupted
by changing the pH of the elution solvents. The polarity and the pH play a crucial role in

the efficient separation of lipids onto defined fractions.

Studies have shown that

consecutive usage of aminopropyl columns have resulted in a very efficient separation of
total lipids into neutral lipids, free fatty acids, phospholipids, cholesterol (or other sterol)

esters, triglycerides, cholesterol (or other sterols), diglycerides, and monoglycerides
[78,79].
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1.2.6. Lipidomics techniques

Mass spectrometry (MS) and nuclear magnetic resonance (NMR) are the two key

techniques for the lipidomics advancement, with mass spectrometry being the major player

in this field. NMR spectroscopy is a technique used for the structural elucidation of lipids.
The sample preparation for this is relatively less time consuming and uses a non-destructive
approach. However, the major drawback of this technique being the low sensitivity and its
limitation to detect only the most abundant species of lipids. These drawbacks have made
the mass spectrometry a spearhead technique for the lipid analysis [80-82]. In this work,
the primary technique used for the analysis of lipids is mass spectrometry which will be
the primary focus in the future discussion.

The variants of mass spectrometry that are used in the lipid analysis are Shotgun
analysis, Liquid chromatography-mass spectrometry (LC-MS), and gas chromatography

mass spectrometry (GC-MS). The shotgun lipidomic analysis deals with the direct infusion
of the lipid solutions into the mass spectrometer without the chromatography involved
whereas LC-MS and GC-MS are chromatography-based approaches. GC-MS is the most

widely used technique, however with the advancement of ionization techniques, LC-MS

has gained popularity in terms of the flexibility to identify and quantitate multiple classes
of lipids in a single injection. Direct infusion MS or shotgun lipidomics is performed by
the direct infusion of the samples into the mass spectrometer for the identification and

quantification of lipid species. The identification of lipids is based on the accurate mass
of the species [83-85]. In this work, LC-MS based lipidomic analysis was performed using
reverse phase chromatography and Agilent QTOF 6540 mass spectrometer. The mass
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spectrometer was operated in both positive and negative mode in data dependent
acquisition mode.

1.2.6.1. Reverse phase liquid chromatography
Liquid chromatography is the separation technique that is used to separate the

analytes from the analyte of interest from the biological matrix components or the complex
compound mixtures.

A LC system comprises of a liquid mobile phase, pumping

mechanism to pump the mobile phases, an autosampler to inject the sample of interest, an

analytical column to separate the analytes of interest from the complex mixtures, and
finally a detector to detect the signal of the analyte. The most commonly used modes of
LC are reverse-phase chromatography RPC), normal-phase chromatography (NPC),

hydrophilic interaction chromatography (HILIC), and ion-pair chromatography (IPC).

Based on the nature of the analyte, different modes of LC separation are employed [86].
As mentioned, this work used the RPC, which was briefly discussed in the previous

sections.

1.2.6.2. Quadrupole time-of-flight mass spectrometry
Mass spectrometry (MS) is a technique that identifies the molecules based on their

mass to charge (m/z) ratio. Mass spectrometer works in a step-wise events which starts
with the sample vaporization and ionization in the ion source which is followed by the

separation or resolution of the ions in the mass analyzer depending on the m/z ratio and
ultimately the ions are detected by the detector producing the mass spectrum.
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The ion source used in the mass spectrometer is dependent on the nature of the

analyte. Commonly used ion sources in mass spectrometry are electrospray ionization

(ESI) and atmospheric pressure chemical ionization (APCI). In ESI the sample passes
through an ion spray needle to which a high voltage is applied. This produces a spray of
droplets which are charged with either positive or negative charge depending on the

potential applied. These ions produced then travel into mass analyzer. The specialty of

ESI with Agilent Jet Stream Technology (Fig. 1.5) is it uses super-heated nitrogen sheath
gas to confine the electrospray which improves the ion density and desolvation leading to
higher MS signal intensities and reduced noise. The MS and MS/MS sensitivity can

improve 5 to 10-fold by Agilent Jet Stream technology at optimal LC flow rates.
In the mass analyzer, the ions interact with the electric and magnetic field and are

separated based on the mass-to-charge (m/z) ratio.

The most commonly used mass

analyzers are quadrupole MS, ion trap MS, and time-of-flight (TOF) MS. This lipidomic

work used the Agilent 6540 quadrupole time-of-flight (Q-TOF) (Fig. 1.6). Q-TOF consists

of a quadrupole, a collision cell and time-of-flight mass analyzer.

The quadrupole

essentially acts as a mass filter and consists of four parallel metal rods where only selected
ions pass through them and the other ions decay by colliding the rods. The ions are guided

from the quadrupole into the collision cell by the hyperbolic rods. Collision cell as the

name suggests is the component which aids in the ion fragmentation. This cell is a high
pressure hexapole assembly where the collision energy voltage is applied over the selected
ions to generate fragments or product ions. The generated fragment ions are guided into

the mass analyzer by the ion beam shaper.
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LC sample inlet

Figure 1.5. ESI with Agilent Jet Stream Technology [105].

34

Figure 1.6. Components of quadrupole time-of-flight mass spectrometer [105].
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The parallel beam of the ions reaches the time of flight analyzer where high

voltage is applied at the pulser of TOF to start the flight of ions to the detector. The ions
leave the pulser to travel through the flight tube to reach the ion mirror called ‘reflectron’

at the end of the tube. This reflectron reflects the ions thus increasing the resolving power

of the instrument by doubling the flight path in the same space. It also performs the
refocusing operation so that the ions with different velocities still reach the detector at the

same time. This analyzer determines the mass-to-charge ratio based on the time taken by
the ion to travel the flight tube. Ions with higher charge possess more kinetic energy

compared to ions with lower charge. Thus mass-to-charge determines the velocity of the
ions i.e., the lighter ions reach the detector earlier than the heavier ions. However, the

reflectron TOF analyzer which consists of a series of ring electrodes with high voltage are

able to efficiently correct the kinetic energy distribution in the direction of ion flight thus
increasing resolution. The ions which possess the greater energy penetrate deeper into the

reflectron while those with lesser energy and same m/z penetrate a shorter distance. This
enables the ions with same m/z reach the detector at the same time (Fig. 1.7). Q-TOF

instruments offer the advantage of high mass resolution and wide m/z range, which makes
these instruments an ideal tool for the discovery mode of work such as identification of

molecules, peptide, protein and oligonucleotide analysis [87,88].
The mass spectrometer was operated in auto MS/MS mode. In this mode, the
instrument can automatically perform secondary mass spectrometry on qualified ions based

on the parameters set by the user. When a particular ion or set of ions meet the preset
conditions, the quadrupole assumes the selected ion monitoring (SIM), and the collision

cell can fragment ions [89-91]. This is followed by the scanning of the fragments to get
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the mass spectrum. This mode is commonly used for the identification and structure
analysis of unknown compounds.

1.2.7.

Data processing tools and resources
The major part of lipid analysis is the data processing where the large sets of data

generated is curated at multiple levels to profile, perform qualitative, quantitative, and
multivariate analysis to build statistical models. Some of the processing steps include
spectral feature picking, spectral alignment, smoothing, de-isotoping, detecting adduct
formation, peak identification, subjecting to statistical analysis and finally the lipid
identification. With the increasing demands and complexity of data processing, numerous

open-source and commercial software are available [92]. The tools used for the data
processing in this work are briefly described below.

1.2.7.1. MassHunter Qualitative Analysis

This is a proprietary software from Agilent, which was used to perform qualitative
check on the retention time drift and correct it. The version used for this work was B.06.00.
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The derivation process of the time that ions pass through
field free region in the liner TOF analyzer:
• The potential energy : E=zeV (ze is the charge of the
particle, and V is the voltage)
• The kinetic energy of ions: E=1/2mv2
• The potential energy is converted into kinetic energy:
zeV=1/2mv2

Thus, v =

2zeV

v m

The time taken by ions to reach the
detector: t=-v
J

Finally, t= d 1-^
x\2zeV

Figure 1.7. Schematic diagram of (A) Quadrupole mass analyzer and (B)Reflector TOF
analyzer [105].
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1.2.7.2. MassHunter Profinder

Agilent MassHunter Profinder software is a stand-alone program used for batch

feature extractions from Q-TOF based profiling data files. It basically picks the features
from the raw data based on the adducts chosen and performs spectral refining. Feature
extraction along with the chromatographic data alignment across multiple data files from

replicates is a crucial step in peak finding and data reduction workflow. This helps to
minimize the false positive and false negative features by “binning” the features in the

chromatographic time domain. This software majorly helps to reduce the acquired data
size and complexity by removing the redundant and non-specific information by

identifying the relevant variables associated with the data. Thus, feature extraction is

performed to produce a smaller data set without losing the information quality, and is easy

to perform analysis. Profinder is optimized to provide an intuitive user interface to inspect
and review and compare extracted ion chromatograms, mass spectral data, and

isotopologies associated with each feature. The feature files generated by Profinder (CEF
files) can be imported into Agilent Mass Profiler Professional (MPP) for further analysis.

The version used for this work was B.06.00.

1.2.7.3. Mass Profiler Professional (MPP)

Agilent Mass Profiler Professional (MPP) software is a powerful chemometrics

platform which is designed to use the high information content of mass spectra (MS) data
and can be used in any MS-based differential analysis to determine relationships among
two or more sample groups and variables. MPP provides advanced statistical analysis and
visualization tools for GC/MS, LC/MS, CE/MS, and ICP-MS data analysis. It also offers
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the integrated identification/ annotation of compounds and integrated pathway analysis for

metabolomic and proteomic studies. It allows the differential analysis of the data obtained

from two or more sample sets, with guided and advanced workflows. It provides the
comprehensive statistical tools like ANOVA, PCA, volcano plots, hierarchical trees, and
multiple methods for class prediction models. It also facilitates the identification of the

unknown compounds by generating the inclusion lists for the subsequent MS/MS-based

analysis.

It also offers the additional help in predicting the biochemical pathways

associated with the identified features via a module called Pathway Architect. MPP is

ideally suited for applications characterized by complex sample matrices such as
metabolomics, proteomics, natural products, food, beverages, flavors, fragrances, and
environmental analyses.

1.2.7.4. SimLipid®

SimLipid® is a high throughput informatics tool from Premier Biosoft for
identification and relative quantitation of lipids using data from LC-MS, MALDI, ShotgunMS. The major challenge posed by the mass spectrometry based lipidomic data is the

complexity and the large range of concentrations of thousands of lipid species found in the
biological samples. Due to the complexity of the lipid structure the identification of lipids

requires sophisticated software for the interpretation of lipid MS/MS spectra.

The

fragmentation pattern and the ionization efficiencies are specific to each class of lipid.

This tool is capable of processing the raw data from hundreds of LC-MS and
MS/MS experimental runs for LC peak detection, peak-picking, molecular feature finding

and retention time alignment. Though this tool is capable of these, in this study these
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functions were carried out by the Agilent software as discussed earlier.

Structure

elucidation can be performed by MS and MS/MS based database search. The isobaric

candidate structures for each MS/MS scan can be distinguished using a proprietary scoring
system. The SimLipid® database contains 40,312 lipids, and 1,508,293 structure-specific

in-silico MS/MS characteristic ions. Apart from this, the database also stores 5,227
transitions of precursor ion scan and neutral loss scan triple quadrupole mass spectrometry

methods

corresponding

to

and

1,179,393

221

unique

fatty

glycerophospholipids, glycerolipids, and sphingolipids respectively.

acyls

from

Correction of

experimental peak intensities for their isotopic overlaps can be performed for the identified
peaks. This software also allows the relative quantitation of the profiled lipids based on
user-specific internal standards [93-95].

Apart from SimLipid®, LIPIDMAPS is an open-source platform for the lipid
database that can be used for the same purpose. LIPIDMAPS is an US based consortium

of lipids that comprises of around 1.6 million lipids and is the most comprehensive database
of lipids. It comprises procedures for extraction of lipids, their purification, analysis,

fragmentation patterns, standard protocols. Though the functionality of this tool is limited,
the fact that it is an open source platform enables researchers to use the database [96-98].

1.2.7.5. MetaboAnalyst®

MetaboAnalyst® is a set of online tools for metabolomic data analysis and

interpretation which provides a range of analysis methods tailored for metabolomic data.

The analysis methods in this tool include metabolomic data processing, normalization,
multivariate statistical analysis and data annotation. In this work, MetaboAnalyst® is used
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for the multivariate analysis and generation of the statistical models i.e., Principal
Component Analysis (PCA), Partial Least Square -discriminant analysis (PLS-DA).
MetaboAnalyst® supports a wide variety of data input types commonly generated

by metabolomic studies including GC/LC-MS raw spectra, MS/NMR peak lists, NMR/MS

peak intensity table, NMR/MS spectral bins, and metabolite concentrations.
MetaboAnalyst® has four modules:
1.

Data processing

2.

Statistical analysis (one-factor, two-factor, and time-series data)

3.

Functional enrichment analysis

4.

Metabolic pathway analysis

The main features of the data processing include peak detection, retention time
correction, peak alignment, baseline filtering, data integrity check and missing value

imputation. These features help to provide the quality check on the data for the reliable
statistical analysis. The statistical analysis features offered by this tool include univariate

analysis, dimension reduction, feature selection, cluster analysis, classification, two-way

ANOVA and temporal comparison.

Functional enrichment analysis includes over

representation analysis, single sample profiling and quantitative enrichment analysis.

Metabolic pathway analysis includes enrichment analysis, topology analysis and
interactive visualization [99-102].

1.3.

Conclusion

This chapter is majorly focused on providing the basic information and background
on the type of work described in this dissertation work. This work is focused on depicting
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the application of mass spectrometry in the clinical studies i.e., quantitative method

development and validation for the PK analysis of anticancer drug, and the identification

of the probabilistic biomarkers for the early diagnosis of Alzheimer’s disease in human.
The workflows, principles and the techniques used for accomplishing this work are briefly
introduced in this chapter. FDA-ICH guidelines for the industrial bioanalytical method
development and validation were used to validate the quantitative method developed for
the PK analysis, which was briefly discussed.
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CHAPTER II

IN-QUEST OF BIOMARKERS FOR ALZHEIMER’S DISEASE IN HUMAN
PLASMA USING LIQUID CHROMATOGRAPHY IN TANDEM WITH HIGH
RESOLUTION MASS SPECTROMETRY (QUADRAPOLE TIME-OF-

FLIGHT(Q-TOF))

2.1.

Introduction
Alzheimer’s

disease

(AD)

is

an

age-related

progressive

multifarious

neurodegenerative disease. Pathologically it is defined by extensive cerebral cortical

atrophy, accumulation of extracellular amyloid beta (AP) plaques and intracellular
neurofibrillary tangles (NFTs), chronic inflammation and neuronal loss [1,2]. Loss of
neuronal communication is attributed to the overproduction of amyloid beta and its

inability to be cleared from the brain resulting in plaques, toxic oligomers, and fibrils.
Neuronal toxicity and loss of neurons (death of neurons) are attributed to NFTs [3,4].
There are four types of AD’s i.e., type1, 2, 3 and 4. Familial AD (early-onset) is associated

with inheritance of genetic mutations which includes type 1 AD caused due to mutation in
APP gene, type 3 AD caused due to mutation in PSEN1 gene, type 4 AD caused due to
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mutation in PSEN2 gene. SporadicAD which include type 2 AD (late-onset, LOAD) is

also associated with ApoE4 gene along with multiple factors like diet, exercise, disease

conditions and environmental. Clinical staging of the AD disease includes preclinical
(AD-P),

mild

cognitive

impairment

(MCI-AD)

and

dementia

[5-7].

The

pathophysiological process of AD begins many years before the diagnosis of clinical MCI
due to AD. This long haul preclinical phase of AD can be used for therapeutic intervention

if appropriate plasma biomarkers were available for early diagnosis of this stage.
Currently, available biomarkers for AD reflect the presence or the progression of the

disease but not it’s early diagnosis. The proposed biomarker models for the diagnosis of
AD-P stage reported in previous studies are either invasive or expensive [8-10].
There are reported studies which reiterate the crucial link between the brain lipids

and AD. Genome-wide association (GWAS) have identified several other genes associated

with AD risk, which are involved in affecting pathways related to lipid metabolism (ApoE,
CLU, and ABCA7), the inflammatory response (CR1, CD33, MS4A, CLU, and TREM2)

and endocytosis (BIN1, PICALM CD2AP, EPHA1 and SORL1) [1]. Along with the

genotypic and the phenotypic studies, AD brains have revealed the higher occurrence of

adipose inclusions or lipoid granules suggesting aberrant lipid metabolism.

These

membrane lipids (glycerophospholipids and sphingolipids) modulate the protein-protein

interactions, protein-lipid interactions and trafficking of the proteins involved in the
pathogenesis of AD [11-13]. Studies have also shown the involvement of membrane lipid
raft (rich in cholesterol and sphingolipids) in the processing of APP, production of Ap and
the clearance of Ap from the intracellular spaces [14-16]. Post-mortem studies on the brain

have demonstrated altered lipidome at the different stages of AD pathogenesis and these
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changes could lead to parallel changes either in the content or composition or both of the

lipid species in the plasma of the AD patients. The use of peripheral plasma markers has
many obvious advantages over brain markers in terms of cost, risks, patient point of care

and ability to monitor a patient over a long period. Over the past years, numerous studies
have been reported on different matrices of AD using the lipidomics approach either using
the targeted shotgun analysis [17,18] or the untargeted liquid chromatography-mass
spectrometry (LC-MS) analysis [19-21]. However, these studies lack the appropriate

classification/ staging of AD patients based on the genetic risk factor, cognitive deficit

levels, other underlying vascular risk factors and existing pathophysiological conditions

which could affect the plasma lipids. The shotgun lipidomic analysis is limited by the
targeted lipid analysis, ion suppression, and isobaric peaks overlapping.

In our study, we employed liquid chromatography- quadrupole time of flight mass
spectrometry (LC-QTOF-MS) based untargeted lipidomics analysis approach to search for

the plausible biomarkers from plasma lipids, which could be differentially regulated
between AD and normal cognitive controls (NCC) study subjects. Appropriate screening

and staging of the patients were performed based on cognitive function (MoCA test), ApoE
genotyping, cerebrospinal fluid (CSF)- Ap 42, total tau, phospho tau and Ap42/t-tau index.
We applied solid-phase extraction (SPE) to fractionate the total lipids into two fractions to

reduce the matrix interference and ion suppression in MS analysis and employed multiple
internal standards representing each sub-class for normalization and semi quantitation of

lipid species. Multivariate analysis was performed to obtain the potential lipid biomarkers

which could be used for early diagnosis of AD.
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2.2.

Materials and Methods

2.2.1.

Chemicals and Standard solutions

2.2.1.1. Chemicals

HPLC-grade acetonitrile, chloroform, isopropanol, methanol and water were

purchased from Fisher Scientific (Hanover Park, IL, USA). Synthetic lipids including 1,2dinonadecanoyl-sn-glycero-3-phosphocholine [PC(19:0/19:0)], 1,2-dipentadecanoyl-snglycero-3-phosphoethanolamine

1,2-diheptadecanoyl-sn-glycero-3-

[PE(15:0/15:0)],

phospho-(1'-rac-glycerol) (sodium salt) [PG(17:0/17:0)], 1,2-dimyristoyl-sn-glycero-3phospho-L-serine (sodium salt) [PS(14:0/14:0)], 1-tridecanoyl-2-hydroxy-sn-glycero-3-

phosphocholine

1-myristoyl-2-hydroxy- sn-glycero-3-

[LPC(13:0/0:0)],

phosphoethanolamine [LPE(14:0/0:0)], 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-(1'rac-glycerol) (sodium salt)

[LPG(14:0/0:0)],

1-(10Z-heptadecenoyl)-2-hydroxy-sn-

glycero-3-phospho-L-serine (sodium salt) [LPS(17:1/0:0)], 1-myristoyl-2-hydroxy- sn-

glycero-3-phosphate (sodium salt) [LPA(14:0/0:0)], N-(heptadecanoyl)-sphing-4-enine
[Cer(d18:1(4E)/17:0)] were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL,

USA).

1,2-dinonadecanoyl-sn-glycerol [DG(19:0/19:0/0:0) (Dinonadecanoin)] was

purchased from Larodan Fine Chemicals AB (Solna, Stockholm, Sweden).
triheptadecanoyl-sn-glycerol

[TG(17:0/17:0/17:0)

(Glyceryl

1,2,3-

triheptadecanoate)],

analytical grade ammonium acetate, glacial acetic acid and hydrochloric acid were

purchased from Sigma-Aldrich (St. Louis, MO, USA).
2.2.1.2. Standard solutions

The standard stock solutions of PC(19:0/19:0), PE(15:0/15:0), PG(17:0/17:0),

PS(14:0/14:0),

LPC(13:0/0:0),

LPE(14:0/0:0),
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LPG(14:0/0:0),

LPS(17:1/0:0),

LPA(14:0/0:0) and Cer(d18:1(4E)/17:0) of 1.00 x 103 pM were prepared by dissolving in

appropriate volumes of chloroform: methanol (2:1).

Standard stock solutions of

DG(19:0/19:0/0:0) and TG (17:0/17:0/17:0) of 1.00 x 103 pM was prepared by dissolving

in appropriate volumes of chloroform. Stock solutions are stored in -20 ° C until further
use.

Working internal standard mix (12 lipids) at a concentration of 5.00 x 104 nM was
prepared by diluting the individual standard stock solutions with appropriate volumes of
chloroform/methanol/300 mM ammonium acetate (30:66.5:3.5, v/v/v).
2.2.2. Study subjects and plasma collection

Caucasian subjects who were 60 years of age and above were recruited from the
Lou Ruvo Center for Brain Health at Cleveland Clinic. The study group includes four age-

matched normal cognitive control patients (n = 4) and three Alzheimer’s disease patients

(n = 3). Patients were diagnosed with AD using the National Institute of Aging (NIA)
guidelines. Patients were interviewed, followed up with the medication history, cognitive
screening, magnetic resonance imaging (MRI) scan, neurological and cerebrovascular
examination, standard blood and cerebrospinal fluid chemistries were performed [5-7].

The patient medical histories were assessed for the presence of cardiovascular disease,
dyslipidemia, and diabetes, any use of dietary supplements, medication and smoking

habits. The Montreal Cognitive Assessment (MoCA) test was employed to assess the
mental status of the patients to categorize AD patients as mild (MoCA score > 20) or

moderate (MoCA score 10 - 20). Normal cognitive control subjects were participants who
were determined to be free of cognition concerns and other significant neuropsychiatric

disorders after reviewing their medical history, functional status, informant interviews and
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MoCA score > 26 [22]. Clinical information of the study subjects were tabulated in Table

1.
Whole blood samples of volume 10 mL were collected into purple top vacutainer
tube (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) with potassium EDTA

(~1.8 mg) by venipuncture procedure from each subject. Blood samples were mixed gently

by inversion for 10 times and centrifuged at 2000 x g for 15 min at 4 o C using Sorvall
Legend RT centrifuge (Thermo Scientific, Waltham, MA, USA). Upper plasma layer was

aspirated with a transfer pipette and transferred into a 15-mL conical centrifuge tube
(Corning Inc., Corning, NY, USA). Plasma samples were aliquoted into amber glass

cryovials (Macherey-Nagel GmbH & Co., Bethlehem, PA, USA) after re-centrifugation at
2000 x g for 15 min at 4 oC and stored at -80 oC until extraction.
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Table 2.1. Clinical information of the study subjects
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Patient No.

Group

Age

Sex

Smoking

Cerebrovascular

ApoE'

MoCAf

Aßg

Tauh

P Taui

ATIj

1

ADa

60

Fc

No

No

3.3

19

320.5

462.5

80.45

0.41

2

AD

65

F

No (Quit > 10 years)

No

4.4

10

ND

ND

ND

ND

3

AD

72

F

No

Yes

3.4

18

371.4

1031

105.8

0.25

4

NCCb

73

F

ND

ND

3.3

30

ND

ND

ND

ND

5

NCC

72

F

NDk

ND

3.3

30

ND

ND

ND

ND

6

NCC

60

Md

ND

ND

3.3

30

ND

ND

ND

ND

7

NCC

62

F

ND

ND

2.3

30

ND

ND

ND

ND

aAD = Alzheimer's disease; bNCC = normal cognitive control; cF = female; dM = male; eApoE = apolipoprotein E genotyping; fMoCA
= Montreal Cognitive Assessment; gAß = amyloid beta 42; hTau = total tau; iP Tau = phospho tau; jATI = Aß42/t-tau index; kND = not
determined.

2.2.3. Plasma sample preparation
The samples were prepared by extracting the total lipids followed by fractionation
using solid-phase extraction (SPE). The study samples (n = 7) includes 4 NCC and 3 AD

subjects. For each patient plasma sample, three sample preparation replicates (same
sample preparation was performed three times in parallel) and three technical replicates on
one of the sample preparation replicate were performed (injected thrice from the same vial)

making a total of five runs for each patient plasma sample.
2.2.3.1. Total lipid extraction

Total lipids were extracted using the modified Bligh-Dyer method [23]. 50 uL of
plasma was diluted to 450 pL with 1 x phosphate buffer solution (PBS) in a borosilicate

glass tube (13 x 100 mm) from Fisher Scientific (Hanover Park, IL, USA) and was spiked
with 15pL of working internal standard mix (12 lipids) followed by acidification using 20
pL of 1 N hydrochloric acid (HCl). The sample was vortexed gently to

mix the solutions.

3mL of chloroform: methanol (1:2) was added to the sample, vortexed for 5 min and left
on ice for 10 min. Then, followed by addition of 1mL of chloroform and 1.3 mL of DI
water which was vortexed for 5 min and centrifuged at 2671 x g (3500 rpm) for 20 min.
Discard the upper phase and carefully pierce through the protein disc.

The lower

chloroform phase was collected into a new borosilicate glass tube (12 x 75 mm) and
subjected to fractionation using solid-phase extraction.
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2.2.3.2. Fractionation of lipids

The total lipid extracted were fractionated into phospho lipid (PL) and neutral
lipid (NL) fractions using a solid-phase extraction method developed by Kaluzny et al [24]
which reported highest recoveries for glycerolipids and glycerophospholipids. The total

lipid extract in chloroform was loaded onto a 500 mg aminopropyl cartridge (Agilent

Technologies, Wilmington, Delaware, USA) previously conditioned with 3 mL of hexane.
The column was first eluted with 3 mL of chloroform: isopropanol (2:1) to collect the NL
fraction. Followed by passing 3 mL of 2% acetic acid in diethyl ether through the column

and the collected fraction was discarded. Another 6 mL of 2% acetic acid in diethyl ether

was passed through the column to collect the free fatty acids fraction (FA). 4 mL methanol
was passed to elute PL fraction. The collected NL and PL fractions were dried under
nitrogen gas (TurboVap® LV evaporator, Biotage, Charlotte, NC, USA) at room
temperature and reconstituted with 500 uL of chloroform: methanol: ammonium acetate

(30:66.5:3.5). 5 uL of the reconstituted sample was subjected for further analysis using

reverse-phase liquid chromatography- quadrupole time of flight mass spectrometry.

2.2.4. UHPLC-QTOF-MS/MS method for lipid profiling
Fractionated samples were subjected to reversed-phase chromatographic separation
on Xterra® C18 (2.1 x 150 mm i.d.; 5 |im particle size) column (Waters, Milford, MA,

USA) maintained at 40 o C. The liquid chromatography system included an Agilent

UHPLC system 1290 (Agilent Technologies, Santa Clara, CA, USA) composed of a
solvent reservoir, a degasser, a binary pump (G4220A), a thermostat (G1330B), an
autosampler (G4226A), and a thermostatted column compartment (G1316C). The gradient
elution was performed using mobile phases: phase A (methanol: water (80:20) with 10mM
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ammonium acetate and 0.1% acetic acid), and phase B (isopropyl alcohol: acetonitrile:

water (70:29:1) with 10mM ammonium acetate and 0.1% acetic acid) at a flow rate of 0.2
mL/min with the following gradient program: 5% B at 0 min, 5-50% B from 0-19 min, 50

65% B from 19-24 min, 65% from 24-29 min, 65-60% B from 29-34 min, 80% B from 34
39 min, 80-100% B from 39-44 min, 100% B from 44- 47 min, 100-5% B from 47-50 min,

5% B from 50-60 min. Total run time was 60 min including column re-equilibration. Prior
to sample analysis, the column was first equilibrated with at least 25 column volumes of

the mobile phase at a flow rate of 0.2 mL/min.

Lipidomic analysis was performed using an Agilent 1290 Infinity series (UHPLC)

system connected to an Agilent 6540 Quadrupole Time of Flight (Q-TOF) equipped with
an orthogonal electrospray ionization (ESI) interface (Agilent Jet Stream, AJS) and was
operated in both positive and negative ion modes. Data was acquired using Agilent
MassHunterTM Acquisition software (version B.05.01). The MS operation parameters are

as follows: Vcap- 4000 V; nebulizer pressure- 35 psig; drying gas flow rate-10 L/min; gas

temperature- 300 oC; sheath gas flow- 11 L/min; sheath gas temperature- 300 oC; skimmer

voltage- 65 V; fragmentor voltage- 100 V. Data was collected in both centroid and profile

mode in extended dynamic range (2GHz). TOF MS accurate mass spectra were recorded
at narrow isolation width of 1.3 m/z across the range of 100-1800 m/z at 5 spectra/s and

MS/MS spectra were recorded across the range of 50 to 1800 m/z at 4 spectra/s. Collision
energies (CE) of 10, 20 and 40 V were used. Data-dependent acquisition (DDA) was

acquired using a maximum of 5 precursor ions per cycle with the absolute threshold of
5000 counts and charge states of 1, 2. Active exclusion of m/z after 3 spectral acquisitions

for 0.4 min was used. TOF was calibrated daily and real-time calibration was performed
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by continuous infusion of reference ions m/z 121. 050873 and 922.009798 (Catalog#

G1969-85001) obtained from Agilent Technologies.
2.2.5. Data processing and multivariate data analysis
Data was evaluated for retention time (tR) and mass shift by checking the extracted
ion chromatograms (EIC) of spiked internal standards and reference ion m/z across the runs

in Agilent MassHunterTM Qualitative Analysis software (Version B.06.00) to determine
retention time and mass window.

The acquired data was processed using Profinder

software (Version B.06.00) which deconvolute the data into individual peaks and filters
the features by performing batch recursive molecular feature extraction. Based on MS
data, the algorithm extracts the features with at least 100 counts in intensity, align and bin

the features based on isotopic pattern, dimers and adducts ([H]+, [M+NH4]+, [2M+H]+2,
[M-H2O+H]+ in positive mode; ([H]-, [CH3COO]-, [2M-H]-2 in negative mode) with charge

state of 1 or 2. Each extracted feature with calculated neutral mass have a corresponding
unique retention time and abundance. Retention time window and mass windows were set
at 0.5 min and 20.00 ppm respectively to perform retention time and mass corrections. The

extracted features carrying MS data with relative standard deviation (%RSD) £ 20% were
exported as compound exchange file (.cef) and comma-separated value (.csv) file for

MSMS extraction and statistical analysis respectively. In Qualitative analysis software,

each raw data (.d) and its corresponding processed .cef with MS data was used as a
template to extract MSMS spectra using “Find by Formula” function. The extracted data
with MS and summed MSMS spectra from different collision energies were exported as

.cef for annotation in SimLipid®.
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The .csv file carrying the details of mass, retention time and peak area of each

feature was used for multivariate and statistical analysis in MetaboAnalyst (v4.0) [25]. The
MS peak list data with mass, retention time and peak area as .csv files were compressed

(.zip) and uploaded onto the server [26]. Mass tolerance of 0.005 Da and retention time
tolerance of 15 s were used for feature alignment. Features with missing values in > 90%

of the samples were excluded for the downstream analysis. Normalization of the data was
performed using the internal standard reference feature (Internal standard PC mass

817.6620 @ tR 26.37 min) followed by transforming the data into logarithmic form using
Pareto scaling (mean-centered and divided by the square root of the standard deviation of
each feature). To compare and obtain statistically significant features between two study
groups, a non-parametric, unpaired Wilcoxon rank-sum t-test was performed by applying

the adjusted p-value (FDR) of £ 0.05 as the cut-off value. Unsupervised 2D PCA and
supervised 2D PLS-DA score plots were plotted on data for the detection of the outliers

and also to depict the inherent covariance between the study groups.

VIP scores

summarizes the significance of the individual feature contribution to the PLS-DA model.
VIP scores are calculated as a weighted sum of the squared correlations between the PLS-

DA components and the original variable.

2.2.6. Identification of lipids

Data acquired in +ESI and -ESI mode were used in complementary to each other
for the identification of lipids against the database. The identification of the lipids was
performed using SimLipid® software (version 5.0) using extracted data with MS and

MSMS peak list (summed spectra from different CEs). SimLipid is an online database
server with MS and MSMS spectral library. Data was searched against the database with

70

a relative threshold cut-off of 2%, mass tolerance of 20 ppm for MS and 30 ppm for MSMS

data. The type of ions matched with the spectral database were annotated in the spectra.
Annotation with the highest score was considered as the identity of lipid.

2.2.7. Pathway analysis
Joint network analysis was performed using the HMDB IDs of significant lipids

and associated protein gene name list in MetaboAnalyst. For this Lipid Maps ID (LM ID),
Human Metabolome Data Base ID (HMDB ID), and PubChem CID were sought from

LIPID MAPS database (http://lipidmaps.org/) [27] which are listed in Table 2.2. Using the

available HMDB IDs (http://www.hmdb.ca/metabolites) [28], proteins associations from
each lipid were obtained and the duplicate proteins were deleted as listed in Table 2.3.

2.2.8. Method validation
The reproducibility of the sample preparation and the UPLC-Q-TOF-MS/MS

method was evaluated by replicate analysis of study samples, which was further evaluated

in 2D PCA and 2D PLS-DA score plots. The intra- and inter-assay precision was evaluated
and expressed as relative standard deviation (%RSD).

The intra-assay precision was

determined by three-replicate measurements of 12 internal standards from one of the
sample preparations of all the study subjects.

Inter-assay precision was determined by

three-replicate measurement of 12 internal standards from three-parallel sample

preparations of all the study subjects.

2.2.9. Semi-quantitation
Semi quantitation of data was performed in Agilent MassHunter Quantitative
analysis software (version: B.06, SP01) using the respective internal standard for each

subclass of lipids (e.g. PC 817.6620 @ tR 26.37 min was used to quantitate all PC lipids).
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For unidentified features, internal standard closer in retention time to the feature was
assigned for semi-quantitation. Raw data (.d file) and its corresponding compound

exchange file (.cef) were used for this process and the results were calculated based on
peak area ratio of the feature to the IS.
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Table 2.2. Different unique IDs of 28 significant lipids from LipidMaps database
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No.

Significant Lipid

LM IDa

HMDB IDb

PubChem CIDc

KEGG IDd

1

LPC(16:0_0:0)

LMGP01050018; LMGP01050113

HMDB0010382

460602; 86544

C04230

2

LPC(18:2_0:0)

LMGP01050035; LMGP01050034

HMDB0010386

11005824; 24779467

C04230

3

LPC(18:1_0:0)

LMGP01050032; LMGP01050138;
LMGP01050029; LMGP01050030;
LMGP01050114

HMDB0002815; HMDB0010385

16081932; 53480465;
24779465; 24779466;
6449974

C04230

4

LPC(18:0_0:0)

LMGP01050026; LMGP01050076

HMDB0010384; HMDB0011128

497299; 24779491

C04230

5

LPC(20:4_0:0)

LMGP01050048
LMGP01050140

HMDB0010395
HMDB0010396

24779476
53480469

C04230

6

PC(O-14:0_18:1)

LMGP01020016

24779279

-

7

PC(15:0_16:0)

LMGP01010532
LMGP01010562

HMDB0007935
HMDB0007967

24778655

C00157

8

PC(O-16:0_20:5)

LMGP01020058

-

10485310

-

9

PC(18:4_18:3)

LMGP01011714; LMGP01011715

HMDB0008238; HMDB0008239

52922907; 52922909

C00157

10

PC(16:0_20:5)

LMGP01011932; LMGP01010633

HMDB0008495; HMDB0007984

52923341; 24778723

C00157

11

PC(16:0_20:4)

LMGP01011049; LMGP01011056;
LMGP01010629; LMGP01012136

HMDB0008429; HMDB0007983;
HMDB0007982

12

PC(18:3_20:5)

HMDB0008501; HMDB0008502;
HMDB0008182; HMDB0008215

13

PC(16:0_21:0)

LMGP01011939; LMGP01011940;
LMGP01011664; LMGP01011693
LMGP01011958
LMGP01011470

-

24779073; 24779079;
24778721; 53478669;
10747814
52923355; 52923357;
52922807; 52922865
52923393
52922422

C00157
C00157
-

52923295; 53479073;
24778979; 53478789
24779130; 24779131;
6506479; 6441886
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LMGP01011909; LMGP01012212;
LMGP01010943; LMGP01012171
LMGP01011115; LMGP01011116;
LMGP01010650; LMGP01012137

HMDB0008434; HMDB0008467;
HMDB0008147; HMDB0008148

PC(P-18:0_22:6)

LMGP01030014

HMDB0011262

42607430

-

17

PC(P-18:0_22:4)

LMGP01030073

HMDB0011259

52923974

-

18

PC(18:0_22:6)

LMGP01012107; LMGP01010821;
LMGP01010823

HMDB0008727
; HMDB0008057

52923691;24778876;
24778878

C00157

19

PC(P-20:0_22:6)

LMGP01030104

-

52924036

-

20

PC(20:3_22:6)

LMGP01012118; LMGP01011896

HMDB0008738; HMDB0008419;
HMDB0008387

52923713; 52923269;
53478995

C00157

21

SM(d18:2/18:0)

LMSP03010050

-

52931161

-

22

SM(d16:1/22:0)

LMSP03010061

-

52931183

-

23

SM(d16:1/23:0)

LMSP03010065

-

52931189

-

24

SM(d16:1/24:1)

LMSP03010071

-

52931201

-

25

GlcCer(d14:1/18:1)

LMSP0501AA41

-

70699222

-

26

TG(18:1/18:1/20:5)

LMGL03010748

HMDB0010464

9544709

-

27

TG(18:2/20:2/20:2)

LMGL03011005

-

9544966

-

28

TG(16:0/20:3/22:0)

LMGL03010963

-

9544924

-

14

PC(18:2_20:4)

15

PC(16:0_22:6)

16

HMDB0008725; HMDB0007991

C00157
C00157

aLM ID = Lipid Maps ID; bHMDB ID = Human Metabolome Database ID for metabolite; cPubChem CID = PubChem compound ID; dKEGG =
Kyoto Encyclopedia of Genes and Genomes ID for compounds.

Table 2.3. Lipid-protein association list for the significant lipids with HMDB IDs.
Protein name

SL

No

HMDBP IDa

UniProt IDb

Gene name

Protein associated lipidsc

1

Sphingomyelin phosphodiesterase 2

HMDBP01090

O60906

SMPD2

3

2

Platelet-activating factor acetylhydrolase

HMDBP00523

Q13093

PLA2G7

1 -5

3

Platelet-activating factor acetylhydrolase IB subunit gamma

HMDBP00528

Q15102

PAFAH1B3

1 -5

4

Platelet-activating factor acetylhydrolase IB subunit beta

HMDBP00530

P68402

PAFAH1B2

1 -5

5

Platelet-activating factor acetylhydrolase 2, cytoplasmic

HMDBP00534

Q99487

PAFAH2

1 -5

6

60 kDa lysophospholipase

HMDBP07300

Q86U10

ASPG

1 -5

7

Acyl-protein thioesterase 1

HMDBP00056

O75608

LYPLA1

1 - 5, 7, 9 - 12, 14, 15, 18, 20

8

Group XV phospholipase A2

HMDBP00057

Q8NCC3

PLA2G15

1 - 5, 7, 9 - 12, 14, 15, 18, 20

9

Calcium-dependent phospholipase A2

HMDBP00058

P39877

PLA2G5

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

10

Group IIF secretory phospholipase A2

HMDBP00059

Q9BZM2

PLA2G2F

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

11

Cytosolic phospholipase A2

HMDBP00060

P47712

PLA2G4A

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

12

Phospholipase A2

HMDBP00061

P04054

PLA2G1B

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

13

Group XIIB secretory phospholipase A2-like protein

HMDBP00062

Q9BX93

PLA2G12B

1 - 5, 7, 9 - 12, 14, 15, 18, 20

14

Group 10 secretory phospholipase A2

HMDBP00063

O15496

PLA2G10

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

15

Group IIE secretory phospholipase A2

HMDBP00065

Q9NZK7

PLA2G2E

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

16

Acyl-protein thioesterase 2

HMDBP00066

O95372

LYPLA2

1 - 5, 7, 9 - 12, 14, 15, 18, 20

7, 9 - 12, 14, 15 - 18, 20
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17

Group XIIA secretory phospholipase A2

HMDBP00067

Q9BZM1

PLA2G12A

18

85/88 kDa calcium-independent phospholipase A2

HMDBP00068

O60733

PLA2G6

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

19

Phosphatidylcholine-sterol acyltransferase

HMDBP00069

P04180

LCAT

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

20

Eosinophil lysophospholipase

HMDBP00070

Q05315

CLC

1 - 5, 7, 9 - 12, 14, 15, 18, 20

21

Phospholipase A2, membrane associated

HMDBP00072

P14555

PLA2G2A

7, 9 - 12, 14, 15 - 18, 20

22

Group IID secretory phospholipase A2

HMDBP00073

Q9UNK4

PLA2G2D

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

23

Phospholipase D2

HMDBP00080

O14939

PLD2

7, 9 - 12, 14, 15 - 18, 20

24

Phosphatidylethanolamine N-methyltransferase

HMDBP00081

Q9UBM1

PEMT

7, 9 - 12, 14, 15 - 18, 20

25

Phospholipase D1

HMDBP00082

Q13393

PLD1

7, 9 - 12, 14, 15 - 18, 20

26

Cytosolic phospholipase A2 gamma

HMDBP00529

Q9UP65

PLA2G4C

7, 9 - 12, 14, 15 - 18, 20

27

Group 3 secretory phospholipase A2

HMDBP00532

Q9NZ20

PLA2G3

28

D-beta-hydroxybutyrate dehydrogenase, mitochondrial

HMDBP00540

Q02338

BDH1

7, 9 - 12, 14, 15 - 18, 20

29

Choline-phosphate cytidylyltransferase B

HMDBP00732

Q9Y5K3

PCYT1B

7, 9 - 12, 14, 15 - 18, 20

30

Choline-phosphate cytidylyltransferase A

HMDBP00755

P49585

PCYT1A

7, 9 - 12, 14, 15 - 18, 20

31

Phosphatidylcholine:ceramide cholinephosphotransferase 2

HMDBP00770

Q8NHU3

SGMS2

7, 9 - 12, 14, 15 - 18, 20

32

Phosphatidylcholine:ceramide cholinephosphotransferase 1

HMDBP00775

Q86VZ5

SGMS1

7, 9 - 12, 14, 15 - 18, 20

33

Choline kinase alpha

HMDBP00778

P35790

CHKA

7, 9 - 12, 14, 15 - 18, 20

34

Probable phospholipid-transporting ATPase IG

HMDBP01131

Q8NB49

ATP11C

7, 9 - 12, 14, 15 - 18, 20

1 - 5, 7, 9 - 12, 14, 15 - 18, 20
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35

Probable phospholipid-transporting ATPase IH

HMDBP01132

P98196

ATP11A

7, 9 - 12, 14, 15 - 18, 20

36

Probable phospholipid-transporting ATPase VA

HMDBP01169

O60312

ATP10A

7, 9 - 12, 14, 15 - 18, 20

37

Probable phospholipid-transporting ATPase IC

HMDBP01192

O43520

ATP8B1

7, 9 - 12, 14, 15 - 18, 20

38

Probable phospholipid-transporting ATPase IIA

HMDBP01220

O75110

ATP9A

7, 9 - 12, 14, 15 - 18, 20

39

Probable phospholipid-transporting ATPase VD

HMDBP01239

Q9P241

ATP10D

7, 9 - 12, 14, 15 - 18, 20

40

Probable phospholipid-transporting ATPase IB

HMDBP01247

Q9NTI2

ATP8A2

7, 9 - 12, 14, 15 - 18, 20

41

Probable phospholipid-transporting ATPase IA

HMDBP01359

Q9Y2Q0

ATP8A1

7, 9 - 12, 14, 15 - 18, 20

42

Probable phospholipid-transporting ATPase IM

HMDBP01463

Q8TF62

ATP8B4

7, 9 - 12, 14, 15 - 18, 20

43

Probable phospholipid-transporting ATPase IF

HMDBP01485

Q9Y2G3

ATP11B

7, 9 - 12, 14, 15 - 18, 20

44

Probable phospholipid-transporting ATPase IK

HMDBP01489

O60423

ATP8B3

7, 9 - 12, 14, 15 - 18, 20

45

Phosphatidylinositol transfer protein beta isoform

HMDBP01672

P48739

PITPNB

7, 9 - 12, 14, 15 - 18, 20

46

Multidrug resistance protein 3

HMDBP01901

P21439

ABCB4

7, 9 - 12, 14, 15 - 18, 20

47

Lecithin retinol acyltransferase

HMDBP01912

O95237

LRAT

7, 9 - 12, 14, 15 - 18, 20

48

Phospholipid scramblase 1

HMDBP01967

O15162

PLSCR1

7, 9 - 12, 14, 15 - 18, 20

49

Phosphatidylserine synthase 1

HMDBP02190

P48651

PTDSS1

7, 9 - 12, 14, 15 - 18, 20

50

Phosphatidylinositol transfer protein alpha isoform

HMDBP02524

Q00169

PITPNA

7, 9 - 12, 14, 15 - 18, 20

51

Phospholipid transfer protein

HMDBP02549

P55058

PLTP

7, 9 - 12, 14, 15 - 18, 20

52

Cholinephosphotransferase 1

HMDBP02855

Q8WUD6

CHPT1

7, 9 - 12, 14, 15 - 18, 20
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53

2-acylglycerol O-acyltransferase 2

HMDBP03089

Q3SYC2

MOGAT2

7, 9 - 12, 14, 15 - 18, 20

54

Choline/ethanolaminephosphotransferase 1

HMDBP03349

Q9Y6K0

CEPT1

7, 9 - 12, 14, 15 - 18, 20

55

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3

HMDBP04457

Q8N3E9

PLCD3

7, 9 - 12, 14, 15 - 18, 20

56

Lysophospholipid acyltransferase 5

HMDBP07287

Q6P1A2

LPCAT3

57

Putative inactive group IIC secretory phospholipase A2

HMDBP07288

Q5R387

PLA2G2C

58

Lysophosphatidylcholine acyltransferase 1

HMDBP07289

Q8NF37

LPCAT1

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

59

Lysophosphatidylcholine acyltransferase 2

HMDBP07290

Q7L5N7

LPCAT2

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

60

Phospholipase D3

HMDBP07291

Q8IV08

PLD3

7, 9 - 12, 14, 15 - 18, 20

61

Phospholipase D4

HMDBP07292

Q96BZ4

PLD4

7, 9 - 12, 14, 15 - 18, 20

62

Phosphatidylcholine transfer protein

HMDBP07293

Q9UKL6

PCTP

7, 9 - 12, 14, 15 - 18, 20

63

Phospholipid scramblase 2

HMDBP07294

Q9NRY7

PLSCR2

7, 9 - 12, 14, 15 - 18, 20

64

Phospholipid scramblase 3

HMDBP07295

Q9NRY6

PLSCR3

7, 9 - 12, 14, 15 - 18, 20

65

Phospholipid scramblase 4

HMDBP07296

Q9NRQ2

PLSCR4

7, 9 - 12, 14, 15 - 18, 20

66

Phospholipid scramblase family member 5

HMDBP07297

A0PG75

PLSCR5

7, 9 - 12, 14, 15 - 18, 20

67

Probable phospholipid-transporting ATPase VB

HMDBP07298

O94823

ATP10B

7, 9 - 12, 14, 15 - 18, 20

68

Probable phospholipid-transporting ATPase ID

HMDBP07299

P98198

ATP8B2

7, 9 - 12, 14, 15 - 18, 20

69

Phospholipase B1, membrane-associated

HMDBP07301

Q6P1J6

PLB1

70

Phosphatidylethanolamine-binding protein 1

HMDBP07304

P30086

PEBP1

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

7, 9 - 12, 14, 15 - 18, 20

7, 9 - 12, 14, 15 - 18, 20, 26
7, 9 - 12, 14, 15 - 18, 20
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Phosphatidylethanolamine-binding protein 4

HMDBP07305

Q96S96

PEBP4

7, 9 - 12, 14, 15 - 18, 20

72

Membrane-associated phosphatidylinositol transfer protein 1

HMDBP07336

O00562

PITPNM1

7, 9 - 12, 14, 15 - 18, 20

73

Membrane-associated phosphatidylinositol transfer protein 2

HMDBP07337

Q9BZ72

PITPNM2

7, 9 - 12, 14, 15 - 18, 20

74

Membrane-associated phosphatidylinositol transfer protein 3

HMDBP07338

Q9BZ71

PITPNM3

7, 9 - 12, 14, 15 - 18, 20

75

Cytosolic phospholipase A2 delta

HMDBP07863

Q86XP0

PLA2G4D

7, 9 - 12, 14, 15 - 18, 20

76

Cytosolic phospholipase A2 epsilon

HMDBP07864

Q3MJ16

PLA2G4E

7, 9 - 12, 14, 15 - 18, 20

77

Cytosolic phospholipase A2 zeta

HMDBP07865

Q68DD2

PLA2G4F

7, 9 - 12, 14, 15 - 18, 20

78

ADP-ribosylation factor GTPase-activating protein 1

HMDBP08305

Q8N6T3

ARFGAP1

7, 9 - 12, 14, 15 - 18, 20

79

Cytosolic phospholipase A2 beta

HMDBP09120

P0C869

PLA2G4B

1 - 5, 7, 9 - 12, 14, 15 - 18, 20

80

Phospholipase D1 variant

HMDBP09354

Q59EA4

81

Phospholipase D6

HMDBP10645

Q8N2A8

PLD6

7, 9 - 12, 14, 15 - 18, 20

82

Neuropathy target esterase

HMDBP10677

Q8IY17

PNPLA6

7, 9 - 12, 14, 15 - 18, 20

83

Apolipoprotein A-V

HMDBP10986

Q6Q788

APOA5

7, 9 - 12, 14, 15 - 18, 20

84

Uteroglobin

HMDBP10987

P11684

SCGB1A1

7, 9 - 12, 14, 15 - 18, 20

88

Pancreatic triacylglycerol lipase

HMDBP00221

P16233

PNLIP

26

89

Hepatic triacylglycerol lipase

HMDBP00226

P11150

LIPC

26

90

Inactive pancreatic lipase-related protein 1

HMDBP00229

P54315

PNLIPRP1

26

91

Patatin-like phospholipase domain-containing protein 3

HMDBP00232

Q9NST1

PNPLA3

26

7, 9 - 12, 14, 15 - 18, 20
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92

Gastric triacylglycerol lipase

HMDBP00236

P07098

LIPF

26

93

Endothelial lipase

HMDBP00239

Q9Y5X9

LIPG

26

94

Bile salt-activated lipase

HMDBP00241

P19835

CEL

26

95

Diacylglycerol O-acyltransferase 1

HMDBP00243

O75907

DGAT1

26

96

Pancreatic lipase-related protein 2

HMDBP00245

P54317

PNLIPRP2

26

97

Lipoprotein lipase

HMDBP00310

P06858

LPL

26

98

Monoglyceride lipase

HMDBP00314

Q99685

MGLL

26

99

Liver carboxylesterase 1

HMDBP00497

P23141

CES1

26

100

Hormone-sensitive lipase

HMDBP00531

Q05469

LIPE

26

101

Microsomal triglyceride transfer protein large subunit

HMDBP01619

P55157

MTTP

26

102

Protein disulfide-isomerase

HMDBP02802

P07237

P4HB

26

103

2-acylglycerol O-acyltransferase 2

HMDBP03089

Q3SYC2

MOGAT2

26

104

Patatin-like phospholipase domain-containing protein 4

HMDBP03160

P41247

PNPLA4

26

105

Diacylglycerol O-acyltransferase 2

HMDBP04483

Q96PD7

DGAT2

26

106

2-acylglycerol O-acyltransferase 1

HMDBP04645

Q96PD6

MOGAT1

26

107

2-acylglycerol O-acyltransferase 3

HMDBP07284

Q86VF5

MOGAT3

26

108

Phospholipase B1, membrane-associated

HMDBP07301

Q6P1J6

PLB1

109

Glycerol-3-phosphate acyltransferase 3

HMDBP07314

Q53EU6

AGPAT9

1 - 5, 26

26

110

Patatin-like phospholipase domain-containing protein 2

HMDBP07347

Q96AD5

PNPLA2

26

111

Pancreatic lipase-related protein 3

HMDBP10934

Q17RR3

PNLIPRP3

26

112

Perilipin-4

HMDBP10984

Q96Q06

PLIN4

26

aHMDBP ID = Human Metabolome Database Protein ID; bUniProt ID = Universal Protein resource ID; cProtein associated lipids = refer
to Table S1 for lipid number designation.
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2.3.

Results

2.3.1. Lipid profiling and multivariate analysis
The lipids were profiled and processed as described in sections 2.2.4 and 2.2.5

respectively. A total of 35 samples were analyzed in each of +ESI and -ESI modes from
PL and NL fractions which were further processed for identification, semi-quantitation,
and multivariate analysis. Representative total ion chromatograms (TIC) for both fractions

in both modes are shown in Fig. 2.1. Venn plots representing a total of 509 and 506
common features in AD and NCC study subjects respectively for PL fraction, and 341 and
340 common features in AD and NCC study subjects respectively for NL fraction as
represented in Fig. 2.2. Of these features, only 498 were common between AD and NCC

groups, 8 were unique to NCC and 11 were unique to AD in PL fraction, whereas 327

features were common between AD and NCC groups, 13 were unique to NCC and 14 were
unique to AD in NL fraction (Fig. 2.2).
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Figure 2.1. Representative total ion chromatograms (TICs) in positive and negative ionization modes of phospholipid fraction
(a, b) and neutral lipid fraction (b, d) respectively.

84

Figure 2.2. Venn plots representing the numbers of the common and unique features within AD, NCC and between AD and NCC study
subjects in (a) phospholipid fraction, (b) neutral lipid fraction.

Unsupervised (PCA, without considering the correlation between the independent and

dependent variables) and supervised (PLS-DA, considering a correlation between the
independent and dependent variables) multivariate analysis performed on the common

features between two groups (498 features from PL and 327 features from NL fractions
respectively). As in Fig. 2.3, PCA score plots showed a total covariance of 56.4% for PL
and 50.7% for NL fractions with a distinct covariance between the two groups for PL
fraction. However, the model could not explain the covariance between groups for NL
fraction. PLS-DA score plots for PL and NL showed a covariance of 54.1% and 42.2%,

respectively, which indicate a distinct covariance between the two groups in both PL and

NL fractions. Variable importance of the projections (VIP) scores were calculated for the

features contributing the highest variability towards the PLS-DA components.

The

features with VIP scores of > 1.25 were considered significant (Table 2.4 and 2.5). Further
statistical analysis was performed on these common features between two groups to obtain

significant features. Though LC-MS data is a continuous gaussian distributed data, for the

selection of significant feature a non-parametric, unpaired, Wilcoxon rank-sum t-test with
false discovery rate (FDR) p-value of £ 0.05 was chosen due to less number of unpaired

samples. A total of 59 significant features were obtained out of which 28 were identified
as lipids (Table 2.4) and 31 were not annotated (Table 2.5).
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Table 2.4. Measured concentration, fold change values and VIP scores of 28 common identified significant lipids with p £ 0.05 (n = 5)
Main
Class

[X]nccs ± SD
(hM)
40 ± 1

[X]ADb ±
SD (hM)
104 ± 1

Fold
Changec
0.38

Regulation

p-valued
2.53E-04

VIP
score e
3.6799

1.69E-04

2.5948

1

PC (16:0_0:0)

495.3340

tR
(min)
6.66

2

PC (18:2_0:0)

519.3368

5.98

19 ± 1

47 ± 1

0.39

Up
Up

PC (18:1_0:0)

521.3520

7.06

13.7 ± 0.6

36 ± 1

0.37

Up

1.69E-04

2.2989

4

PC (18:0_0:0)

523.3670

8.72

20.7 ± 0.9

48 ± 1

0.41

Up

2.96E-04

2.4356

5

PC (20:4_0:0)

543.3350

5.90

4.6 ± 0.5

11.9 ± 0.3

0.37

Up

5.59E-04

1.7504

6

PC (O-14:0_18:1)

717.5752

21.41

0.73 ± 0.03

0.43 ± 0.02

1.7

Down

6.48E-04

1.5189

7

PC (15:0_16:0)

719.5880

22.46

0.89 ± 0.02

0.59 ± 0.02

1.5

Down

1.21E-03

1.5176

8

PC(O-16:0_20:5)

765.5710

22.54

5.5 ± 0.2

4.1 ± 0.3

1.3

Down

2.53E-04

1.5632

9

PC (18:4_18:3)

775.5622

22.69

0.79 ± 0.03

0.43 ± 0.01

1.9

Down

1.69E-04

1.5069

PC(16:0_20:5)

779.5520

20.24

41.3 ± 0.5

30 ± 1

1.4

Down

1.69E-04

1.9478

PC(16:0_20:4)

781.5650

21.52

46.1 ± 0.8

37.4 ± 0.9

1.2

Down

7.56E-04

1.8206

PC(18:3_20:5)

801.5340

18.84

15.7 ± 0.7

4.2 ± 0.4

3.7

Down

1.91E-03

1.9305

PC (16:0_21:0)

803.5500

19.95

5.3 ± 0.2

4.1 ± 0.1

1.3

Down

2.57E-03

1.5609

14

PC (18:2_20:4)

805.5668

19.85

1.31 ± 0.02

1.0 ± 0.5

1.4

Down

2.98E-03

1.5306

15

PC (16:0_22:6)

805.5602

20.86

7.23 ± 0.08

5.6 ± 0.2

1.3

Down

2.71E-02

1.5589

16

PC (P-18:0_22:6)

817.6020

23.17

1.71 ± 0.08

1.2 ± 0.1

1.5

Down

1.69E-04

1.5409

17

PC(P-18:0/22:4)

821.5396

20.82

24 ± 1

16.0 ± 0.8

1.5

Down

1.57E-04

18

PC (18:0_22:6)

833.5970

22.84

8.4 ± 0.2

3.4 ± 0.2

2.5

Down

5.59E-04

1.8109
1.6891

19

PC (P-20:0/22:6)

845.5413

21.04

5.2 ± 0.2

2.0 ± 0.1

2.6

Down

1.91E-03

1.6378

20

PC(20:3_22:6)

855.5810

21.83

7.3 ± 0.2

3.6 ± 0.2

2.1

Down

1.69E-04

1.6508

No

Category

3
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10

11

LPCi

GPf

12

13

PCj

Lipid

Mass

21

SM (d18:2/18:0)

728.5880

19.53

9.6 ± 0.1

7.6 ± 0.2

1.3

Down

4.88E-03

1.5962

22

SM (d16:1/22:0)

758.6360

23.22

13.2 ± 0.3

9.8 ± 0.3

1.4

Down

2.66E-04

SM(d16:1/23:0)

772.6510

24.16

9.0 ± 0.2

8.2 ± 0.2

1.1

Down

1.69E-04

1.6489
1.5269

SM(d16:1/24:1)

784.6480

23.47

13.6 ± 0.3

13.0 ± 0.4

1.0

Down

3.48E-04

1.8203

GlcCer(d14:1/18:1)

669.5168

35.80

16.5 ± 0.5

11.7 ± 0.8

1.42

Down

9.62E-05

1.5182

TG(18:1_18:1_20:5)

904.7545

36.47

20.6 ± 0.8

29 ± 2

0.71

9.62E-05

1.7089

TG(18:2_20:2_20:2)

934.7800

34.98

1.15 ± 0.04

3.1 ± 0.3

0.37

Up
Up

8.38E-05

1.3522

23

SLg

SMk

24
25

NGSLl

26
27
28

GLh

TGm

TG(16:0_20:3_22:0) 940.8290 37.44
34 ± 1
49 ± 4
0.70
9.28E-06 1.9914
Up
a[X]NCC = mean measured concentration in NCC subjects (n = 4); b[X]AD = mean measured concentration in AD subjects (n = 3); cFold Change =
[X]NCC/[X]AD; dp-value = false discovery rate adjusted p-values; eVIP = Variable Importance in Projection score; fGP = glycerophospholipids; gSL
= sphingolipids; hGL = glycerolipids; iLPC = lysophosphocholines; jPC = glycerophosphocholine; kSM = sphingomyelins; lNGSL = neutral
glycosphingolipids; mTG = triacylglyceride.
87

Table 2.5. Measured concentration, fold change values and VIP scores of 31 common unidentified lipids with p £ 0.05

2.62

[X]Ncca ± SD
(HM
3.0 ± 0.6

[X]ADb ± SD
(hM)
1.1 ± 0.2

650.6503

26.32

1.2 ± 0.1

3

791.5910

21.24

4

822.6165

Fold Changec

Regulation

p-valued

VIP scoree

2.9

Down

3.48E-04

1.5962

1.00 ± 0.05

1.3

Down

4.60E-03

1.5109

31 ± 7

13 ± 10

2.4

Down

7.56E-04

2.1609

23.71

9.5 ± 0.9

6± 1

1.5

Down

3.47E-03

1.6245

825.5674

23.48

26 ± 3

16 ± 1

1.6

Down

1.04E-03

837.6048

18.86

31 ± 17

11 ± 1

2.7

Down

1.21E-03

1.8603
2.2355

7

850.6426

25.14

17 ± 3

12 ± 1

1.4

Down

4.78E-04

1.6901

8

855.6241

26.44

1.3 ± 0.1

0.97 ± 0.08

1.3

Down

5.59E-04

1.5106

9

865.6337

21.05

13 ± 6

5.3 ± 0.2

2.3

Down

4.06E-04

1.7646

10

871.5533

21.87

9±2

3.0 ± 0.5

3.1

Down

1.69E-04

1.7201

11

1027.6232

21.88

1.2 ± 0.3

0.6 ± 0.1

1.9

Down

1.69E-04

1.5397

12

414.2066

3.72

36 ± 2

23 ±2

1.6

Down

2.82E-03

1.8201

13

430.3843

21.62

2.50 ± 0.06

3.3 ± 0.5

0.8

Up

1.41E-02

1.2962

14

487.4321

21.62

4.6 ± 0.1

6.6 ± 0.5

0.7

Up

9.46E-04

1.3607

521.5956

21.24

27 ± 2

35 ± 5

0.8

Up

1.79E-03

1.8593

535.4360

29.92

2.1 ± 0.1

5.0 ± 0.7

0.4

Up

6.93E-03

1.3991

17

602.5302

25.87

2.1 ± 0.1

1.3 ± 0.5

1.6

Down

5.16E-03

1.2898

18

634.5939

30.26

8.4 ± 0.2

6.6 ± 0.2

1.3

Down

3.18E-02

1.3406

19

687.6016

34.06

20.1 ± 0.7

53 ± 11

0.4

Up

1.06E-02

2.2963

20

688.5628

36.97

2.4 ± 0.1

4.0 ± 0.5

0.6

Up

9.21E-03

1.3412

No

Mass

tR (min)

1

492.0114

2

5
6
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15
16

Phospholipid
fraction [PL]

Neutral lipid
fraction [NL]

21

690.5626

30.26

6.7 ± 0.2

16 ± 14

0.4

Up

6.93E-03

1.4201

22

708.5319

34.06

9.6 ± 0.5

24 ± 6

0.4

Up

1.82E-04

2.1723

23

710.5440

35.29

7.1 ± 0.5

11 ± 1

0.7

Up

4.14E-02

1.4682

24

833.6801

26.78

0.50 ± 0.07

2.6 ± 2.8

0.2

Up

1.22E-02

1.2814

25

886.7493

38.93

7.1 ± 0.1

8± 1

0.9

Up

5.82E-04

1.3592

26

907.3869

26.24

3.6 ± 0.2

4.0 ± 0.5

0.9

Up

4.14E-02

1.2816

27

927.8272

37.55

13.9 ± 0.5

7.1 ± 0.1

2.0

Down

2.13E-02

1.6094

28

1006.8341

41.14

1.4 ± 0.1

0.200 ± 0.007

6.9

Down

3.18E-02

1.3202

29

1096.3260

28.01

15.0 ± 0.9

23 ± 3

0.7

Up

2.13E-04

1.7889

30

1170.3461

29.26

35 ± 2

55 ± 7

0.6

Up

2.43E-03

2.6512

89

31
1688.4848
38.06
14 ± 1
5.4 ± 0.4
1.82E-04
2.6
Down
1.6976
a[X]NCC = mean measured concentration in NCC subjects (n = 4); b[X]AD = mean measured concentration in AD subjects (n = 3); cFold Change =
[X]NCC/[X]AD; dp-value = false discovery rate adjusted p-values; eVIP = Variable Importance in Projection score.
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Figure 2.3. (a) PCA score plots and (b) PLS-DA score plots with VIP scores of AD and NCC study subjects. (1) phospholipid fraction,
(2) neutral lipid fraction of the common features.

2.3.2. Identification of lipids
The identification of features was performed as per the procedure described in
Section 2.2.6. A total of 148 and 108 lipid species were annotated in PL and NL fractions
respectively (Table 2.6).

In general, structural characterization of lipid requires

identification of head group, sn-1 and sn-2 fatty acyl chains. In this study, the identification

of the lipid against the database doesn’t provide the information on position of the fatty
acyl chain on glycerol backbone, and the location of the double bonds in the fatty acids.

Therefore lipids are represented in the format PC(18:3_20:5) instead of PC(18:3/20:5). “_”
indicates the uncertainty in the position of fatty acids on glycerol backbone.
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Table 2.6. The total lipid identified from the phospho and neutral lipid fractions in AD and NCC study subjects.
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No

Lipid Name

Observed
Mass

tR (min)

Precursor ion, m/z

ESI
Mode

Category

Main Class

1

LacCer(d18:1_16:0)

861.6231

18.55

862.6283 [M+H]+;
860.6156 [M-H]-

Ph, Ni

Sphingolipids [SP]

Neutral glycosphingolipids

2

(3'-sulfo)Galbeta-Cer(d18:1_24:0)

891.6520

21.83

892.6585 [M+H]+

P

Sphingolipids [SP]

Acidic glycosphingolipids

3

CL(1'-[18:1_20:4],3'-[20:0_20:0])

1539.1330

20.11

1540.1379 [M+H]+

P

Glycerophospholipids [GP]

Cardiolipin

4

CL(1'-[20:0_20:0],3'-[20:4_20:4])

1561.0936

20.04

1562.1198 [M+H]+

P

Glycerophospholipids [GP]

Cardiolipin

5

PA(14:0/0:0) (IS)

382. 1089

4.42

383. 3467 [M+H]+;
404.1946 [M+Na]+

P

Glycerophospholipids [GP]

PAa

6

PC(13:0/0:0) (IS)

453.2887

4.45

454.2841 [M+H]+;
452.1989 [M-H]-

P, N

Glycerophospholipids [GP]

PCb

7

PC(16:1_0:0)

493.3170

5.42

494.3265 [M+H]+;
492.2998 [M-H]-

P, N

Glycerophospholipids [GP]

PC

8

PC(16:0_0:0)

495.3340

6.66

496.3425 [M+H]+

P

Glycerophospholipids [GP]

PC

9

PC(18:3_0:0)

517.3215

6.66

518.3245 [M+H]+;
516.3102 [M-H]-

P, N

Glycerophospholipids [GP]

PC

10

PC(18:2_0:0)

519.3368

5.98

520.3328 [M+H]+

P

Glycerophospholipids [GP]

PC

11

PC(18:1_0:0)

521.3520

7.06

522.3585 [M+H]+

P

Glycerophospholipids [GP]

PC

12

PC(O-16:0_2:0)

523.3646

8.22

524.3747 [M+H]+

P

Glycerophospholipids [GP]

PC
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13

PC(0:0_18:0)

523.3670

8.72

524.3743 [M+H]+;
522.3240 [M-H]-

P, N

Glycerophospholipids [GP]

PC

14

PC(20:5_0:0)

541.3200

5.15

542.3250 [M+H]+

P

Glycerophospholipids [GP]

PC

15

PC(20:4_0:0)

543.3350

5.90

544.3402 [M+H]+;
542.3019 [M-H]-

P, N

Glycerophospholipids [GP]

PC

16

PC(20:3_0:0)

545.3510

6.64

546.3564 [M+H]+

P

Glycerophospholipids [GP]

PC

17

PC(12:0_18:0)

705.5360

19.07

706.5416 [M+H]+

P

Glycerophospholipids [GP]

PC

18

PC (O-14:0_18:1)

717.5752

21.41

718.5816 [M+H]+;
716.5545 [M-H]-

P, N

Glycerophospholipids [GP]

PC

19

PC(O-14:0_18:0)

719.5880

22.46

720.5930 [M+H]+

P

Glycerophospholipids [GP]

PC

20

PC(14:0_18:2)

729.5360

18.02

730.5425 [M+H]+

P

Glycerophospholipids [GP]

PC

21

PC(16:0_16:1)

731.5510

19.48

732.5574 [M+H]+

P

Glycerophospholipids [GP]

PC

22

PC(10:0_22:0)

733.5670

21.16

734.5732 [M+H]+

P

Glycerophospholipids [GP]

PC

23

PC(O-16:0_18:3)

741.5720

21.21

742.5778 [M+H]+;
740. 5536 [M-H]-

P, N

Glycerophospholipids [GP]

PC

24

PC(15:0_18:2)

743.5510

19.16

744.5568 [M+H]+

P

Glycerophospholipids [GP]

PC

25

PC(15:0_18:1)

745.5670

20.54

746.5728 [M+H]+

P

Glycerophospholipids [GP]

PC

26

PC(O-16:1_18:0)

745.6040

22.68

746.6096 [M+H]+;
744.5816 [M-H]-

P, N

Glycerophospholipids [GP]

PC
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27

PC(14:0_20:5)

751.5180

18.02

752.5242 [M+H]+

P

Glycerophospholipids [GP]

PC

28

PC(14:0_20:4)

753.5340

19.48

754.5396 [M+H]+

P

Glycerophospholipids [GP]

PC

29

PC(16:0_18:3)

755.5480

21.21

756.5577 [M+H]+

P

Glycerophospholipids [GP]

PC

30

PC(16:1_18:2)

755.5510

19.11

756.5582 [M+H]+

P

Glycerophospholipids [GP]

PC

31

PC(16:0_18:2)

757.5670

20.19

758.5728 [M+H]+

P

Glycerophospholipids [GP]

PC

32

PC(16:0_18:1)

759.5820

21.52

760.5800 [M+H]+

P

Glycerophospholipids [GP]

PC

33

PC(16:0_18:0)

761.6000

23.17

762.6053 [M+H]+;
760.5897 [M-H]-

P, N

Glycerophospholipids [GP]

PC

34

PC(O-16:0_20:5)

765.5710

22.54

766.5782 [M+H]+;
764.5620 [M-H]-

P, N

Glycerophospholipids [GP]

PC

35

PC(18:2_17:2)

767.5470

19.53

768.5572 [M+H]+

P

Glycerophospholipids [GP]

PC

36

PC(15:0_20:4)

767.5510

18.98

768.5572 [M+H]+

P

Glycerophospholipids [GP]

PC

37

PC(O-16:0_20:4)

767.5530

22.46

768.5939 [M+H]+;
766.5432 [M-H]-

P, N

Glycerophospholipids [GP]

PC

38

PC(P-16:0_20:3)

767.5880

21.79

768.5939 [M+H]+;
766.5699 [M-H]-

P, N

Glycerophospholipids [GP]

PC

39

PC(O-16:0_20:3)

769.6070

23.17

770.6091 [M+H]+;
768.5964 [M-H]-

P, N

Glycerophospholipids [GP]

PC

40

PC(17:0_18:2)

771.5228

21.23

772.5898 [M+H]+

P

Glycerophospholipids [GP]

PC
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41

PC(13:0_22:2)

771.5230

21.21

772.5891 [M+H]+

P

Glycerophospholipids [GP]

PC

42

PC(O-18:0_18:2)

771.6187

24.45

772.6254 [M+H]+,
770.6002 [M-H]-

P, N

Glycerophospholipids [GP]

PC

43

PC(O-16:0_20:2)

771.6200

23.30

772.6255 [M+H]+

P

Glycerophospholipids [GP]

PC

44

PC(17:0_18:1)

773.5990

22.50

774.6043 [M+H]+

P

Glycerophospholipids [GP]

PC

45

PC(16:1_20:5)

777.5330

18.60

778.5392 [M+H]+

P

Glycerophospholipids [GP]

PC

46

PC(18:3_18:3)

777.5330

19.11

778.5394 [M+H]+

P

Glycerophospholipids [GP]

PC

47

PC(18:2_18:3)

779.5490

20.24

780.5552 [M+H]+;
778.5209 [M-H]-

P, N

Glycerophospholipids [GP]

PC

48

PC(16:0_20:5)

779.5520

18.84

780.5552 [M+H]+

P

Glycerophospholipids [GP]

PC

49

PC(16:0_20:4)

781.5650

21.52

782.5711 [M+H]+

P

Glycerophospholipids [GP]

PC

50

PC(18:2_18:2)

781.5650

19.16

782.5727 [M+H]+

P

Glycerophospholipids [GP]

PC

51

PC(18:1_18:3)

781.5670

19.99

782.5726 [M+H]+;
780.5478 [M-H]-

P, N

Glycerophospholipids [GP]

PC

52

PC(18:1_18:2)

783.5820

20.80

784.5800 [M+H]+

P

Glycerophospholipids [GP]

PC

53

PC(18:0_18:2)

785.5990

22.18

786.6049 [M+H]+

P

Glycerophospholipids [GP]

PC

54

PC(18:0_18:1)

787.6150

23.43

788.6208 [M+H]+

P

Glycerophospholipids [GP]

PC

55

PC(O-16:0_22:5)

793.6040

22.97

794.6097 [M+H]+;
792.5986 [M-H]-

P, N

Glycerophospholipids [GP]

PC
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56

PC(17:0_20:4)

795.5850

21.06

796.5892 [M+H]+

P

Glycerophospholipids [GP]

PC

57

PC(O-18:0_20:4)

795.6190

23.17

796.6247 [M+H]+;
800.5674 [M-H]-

P, N

Glycerophospholipids [GP]

PC

58

PC(18:3_20:5)

801.5340

18.84

802.5403 [M+H]+

P

Glycerophospholipids [GP]

PC

59

PC(18:4_20:4)

801.6030

19.16

802.5403 [M+H]+

P

Glycerophospholipids [GP]

PC

60

PC(16:1_22:5)

803.5500

19.95

804.5551 [M+H]+

P

Glycerophospholipids [GP]

PC

61

PC(16:0_22:6)

805.5602

20.86

806.5709 [M+H]+

P

Glycerophospholipids [GP]

PC

62

PC(18:2_20:4)

805.5668

19.85

806.5715 [M+H]+

P

Glycerophospholipids [GP]

PC

63

PC(16:1_22:5)

805.5679

19.22

806.5734 [M+H]+

P

Glycerophospholipids [GP]

PC

64

PC(16:0_22:5)

807.5810

22.24

808.5868 [M+H]+,
806.5629 [M-H]-

P, N

Glycerophospholipids [GP]

PC

65

PC(18:1_20:4)

807.5820

20.54

808.5882 [M+H]+

P

Glycerophospholipids [GP]

PC

66

PC(18:0_20:5)

807.5830

22.33

808.5869 [M+H]+

P

Glycerophospholipids [GP]

PC

67

PC(18:0_20:4)

809.5970

23.43

810.6028 [M+H]+

P

Glycerophospholipids [GP]

PC

68

PC(16:0_22:4)

809.5990

22.00

810.6031 [M+H]+;
808.5790 [M-H]-

P, N

Glycerophospholipids [GP]

PC

69

PC(18:2_20:1)

811.5536

22.56

812.6118 [M+H]+

P

Glycerophospholipids [GP]

PC

70

PC(18:0_20:3)

811.6096

22.87

812.6118 [M+H]+

P

Glycerophospholipids [GP]

PC

96

71

PC(18:0_20:2)

813.6310

23.85

814.6273 [M+H]+

P

Glycerophospholipids [GP]

PC

72

PC(P-18:0_22:6)

817.6020

23.17

818.6079 [M+H]+;
816.5904 [M-H]-

P, N

Glycerophospholipids [GP]

PC

73

PC(19:0/19:0) (IS)

817.6615

26.42

818.6674 [M+H]+;
816.6430 [M-H]-

P, N

Glycerophospholipids [GP]

PC

74

PC(P-18:0_22:4)

821.6350

20.82

822.6414 [M+H]+;
820.6230 [M-H]-

P, N

Glycerophospholipids [GP]

PC

75

PC(17:0_22:4)

823.6599

25.81

824.6210 [M+H]+

P

Glycerophospholipids [GP]

PC

76

PC(18:3_22:6)

827.5500

19.78

828.5558 [M+H]+

P

Glycerophospholipids [GP]

PC

77

PC(18:2_22:6)

829.5650

20.54

830.5717 [M+H]+

P

Glycerophospholipids [GP]

PC

78

PC(20:4_20:4)

829.5660

18.72

830.5709 [M+H]+

P

Glycerophospholipids [GP]

PC

79

PC(18:1_22:6)

831.5810

22.00

832.5872 [M+H]+

P

Glycerophospholipids [GP]

PC

80

PC(18:2_22:5)

831.5820

20.50

832.5884 [M+H]+;
830.5640 [M-H]-

P, N

Glycerophospholipids [GP]

PC

81

PC(18:3_22:4)

831.6480

22.54

832.5866 [M+H]+

P

Glycerophospholipids [GP]

PC

82

PC(18:0_22:6)

833.5970

22.84

834.6023 [M+H]+

P

Glycerophospholipids [GP]

PC

83

PC(18:0_22:5)

835.6069

22.46

836.6182 [M+H]+

P

Glycerophospholipids [GP]

PC

84

PC(20:2_20:3)

835.6132

23.90

836.6182 [M+H]+;
834.5924 [M-H]-

P, N

Glycerophospholipids [GP]

PC

97

85

PC(18:0_22:3)

839.6430

26.37

840.6499 [M+H]+

P

Glycerophospholipids [GP]

PC

86

PC(20:3_22:6)

855.5810

21.83

856.5865 [M+H]+

P

Glycerophospholipids [GP]

PC

87

PC(20:2_22:6)

857.5980

22.50

858.6026 [M+H]+

P

Glycerophospholipids [GP]

PC

88

PC(20:1_22:6)

859.6074

23.45

860.6168 [M+H]+

P

Glycerophospholipids [GP]

PC

89

PC(O-22:2_22:3)

877.7010

26.42

878.7051 [M+H]+;
876.6932 [M-H]-

P, N

Glycerophospholipids [GP]

PC

90

PE(14:0/0:0) (IS)

425.2579

6.74

426. 2627 [M+H]+;
424.3098 [M-H]-

P, N

Glycerophospholipids [GP]

PEc

91

PE(16:0_0:0)

453.2862

6.83

545.3256 [M+H]+

P

Glycerophospholipids [GP]

PE

92

PE(18:2_0:0)

477.2850

6.17

478.3001 [M+H]+

P

Glycerophospholipids [GP]

PE

93

PE(18:1_0:0)

479.3379

7.54

480.4586 [M+H]+

P

Glycerophospholipids [GP]

PE

94

PE(24:6_0:0)

553.3896

6.66

554.3900 [M+H]+

P

Glycerophospholipids [GP]

PE

95

PE(15:0/15:0) (IS)

663.4881

19.45

664.4939 [M+H]+;
662.4532 [M-H]-

P, N

Glycerophospholipids [GP]

PE

96

PE (p-16:0_20:5)

721.5051

21.19

722.5162 [M+H]+

P

Glycerophospholipids [GP]

PE

97

PE (p-16:0_20:4)

723.5199

21.44

724.5269 [M+H]+;
722.5258 [M-H]-

P, N

Glycerophospholipids [GP]

PE

98

PE (p-18:1_18:2)

725.5385

22.01

726.5432 [M+H]+

P

Glycerophospholipids [GP]

PE

98

99

PE (p-18:1_18:1)

727.5519

23.63

728.5634 [M+H]+

P

Glycerophospholipids [GP]

PE

100

PE (16:0_20:5)

737.5004

20.82

738.5130 [M+H]+;
736.4986 [M-H]-

P, N

Glycerophospholipids [GP]

PE

101

PE(16:0_20:4)

739.5223

21.14

738.5178 [M-H]-

P

Glycerophospholipids [GP]

PE

102

PE(18:0_18:2)

743.5476

19.17

742.5482 [M-H]-

P, N

Glycerophospholipids [GP]

PE

103

PE (p-16:0_22:6)

747.5234

20.67

748.5426 [M+H]+;
746.5134 [M-H]-

P, N

Glycerophospholipids [GP]

PE

104

PE(O-38:6) OR PE(P-38:5)

749.5359

21.82

750.5569 [M+H]+

P

Glycerophospholipids [GP]

PE

105

PE(P-18:0_20:4)

751.5575

23.41

752.5627 [M+H]+;
750.5541 [M-H]-

P, N

Glycerophospholipids [GP]

PE

106

PE(16:0_22:6)

763.5872

19.15

762.5175 [M-H]-

P, N

Glycerophospholipids [GP]

PE

107

PE(18:0_20:4)

767.5559

21.59

766.5491 [M-H]-

N

Glycerophospholipids [GP]

PE

108

PE (p-18:1_22:6)

773.5315

23.41

774.5430 {M+H]+

P

Glycerophospholipids [GP]

PE

109

PE (p-18:0_22:6)

775.5518

23.22

776.5701 [M+H]+

P

Glycerophospholipids [GP]

PE

110

PE (18:2_22:6)

787.5213

18.20

788.5421 [M+H]+

P

Glycerophospholipids [GP]

PE

111

PE(18:0_22:6)

791.5468

21.43

790.5536 [M-H]-

N

Glycerophospholipids [GP]

PE

112

PE(19:0_22:6)

805.5537

17.86

806.5729 [M+H]+

P

Glycerophospholipids [GP]

PE

99

113

PE(19:0_22:6)

805.5537

17.86

806.5704 [M+H]+

P

Glycerophospholipids [GP]

PE

114

PG(14:0/0:0) (IS)

456.2727

4.46

457.2488 [M+H]+;
478.2310 [M+Na]+;
455.2016 [M-H]-

P, N

Glycerophospholipids [GP]

PGd

115

PG(17:0/17:0) (IS)

750.9856

20.50

749.5643 [M-H]-;
773.6026 [M+Na]+

P, N

Glycerophospholipids [GP]

PG

116

PG(17:0_22:0)

820.621

20.73

819.6072 [M-H]-

N

Glycerophospholipids [GP]

PG

117

PG(21:0_20:3)

842.6098

18.35

841.5879 [M-H]-

N

Glycerophospholipids [GP]

PG

118

PG(19:0_22:2)

844.6209

20.05

843.6060 [M-H]-

N

Glycerophospholipids [GP]

PG

119

PS(17:1/0:0) (IS)

509.3494

7.64

508.3126 [M-H]-

N

Glycerophospholipids [GP]

PG

120

PS(22:1_0:0)

579.3545

5.57

578.354 [M-H]-

N

Glycerophospholipids [GP]

PSe

121

PS(22:0_0:0)

581.3709

6.64

580.3688 [M-H]-

N

Glycerophospholipids [GP]

PS

122

PS(14:0/14:0) (IS)

679.3678

18.08

678.4424 [M-H]-

123

PS(16:0_20:0)

791.5863

18.73

790.5674 [M-H]-

N

Glycerophospholipids [GP]

PS

124

PS(16:1_22:1)

815.5684

17.73

814.5684 [M-H]-

N

Glycerophospholipids [GP]

PS

125

PS(22:1_16:0)

817.5839

19.39

816.5903 [M-H]-

N

Glycerophospholipids [GP]

PS

126

PS(22:0_16:0)

819.6134

20.73

818.6038 [M-H]-

N

Glycerophospholipids [GP]

PS

127

PS(20:0_20:3)

841.5860

18.35

840.5849 [M-H]-

N

Glycerophospholipids [GP]

PS

100

128

PS(18:2_22:1)

841.58345

19.21

840.5868 [M-H]-

N

Glycerophospholipids [GP]

PS

129

PS(18:1_22:2)

841.6001

19.23

840.5905 [M-H]-

N

Glycerophospholipids [GP]

PS

130

PS(18:1_22:1)

843.6017

20.05

842.6036 [M-H]-

N

Glycerophospholipids [GP]

PS

131

PS(18:2_22:0)

843.5989

19.76

842.6058 [M-H]-

N

Glycerophospholipids [GP]

PS

132

PS(18:0_22:1)

845.6378

21.43

844.6227 [M-H]-

N

Glycerophospholipids [GP]

PS

133

PS(22:0_18:0)

847.6315

22.76

846.6368 [M-H]-

N

Glycerophospholipids [GP]

PS

134

PS(20:5_22:0)

865.5840

19.07

864.5900 [M-H]-

N

Glycerophospholipids [GP]

PS

135

PS(20:4_22:0)

867.6009

19.81

866.6028 [M-H]-

N

Glycerophospholipids [GP]

PS

136

PS(20:1_22:2)

869.6257

21.26

868.6227 [M-H]-

N

Glycerophospholipids [GP]

PS

137

PS(20:1_22:1)

871.6403

22.12

870.6337 [M-H]-

N

Glycerophospholipids [GP]

PS

138

PS(22:2_22:2)

895.6419

21.73

894.6337 [M-H]-

N

Glycerophospholipids [GP]

PS

139

SM(d18:1_14:0)

674.5420

16.57

675.5476 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

140

SM(d16:1_17:0)

688.5570

17.81

689.5628 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

141

SM(d18:2_16:0)

700.4060

21.16

701.5633 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

142

SM(d18:1_16:0)

702.5720

18.93

703.5784 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

143

SM(d18:0_16:0)

704.5880

19.82

705.5942 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

101

144

SM(d18:1_18:1)

728.5880

19.53

729.5943 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

145

SM(d18:1_18:0)

730.6030

21.16

731.6096 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

146

SM(d18:2_20:0)

756.6190

21.76

757.626 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

147

SM(d16:1_22:1)

756.6470

22.88

757.6255 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

148

SM(d16:1_22:0)

758.6360

23.22

759.6417 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

149

SM(d16:1_23:0)

772.6510

24.16

773.657 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

150

SM(d18:1_22:1)

784.6480

23.47

785.6572 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

151

SM(d18:1_22:0)

786.6660

24.97

787.6730 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

152

SM(d18:0_22:0)

788.6812

25.69

789.6811 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

153

SM(d17:1_24:1)

798.6670

24.47

799.6729 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

154

SM(d16:1_25:0)

800.6820

25.74

801.6882 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

155

SM(d18:2_24:1)

810.6060

24.11

811.6725 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

156

SM(d18:1_24:1)

812.6820

25.01

813.6893 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

157

SM(d18:1_24:0)

814.6979

26.55

815.7043 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

158

SM(d17:1_26:1)

826.6911

25.51

827.7037 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

159

SM(d18:1_25:0)

828.7061

27.02

829.7194 [M+H]+

P

Sphingolipids [SP]

Phosphosphingolipids

102

160

Cer(d18:1/17:0) (IS)

551.5320

23.76

552.5381 [M+H]+

P

Sphingolipids [SP]

Ceramides

161

Cer(d18:1/24:0)

649.6420

29.65

650.6535 [M+H]+

P

Sphingolipids [SP]

Ceramides

162

GlcCer(d14:1/18:1)

669.5168

35.80

670.5294 [M+H]+,
687.5567 [M+NH4]+

P

Sphingolipids [SP]

Neutral glycosphingolipids

163

DG(16:0_18:2_0:0)

592.5099

23.76

593.5165 [M+H]+,
610.5438 [M+NH4]+

P

Glycerolipids [GL]

DGf

164

DG(18:1_16:0_0:0)

594.5285

26.63

595.5329 [M+H]+,
612.5594 [M+NH4]+

P

Glycerolipids [GL]

DG

165

DG(18:1_18:1_0:0)

620.5412

26.87

621.5482 [M+H]+,
638.5755 [M+NH4]+

P

Glycerolipids [GL]

DG

166

DG(18:1_18:2_0:0)

618.5299

25.77

619.5324 [M+H]+,
636.5597 [M+NH4]+

P

Glycerolipids [GL]

DG

167

DG(18:1_20:5_0:0)

640.5090

25.77

641.5209 [M+H]+

P

Glycerolipids [GL]

DG

168

DG(19:0/19:0/0:0) (IS)

652.6090

31.61

653.6104 [M+H]+,
670.6377 [M+NH4]+

P

Glycerolipids [GL]

DG

169

TG(12:0_16:1_18:1)

774.6744

34.40

775.6891 [M+H]+,
792.7164 [M+NH4]+

P

Glycerolipids [GL]

TGg

170

TG(13:0_19:0_19:1)

846.7695

34.84

847.7630 [M+H]+

P

Glycerolipids [GL]

TG

171

TG(14:0_14:0_18:1)

776.6915

35.67

777.7054 [M+H]+,
794.7327 [M+NH4]+

P

Glycerolipids [GL]

TG

172

TG(14:0_16:0_16:0)

778.7096

36.87

779.7215 [M+H]+,
796.7488 [M+NH4]+

P

Glycerolipids [GL]

TG

103

173

TG(14:0_16:0_18:1)

804.7289

36.12

805.7377 [M+H]+,
822.7650 [M+NH4]+

P

Glycerolipids [GL]

TG

174

TG(14:0_16:0_19:0)

820.7540

36.95

821.7477 [M+H]+

P

Glycerolipids [GL]

TG

175

TG(14:0_16:1_18:2)

800.6920

34.59

801.7055 [M+H]+,
818.7328 [M+NH4]+

P

Glycerolipids [GL]

TG

176

TG(14:0_17:0_22:1)

874.7993

35.33

875.7923 [M+H]+

P

Glycerolipids [GL]

TG

177

TG(14:0_18:1_18:2)

828.7211

35.99

829.7378 [M+H]+,
846.7651 [M+NH4]+

P

Glycerolipids [GL]

TG

178

TG(14:0_18:2_20:5)

848.6930

34.94

849.7046 [M+H]+

P

Glycerolipids [GL]

TG

179

TG(14:0_20:0_20:0)

890.8140

38.09

891.8223 [M+H]+

P

Glycerolipids [GL]

TG

180

TG(14:0_21:0_22:6)

920.7898

34.43

921.7842 [M+H]+,
938.8115 [M+NH4]+

P

Glycerolipids [GL]

TG

181

TG(14:0_22:0_22:4)

938.8302

35.51

939.8253 [M+H]+

P

Glycerolipids [GL]

TG

182

TG(14:1_20:1_22:1)

912.7970

36.19

913.809 [M+H]+

P

Glycerolipids [GL]

TG

183

TG(15:0_15:0_18:2)

802.7091

35.84

803.7165 [M+H]+,
820.7438 [M+NH4]+

P

Glycerolipids [GL]

TG

184

TG(15:0_15:0_20:5)

824.6940

35.80

825.6992 [M+H]+

P

Glycerolipids [GL]

TG

185

TG(15:0_16:0_18:1)

818.7389

37.49

819.7524 [M+H]+,
836.7797 [M+NH4]+

P

Glycerolipids [GL]

TG

104

186

TG(15:0_17:1_17:1)

816.7218

36.48

817.7321 [M+H]+,
834.7594 [M+NH4]+

P

Glycerolipids [GL]

TG

187

TG(15:0_18:1_18:2)

842.7389

36.62

843.7541 [M+H]+,
860.7814 [M+NH4]+

P

Glycerolipids [GL]

TG

188

TG(15:1_17:0_19:1)

844.7589

33.61

845.7476 [M+H]+

P

Glycerolipids [GL]

TG

189

TG(15:1_18:0_19:0)

860.7876

35.55

861.7787 [M+H]+

P

Glycerolipids [GL]

TG

190

TG(15:1_18:1_20:3)

866.7325

38.41

867.7597 [M+H]+,
884.787 [M+NH4]+

P

Glycerolipids [GL]

TG

191

TG(15:1_18:1_20:4)

864.7239

37.34

865.7432 [M+H]+,
882.7705 [M+NH4]+

P

Glycerolipids [GL]

TG

192

TG(15:1_19:1_21:0)

900.8192

36.38

901.8099 [M+H]+

P

Glycerolipids [GL]

TG

193

TG(16:0_16:0_18:0)

834.7490

35.63

835.759 [M+H]+

P

Glycerolipids [GL]

TG

194

TG(16:0_16:0_18:1)

832.7571

38.05

833.7677 [M+H]+,
850.795 [M+NH4]+

P

Glycerolipids [GL]

TG

195

TG(16:0_16:0_20:0)

862.7800

36.95

863.7988 [M+H]+

P

Glycerolipids [GL]

TG

196

TG(16:0_16:0_20:1)

860.7878

39.24

861.7865 [M+H]+,
878.8138 [M+NH4]+

P

Glycerolipids [GL]

TG

197

TG(16:0_16:0_20:5)

852.7217

36.01

853.7304 [M+H]+

P

Glycerolipids [GL]

TG

198

TG(16:0_16:0_21:0)

876.8193

37.33

877.8151 [M+H]+

P

Glycerolipids [GL]

TG

199

TG(16:0_16:1_18:1)

830.7398

37.03

831.7531 [M+H]+,
848.7804 [M+NH4]+

P

Glycerolipids [GL]

TG
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200

TG(16:0_16:1_20:0)

860.7650

35.80

861.7757 [M+H]+

P

Glycerolipids [GL]

TG

201

TG(16:0_17:0_18:1)

846.7639

38.51

847.7842 [M+H]+,
864.8115 [M+NH4]+

P

Glycerolipids [GL]

TG

202

TG(16:0_17:0_19:0)

862.7923

36.66

863.7944 [M+H]+

P

Glycerolipids [GL]

TG

203

TG(16:0_17:1_18:1)

844.7511

37.57

845.7688 [M+H]+,
862.7961 [M+NH4]+

P

Glycerolipids [GL]

TG

204

TG(16:0_17:2_19:0)

858.7692

36.22

859.7699 [M+H]+,
876.7972 [M+NH4]+

P

Glycerolipids [GL]

TG

205

TG(16:0_18:0_18:1)

860.7833

37.19

861.7865 [M+H]+,
878.8138 [M+NH4]+

P

Glycerolipids [GL]

TG

206

TG(16:0_18:0_18:2)

858.7626

33.42

859.7596 [M+H]+

P

Glycerolipids [GL]

TG

207

TG(16:0_18:0_19:0)

876.8111

36.38

877.8064 [M+H]+

P

Glycerolipids [GL]

TG

208

TG(16:0_18:1_18:1)

858.7677

36.38

859.7753 [M+H]+,
876.8026 [M+NH4]+

P

Glycerolipids [GL]

TG

209

TG(16:0_18:1_18:2)

856.7237

37.17

857.7629 [M+H]+,
874.7902 [M+NH4]+

P

Glycerolipids [GL]

TG

210

TG(16:0_18:1_18:3)

854.7410

38.01

855.7506 [M+H]+

P

Glycerolipids [GL]

TG

211

TG(16:0_18:1_19:0)

874.7090

35.40

875.7938 [M+H]+

P

Glycerolipids [GL]

TG

212

TG(16:0_18:1_20:4)

880.7535

36.38

881.7697 [M+H]+,
898.797 [M+NH4]+

P

Glycerolipids [GL]

TG

TG(16:0_18:1_21:0)

902.8397

37.45

903.8307 [M+H]+

P

Glycerolipids [GL]

TG

214

TG(16:0_18:1_22:5)

906.7685

36.99

907.7853 [M+H]+,
924.8126 [M+NH4]+

P

Glycerolipids [GL]

TG

215

TG(16:0_18:2_19:0)

872.7898

35.15

873.7786 [M+H]+

P

Glycerolipids [GL]

TG

216

TG(16:0_20:1_20:3)

910.7992

36.19

911.7924 [M+H]+

P

Glycerolipids [GL]

TG

217

TG(16:0_20:1_20:5)

906.7627

37.42

907.7791 [M+H]+

P

Glycerolipids [GL]

TG

218

TG(16:0_20:3_20:4)

904.7598

36.53

905.7642 [M+H]+,
922.7915 [M+NH4]+

P

Glycerolipids [GL]

TG

219

TG(16:0_20:3_22:0)

940.8290

37.44

941.8389 [M+H]+

P

Glycerolipids [GL]

TG

220

TG(16:1_16:1_18:2)

826.7050

34.98

827.7170 [M+H]+,
844.7443 [M+NH4]+

P

Glycerolipids [GL]

TG

221

TG(16:1_18:0_18:1)

858.7612

38.09

859.7797 [M+H]+,
876.807 [M+NH4]+

P

Glycerolipids [GL]

TG

222

TG(16:1_18:1_18:2)

854.7364

36.26

855.7544 [M+H]+,
872.7817 [M+NH4]+

P

Glycerolipids [GL]

TG

223

TG(16:1_18:1_18:3)

852.7250

34.31

853.7386 [M+H]+,
870.7659 [M+NH4]+

P

Glycerolipids [GL]

TG

224

TG(16:1_18:1_18:3)

852.7250

36.99

853.7359 [M+H]+

P

Glycerolipids [GL]

TG

225

TG(16:1_18:1_18:4)

850.7100

35.99

851.7212 [M+H]+

P

Glycerolipids [GL]

TG

226

TG(16:1_18:1_19:0)

872.7828

38.56

873.8002 [M+H]+,
890.8275 [M+NH4]+

P

Glycerolipids [GL]

TG

106
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227

TG(16:1_18:1_20:4)

878.7477

37.17

879.7518 [M+H]+

P

Glycerolipids [GL]

TG

228

TG(16:1_18:1_21:0)

900.7260

35.99

901.8149 [M+H]+

P

Glycerolipids [GL]

TG

229

TG(16:1_18:2_19:0)

870.7655

33.94

871.7684 [M+H]+

P

Glycerolipids [GL]

TG

230

TG(16:1_20:0_20:0)

916.6990

35.99

917.8383 [M+H]+

P

Glycerolipids [GL]

TG

231

TG(17:0/17:0/17:0) (IS)

848.7859

39.90

849.8004 [M+H]+,
866.8277 [M+NH4]+

P

Glycerolipids [GL]

TG

232

TG(17:0_17:1_17:1)

844.7571

36.66

845.7641 [M+H]+,
862.7914 [M+NH4]+

P

Glycerolipids [GL]

TG

233

TG(17:0_18:0_22:4)

924.8378

36.61

925.8149 [M+H]+,
942.8422 [M+NH4]+

P

Glycerolipids [GL]

TG

234

TG(17:0_18:1_19:0)

888.7970

37.06

889.8091 [M+H]+

P

Glycerolipids [GL]

TG

235

TG(17:0_20:1_20:2)

926.8346

36.53

927.8312 [M+H]+,
944.8585 [M+NH4]+

P

Glycerolipids [GL]

TG

236

TG(17:1_18:0_18:1)

872.7867

37.68

873.7953 [M+H]+,
890.8226 [M+NH4]+

P

Glycerolipids [GL]

TG

237

TG(17:1_18:1_18:1)

870.7627

37.66

871.7842 [M+H]+,
888.8115 [M+NH4]+

P

Glycerolipids [GL]

TG

238

TG(17:1_18:1_19:0)

886.7810

35.99

887.7927 [M+H]+

P

Glycerolipids [GL]

TG

239

TG(17:2_18:1_18:1)

868.7559

36.66

869.7522 [M+H]+,
886.7795 [M+NH4]+

P

Glycerolipids [GL]

TG

TG(17:2_19:0_19:1)

898.7972

35.34

899.7947 [M+H]+

P

Glycerolipids [GL]

TG

241

TG(18:0_18:0_18:2)

886.7934

39.28

887.8106 [M+H]+,
904.8379 [M+NH4]+

P

Glycerolipids [GL]

TG

242

TG(18:0_18:0_20:2)

914.8398

37.72

915.8251 [M+H]+,
932.8524 [M+NH4]+

P

Glycerolipids [GL]

TG

243

TG(18:0_18:1_19:0)

902.8389

36.75

903.8223 [M+H]+

P

Glycerolipids [GL]

TG

244

TG(18:0_18:1_20:4)

908.7842

35.45

909.7992 [M+H]+

P

Glycerolipids [GL]

TG

245

TG(18:0_18:2_19:0)

900.8172

36.38

901.8099 [M+H]+

P

Glycerolipids [GL]

TG

246

TG(18:0_18:3_19:0)

898.7989

35.34

899.7947 [M+H]+

P

Glycerolipids [GL]

TG

247

TG(18:0_18:4_19:0)

896.7629

35.27

897.7856 [M+H]+,
914.8129 [M+NH4]+

P

Glycerolipids [GL]

TG

248

TG(18:1_18:1_18:1)

884.7876

38.22

885.7913 [M+H]+,
902.8186 [M+NH4]+

P

Glycerolipids [GL]

TG

249

TG(18:1_18:1_18:2)

882.7626

37.30

883.7789 [M+H]+,
900.8062 [M+NH4]+

P

Glycerolipids [GL]

TG

250

TG(18:1_18:1_18:3)

880.7570

38.09

881.7669 [M+H]+

P

Glycerolipids [GL]

TG

251

TG(18:1_18:1_19:0)

900.8165

36.38

901.8099 [M+H]+

P

Glycerolipids [GL]

TG

252

TG(18:1_18:1_19:0)

900.8237

34.52

901.8147 [M+H]+,
918.842 [M+NH4]+

P

Glycerolipids [GL]

TG

253

TG(18:1_18:1_20:4)

906.7689

39.24

907.7834 [M+H]+

P

Glycerolipids [GL]

TG

108

240

109

254

TG(18:1_18:1_20:5)

904.7545

36.47

905.7621 [M+H]+

P

Glycerolipids [GL]

TG

255

TG(18:1_18:2_18:2)

880.7519

35.49

881.7709 [M+H]+,
898.7982 [M+NH4]+

P

Glycerolipids [GL]

TG

256

TG(18:1_18:2_19:0)

898.7470

39.24

899.7947 [M+H]+

P

Glycerolipids [GL]

TG

257

TG(18:1_18:2_20:4)

904.7290

38.31

905.767 [M+H]+

P

Glycerolipids [GL]

TG

258

TG(18:1_18:2_21:0)

926.7410

36.53

927.8306 [M+H]+

P

Glycerolipids [GL]

TG

259

TG(18:1_18:3_18:3)

876.7298

35.33

877.738 [M+H]+

P

Glycerolipids [GL]

TG

260

TG(18:1_19:0_20:4)

922.7986

34.87

923.7946 [M+H]+

P

Glycerolipids [GL]

TG

261

TG(18:2_18:2_18:3)

876.7278

35.07

877.7377 [M+H]+,
894.765 [M+NH4]+

P

Glycerolipids [GL]

TG

262

TG(18:2_18:2_20:4)

902.7410

36.43

903.7538 [M+H]+

P

Glycerolipids [GL]

TG

263

TG(18:2_18:2_20:5)

900.7227

34.40

901.7367 [M+H]+

P

Glycerolipids [GL]

TG

264

TG(18:2_19:0_19:0)

914.8130

37.20

915.8227 [M+H]+

P

Glycerolipids [GL]

TG

265

TG(18:2_19:0_20:3)

922.7470

38.31

923.8011 [M+H]+

P

Glycerolipids [GL]

TG

266

TG(18:2_20:2_20:2)

934.7800

34.98

935.7914 [M+H]+

P

Glycerolipids [GL]

TG

267

TG(20:1_20:1_20:4)

962.8130

36.03

963.8246 [M+H]+

P

Glycerolipids [GL]

TG

aPA= phosphatidic acid; bPC= glycerophosphocholine; cPE= glycerophosphorylethanolamines; dPG= phosphatidylglycerol; ePS=
phosphatidylserine; fDG= diacylglycerol; gTG= triacylglycerol; hP = positive; iN = negative.

2.3.3. Joint pathway analysis
The results from the lipid-gene centric pathway analysis suggested that the key
genes and metabolites were involved in 13 metabolic pathways. The pathways with raw p
£

0.05 were listed in the Table 2.7 and as shown in Fig. 2.4, glycerophospholipid

metabolism pathway was the top-ranking enriched pathway.

2.3.4. Method validation
The intra- and inter-assay precision calculated using 12 spiked internal standards
are shown in Table 2.8. The intra- and inter-assay precision of the method from 7 study

subjects plasma sample by three replicate measurements from one of the sample

preparation and three replicate measurements from three-parallel sample preparations were
£

5% and £ 8% respectively. The results indicate the coefficient of variation of internal

standards are within limits set for fit-for-purpose biomarker research by US Food and Drug
Administration (£ 30%) [29] and the method is reliable to quantitate the lipids using

internal standards.
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Table 2.7. Lipid-gene centric pathways with raw p £ 0.05 of significant lipids with HMDB ID’s

111

No

Pathway

-loge(p)a

Impact
scoreb

KEGG
pathway

AD relevant genes

AD relevant
lipidsc

1

Glycerophospholipid
metabolism

55.598

0.733

map00564

LPLAT1; LPCAT3; LYPLA1; PNPLA6; PLA2G4B;
CEPT1; PLD1; PEMT; PTDSSA; PCYT1A; CHKA;
AGPAT6; LYPLA1; LPCAT3; LCAT

1 - 5, 7, 9 - 12,
14, 15 - 18, 20

2

Ether lipid metabolism

54.231

0.759

map00565

CEPT1; PAFAH1B1; LPCAT4; LPCAT2;
PLA2G4B; PLD1; CEPT1

1 - 5, 7, 9 - 12,
14, 15 - 18, 20

3

alpha-Linolenic acid
metabolism

34.120

0.150

map00592

PLA2G4B

1 - 5, 7, 9 - 12,
14, 15 - 18, 20

4

Linoleic acid
metabolism

34.120

0.375

map00591

PLA2G4B

1 - 5, 7, 9 - 12,
14, 15 - 18, 20

5

Glycerolipid
metabolism

15.591

0.486

map00561

AGPAT6; MGLL; CEL; LPL; MOGAT3

26

6

Arachidonic acid
metabolism

14.492

0.077

map00590

PLA2G4B

1 - 5, 7, 9 - 12,
14, 15 - 18, 20

a-loge(p) = natural log of (p) value calculated from the enrichment analysis (Fisher’ Exact test); bImpact score = pathway impact value calculated
from topology analysis (degree centrality); cAD relevant lipids = refer to Table S1 for significant lipid number designation.

Glycerolipid metabolism

Lipid-gene centric pathway analysis
phospholipid metal olism —►

lipid metabolism

Linoleic acid meta

KEGG:
K01059/ hsa:4023,
is implicated in AD

112

Arachidonic acid metabolism

Drug metabolism- other enzymes
Ilnositol
Steroid Phosphate
metabolism

Sphingolipid metabolism
Butanoate metabolism
<
Retinol metabolismi

0.2

Synthesis apd degradation
of ketone b

0.4

Pathway impact

Figure 2.4. Lipid-gene centric pathway analysis on significant lipids. All matched pathways are plotted according to p-value from
pathway enrichment analysis (Red: higher p-value and yellow: lower p-value) and pathway impact score from pathway topology analysis
(larger the circle higher the impact score) respectively. By selecting the circle displays the overall pathway with matched genes from
the data set.

Table 2.8. Intra- and inter-assay precision of the internal standards spiked in four AD and three NCC study subjects (n = 21)

Lipid
No.
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1
2
3
4
5
6
7
8
9
10

11
12
a

Internal standarda
PA(14:0/0:0)
PE(14:0/0:0)
PC(13:0/0:0)
PG(14:0/0:0)

PS(17:1/0:0)
Cer(d18:1/17:0)
DG(19:0/19:0/0:0)
PE(15:0/15:0)
PS(14:0/14:0)
PG(17:0/17:0)
PC(19:0/19:0)
TG(17:0/17:0/17:0)

Mass
382.1089

tR (min)
4.42

425.2579
453.2887
456.2727
509.3494
551.5320
652.6090
663.4881
679.3678
750.9856
817.6615
848.7859

(PAavgb

Intra assay
± SD) X 105

Inter assay
%RSDc

6.30 ± 0.02

0.3

6.74

2.20 ± 0.04

2

4.45
4.46
7.64
23.76
31.61
19.45
18.08
20.50
26.42
39.90

16.2 ± 0.2
6.6 ± 0.3
4.0 ± 0.1
11.0 ± 0.2
4.6 ± 0.1
11.0 ± 0.1
117 ± 1
2.50 ± 0.01
23.0 ± 0.3
13.0 ± 0.2

1
5
3
2
2
1
1
0.4
1
2

(PAavg ± SD) x 105
6.4 ± 0.2
2.13 ± 0.04
16.0 ± 0.4
6.4 ± 0.5
4.0 ± 0.1
11.3 ± 0.4
5.0 ± 0.2
11.0 ± 0.3
118 ± 1
2.52 ± 0.04
22.6 ± 0.7
13.6 ± 0.5

The concentration of each lipid in final sample for analysis was 1.5 ^M.

bPAavg= average of peak areas of each internal standard across all the study subjects.

c%RSD = (SD/PAavg)x100, relative standard deviation of peak areas of each internal standard in all study subjects .

%RSD
3

2
3
8
3
4
4
3
1
2
3

4

2.3.5. Quantitative lipidomics
Quantitation of the identified and unidentified lipids was performed by assigning
the respective class of spiked internal standards as described in Section 2.2.9.

The

concentrations obtained were multiplied with the dilution factor of 10 to calculate the final
concentrations, expressed in pM. Table 2.3 and Table 2.4 represents the mean measured
micromolar (pM) concentrations of identified and unidentified significant features in NCC

and AD study subjects. Fold changes were calculated by the ratio between the mean

measured micromolar concentrations in NCC to AD. The list of internal standards and
their retention times were listed in Table 2.8.

2.3.6. Unique lipids in AD and NCC
In our study, we found the features unique to each group. A total of 21 features are
unique to NCC whereas 25 features are unique to AD. Table 2.9 and 2.10 summarizes the
unique features in AD and NCC respectively with mean measured micromolar

concentrations (pM).
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Table 2.9. Unique unidentified features common in four AD study subjects (n = 20)
Neutral lipid

Phospholipid
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No.

Mass

tR (min)

_
[X]pLa ± SD

1

162.0791

3.29

1.4 ± 0.3

161.0718 [M-H]-

125.0872

2.77

6.0 ± 0.5

126.0945 [M+H]+

2

162.0867

3.56

1.0 ± 0.2

161.0794 [M-H]-

153.0810

2.77

7.1 ± 0.6

154.0883 [M+H]+

3

220.1129

4.30

1.6 ± 0.4

221.1206 [M+H]+

290.0477

2.92

8±1

291.0550 [M+H]+; 289.0404 [M-H]-

4

375.2932

14.41

4± 1

376.3010 [M+H]+

292.0859

2.82

8.5 ± 0.6

293.0932 [M+H]+

5

519.3318

2.70

2.5 ± 0.4

520.3387 [M+H]+

310.1456

2.96

8.0 ± 0.6

311.1529 [M+H]+; 309.1383 [M-H]-

6

579.4016

7.09

8±4

580.4096 [M+H]+

436.1887

3.72

10 ± 1

437.1960 [M+H]+; 454.2225 [M+NH4]+

7

721.5114

19.80

1.3 ± 0.7

722.5187 [M+H]+; 720.5041 [M-H]-

488.1890

3.06

4.0 ± 0.3

489.1963 [M+H]+

8

800.6723

24.56

2.7 ± 0.3

801.6802 [M+H}+

722.6408

29.22

8±3

723.6481 [M+H]+; 740.6746 [M+NH4]+

9

817.5965

21.44

1.0 ± 0.5

818.6037 [M+H]+; 816.5899 [M-H]-

936.8206

39.49

4±0

937.8279 [M+H}+

10

833.0848

21.92

1.3 ± 0.3

834.0921 [M+H]+

938.8335

40.76

1.7 ± 0.1

939.8408 [M+H]+

11

1055.2989

28.01

1.8 ± 0.3

1056.3062 [M+H]+

954.8065

40.95

1±2

955.8138 [M+H]+

12

962.8310

39.78

1±2

963.8385 [M+H]+

13

964.8523

40.76

4.1 ± 0.1

965.8603 [M+H]+

14

1026.9411

40.97

3.4 ± 0.1

1027.9484 [M+H]+

Precursor ion, m/z

Mass

tR (min)

[X]NLb ± SD

Precursor ion, m/z

a[JC]pL

= mean measure concentration in phospholipid fraction.

b[X]NL

= mean measured concentration in neutral lipid fraction.

Table 2.10. Unique unidentified features common in three NCC study subjects (n = 15)
Neutral lipid

Phospholipid
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No.

Mass

tR (min)

_
[X]pLa ± SD

Precursor ion, m/z

Mass

tR (min)

[X]NLb ± SD

Precursor ion, m/z

1

227.1918

10.33

45± 15

226.9089 [M-H]-

152.1214

3.41

11.0 ± 0.4

153.1923 [M+H]+; 151.0956 [M-H]-

2

260.1260

2.73

1.0 ± 0.1

261.2087 [M+H]+

258.0520

3.15

11 ± 1

259.1024 [M+H]+; 257.0023 [M-H]-

3

298.1579

4.15

1.2 ± 0.6

297.0089 [M-H]-

270.1110

2.86

12 ± 5

271.1206 [M+H]+; 269.0975 [M-H]-

4

334.2273

4.15

0.8 ± 0.2

335.3561 [M+H]+

276.0997

2.71

2.3 ± 0.4

277.1078 [M+H]+; 275.0924 [M-H]-

5

676.5499

17.58

2.0 ± 0.3

368.3486

29.19

1.7 ± 0.3

369.2398 [M+H]+; 367.4927 [M-H]-

6

732.6146

22.04

2.3 ± 0.2

658.5014

25.84

4 ±2

659.5123 [M+H]+; 657.4901 [M-H]-

7

827.5530

18.58

22 ± 14

716.3846

24.25

2 ±1

717.4001 [M+H]+

8

993.7218

23.58

4.4 ± 0.5

720.5062

21.21

7 ±1

721.5135 [M+H]+

9

757.5707

20.30

56 ± 5

758.5780 [M+H]+

10

783.5852

20.91

20 ± 3

784.5925 [M+H]+; 801.6190
[M+NH4]+

11

832.6487

23.20

3.2 ± 0.3

833.6560 [M+H]+

12

834.6629

24.33

4.4 ± 0.2

835.6702 [M+H]+; 852.6967
[M+NH4]+

13

836.6786

25.70

2.4 ± 0.5

837.6859 [M+H]+

677. 6904 [M+H]+; 675.5326 [M
H]733.7290 [M+H]+

828.6006 [M+H]+; 826.4603 [M
H]-

994.7986 [M+H]+

a[JC]pL

= mean measure concentration in phospholipid fraction.

b[X]NL

= mean measured concentration in neutral lipid fraction.

2.4.

Discussion

2.4.1. Optimization of sample preparation and UHPLC-QTOF-MS/MS
Total lipids extracted and fractionated from plasma samples were analyzed as

described in sections 2.2.3 and 2.2.4. The Bligh-Dyer method was modified by acidifying
the samples with 1 N HCl for higher recoveries of the acidic lipids. Two-step sample

separation was performed on the extracted total lipids. In the first step, the total lipids were
fractionated using aminopropyl SPE, to separate the interfering analytes and thus reducing
the matrix interference and ion suppression in MS analysis for the detection of low

abundant lipids. Secondly, liquid chromatography was performed on each fraction for the

separation of the analytes and to eliminate the isobaric overlap.

Different percent

compositions of isopropyl alcohol in mobile phase B were tested to minimize the column
carry over in the gradient profile. Based on the analyte structure, they require different
collision energies to generate adequate MSMS fragments. So, collision energies of 10, 20
and 40 eV were used to get MS/MS spectra which were summed and used for the

unambiguous identification of the analyte against the database.

2.4.2. Comparison of Up- and Down regulated lipids in AD
In the current study, our results indicate an overall trend in abundance for LPC

(NCC < AD), PC (NCC >AD), SM (NCC > AD), GlcCer (NCC >AD) and TG (NCC <
AD). These lipid species belong to three major categories i.e., glycerophospholipids,
sphingolipids and glycerolipids. The pathways referenced in this section are from Kyoto

Encyclopedia

of

Genes

and

Genomes

(https://www.genome.jp/kegg/pathway.html ) [30]

117

(KEGG)

database

for

human

2.4.2.1 Glycerophospholipids (GP)
In AD (map05010, Fig. 2.7), the Wnt signaling pathway (map04310, Fig. 2.8) is

affected which in turn affects the MAPK signaling (map04010) and Ras signaling

(map04014) pathways leading to increased activation or levels of PLA2 (entry: K01047).

The elevated levels of PLA2 cause the dysregulation in the glycerophospholipid
metabolism pathway (map00564, Fig. 2.5, 2.6 and 2.9).

To maintain the neuronal

membrane integrity and normal cellular events, LPC is generated transiently during the
deacylation and reacylation cycle. LPCs are generated by the action of phospholipase A2

(PLA2,3.1.1.4 in map00564, Fig. 2.9) on PCs, releasing the fatty acid from its sn-2 position.

Studies have reported the increased levels of PLA2 in AD plasma [31-33]. From our
results, we report the increased levels of LPCs (LPC 16:0; LPC 18:0; LPC 18:1; LPC 20:4)

(Table 3) along with the LPC 18:2 reported in previous study [19]. LPCs are not only the

intermediate products in the metabolism of glycerophospholipids but also serve as

mediators in many pathways involved in AD [34]. LPC 16:0 is a precursor for the platelet
activating factor (PAF), an important mediator in inflammation-related processes [35].
LPC 20:4 serves as a precursor for the mediators involved in the immune response via

arachidonic acid metabolism pathway. Further investigation is required to validate whether
the catabolic or the anabolic stimulation leads to the elevated levels of these lipids in AD
plasma [20]. PLA2 is also involved in ether lipid, arachidonic acid, linoleic acid, alpha

linolenic acid metabolism pathways.

Fatty acid composition in membrane

glycerophosphocholine lipids influences their biophysical properties like permeability,
charge, and fluidity [14].

In AD plasma, decreased concentrations of PCs with

polyunsaturated fatty acid (PUFA)
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tails were observed (Table 3) [21,36]. Decreased levels of alpha-linolenic acid (18:3, n-

3), eicosapentaenoic acid (EPA) (20:5, n-3) and docosahexaenoic acid (DHA) (22:6, n-3)
containing PCs were observed [37]. These fatty acids are utilized in the generation of anti
inflammatory and neuroprotective metabolites like docosanoids [38]. In neurons at cell
junction, lipid raft contains a high concentration of lipids with docosahexaenoic acid

(DHA) fatty acid tail. Disruption to the lipid raft leads to loss of communication between
the neurons, causing a decline in cognition. Randomized trial of DHA administration
showed an increase in cognition in AD, relating DHA to cognition in AD [39,40]. Studies

have reported the release of arachidonic acid (AA) (20:4 n-6) implicates the activation of
the immune system, which is common in AD pathophysiology. AA generates a wide
variety of eicosanoids mediators which cause neuroinflammation [14].
2.4.2.2. Sphingolipids (SL)

Sphingolipids play an important role in many biological functions like cell

growth, differentiation, senescence and apoptosis [41,42]. In our study, we found the
decreased levels of sphingomyelins (SM) and neutral glycosphingolipids in AD plasma.
Our results from the lipid-gene centric pathway analysis suggested that the associated

genes and lipids were involved in sphingolipid metabolism, however it did not meet the
criteria of p £ 0.05.

In AD, it is evident that the sphingolipid signaling pathway

(map04071, Fig. 2.10) is affected via phosphatidylinositol phospholipase C (PLC, entry:
K05858). Previous studies have reported that amyloid-b induces the increased activity of

neutral sphingomyelinase (N-SMase) in oligodendrocytes of the brain in AD patients [43].

The post-mortem on brain from AD patients showed decreased sphingomyelins
(SM) and increased ceramide (Cer) accumulation. Mediators (AA, eicosanoids, PAF)
119

generated by the PLA2also stimulates sphingolipid signaling pathway by activating SMase
[41].
2.4.2.3. Glycerolipids (GL)

In our study, we found the increased levels of triacylglycerols (TG) in AD plasma

suggesting the changes in the glycerolipid metabolism pathway (map00561, Fig. 2.11).

These changes were related to lipoprotein lipase (LPL, entry: K01059) which is associated
with the ApoE gene in AD [44]
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Fig 2.5. A) Increased activity or expression of PLA2 in Alzheimer’s disease via
MAPK/Ras signaling pathways. B) Conversion of phosphocholine to lysophosphocholine
by the action of PLA2
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Fig 2.6. Increased activity or expression of PLA2 in AD via Ras signaling pathway.
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Figure 2.7. Alzheimer’s disease pathway (map05010) from the KEGG database indicating the implicated disease genes (pink), drug
targets (blue), disease gene-drug target (pink | blue) and organism specific pathways (green). The red text genes indicates the perturbed
and implicated genes in the AD. Circled genes implicate the glycerolipid metabolism (red), Ras signaling pathway and sphingolipid
signaling pathway (purple) [30].
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Figure 2.8. Implication of \\\ Signaling pathway (map04310) in AD. Circled genes activates the MAPK and Ras signaling (black) and
sphingolipid signaling pathway (purple) which in-turn implicate glycerophospholipid metabolism [30].

| GLYCEROPHOSPHOLIPID METABOLISM

|

Q Glycerolipid metabolism")

2,3-Bis-(O-gpranylgpranyl)_______
_________ sn-glycerol-1P
1.5.1.41 12.5.1.42|—»-O1 2.7.7.671—^012.7.8.381—•

sn-Glycerol-lP

2,3-Bis-O-(geranylgeranyl).ajtglycero- I-phospho-E-seiine

^£2
2.3.1.43
,. .
° l

sn-Glyceiol-3P

1.1.1.94

Glycerone-P

2,3-Bis-(O-phytanyl)A sn-glycerol-lOPhosphatn^rlcholme|

7.7.39(-►O

^3.1.1.^

,o 1-Acyl-sn-glyceroI I3-phosphochohne
3.1.4.2

LPCAT

f

sn-glycero-3Phosphocholine

AcyhCoA

1.1.53

I 2.1.1.711
[23;.1.421

1-Acylglycerone-3P

12.3.1.15

1.1 1.101b

2.3.12751 | 23.1.198 |

1-Acylsn-glycerol-3P

1

1 r 2-Acylq sn-gJycerol-3P

CDP-choline

■ O O-Acetylcholine

Choline

BTA1
Monomethyl- 1

BTA1

BtaA

DGHS

phosphatidvl- y

[2G L52]

ethanolamine

BtaB

*“O
DGTS

Phosphodimethylethanolamine

| 2.1. .1031

J

3.1.3.4

1,2-Diacylsn-glycerol-3P

J 2.3.1.6

I 2111031

| Ptdssl |

(^Ether lipid metabolism")

2-Acyl-sn-glycero3-phosphocnoline
Phospho-

2.7.8.2
Dimethyl
| 31.4.3
phosphatidyl- A
ethanolamine

Acyl-CoA

1,2-Diacylsn-glycerol

3.1.3.81

------------ t>QPynivate metabolism))

N-Methylethanolamine phosphate

L-Serine-phosphoethano lamine

I <-

| 2.1. .1031

,

125

2.7.1.82

GPI-anchor biosynthesis')

c----------------------

| 3.6.1.26

LFIAT

1 2.7.8.111
IphosphatidylI lD-myo-inositol
!

ethanolamine

| 3.1.4.3
oto i I
J ° 1 I

1 -Acyl-sn-gjycero3-phosphoserine

2.7.7.41|

3.1.1.52

►O

TT

sn-glyceio3-Fnos_phoethanolamine

—£~o-----

4.1.1.65
Phosphatidyl-^
ethanolamine I I

Phosphatidyl
L-senne

inositol phosphate metabolism)

Phospho
ethanblamine

3.13.75

=►0K--'Ethanolamine

Diethanolamine

Triethanolamine

l-Acyl-sn-glycero-3phosphoethanolamine

H LPSAT |—O
CDP-diacylL
glycerol --------------O ----------------1 2.7.8.8

< Aceti

143'1.71T
I 2.7.8 4 |

3.1.4.4

5

---------- oQjlycolysis))

2.7.1.107
2.7.1.174

1 -Acyl-sn-glyceio3-phosphoinositol

O
sn-Glycerol-3P

3.1.4.46

1.1.3.21

3.1.4.2

3.1.4.46

-------_
sn-Glycerol-3P

I 2-7 8.5 |

I 3.1 3.271
I1GLAT

CLD1
Monolysocaidiohpin

■

I PhosphatidylT glycerol

Cardiolipin

3.1.43

—----- 2.7.8.41
3.1.4-

ClsA/B
ClsC

2-Acyl-sn-glyceio-3phosphoethanolamine

2-Acyl-sn-glycero3-phosphoserine

▼ Phosphatidyly glycerophosphate

„ 1,2-Diacylsn-glyceiol

0

Glycine, serine and

i

threonine metabolism J

Aminoacyl‘O phosphaf idylglycerol

|lpgat|

Lysophosphatidylglyceiol
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acid, linoleic acid, alpha-linolenic acid metabolisms. Our results from gene- lipid centric pathway analysis also indicate the same as
represented in Table 2.7 [30].

Figure 2.10. Circled genes
implicate the sphingolipid
signaling
pathway.
Increased activity of NSMase in AD leads to
decreased concentration of
sphingomyelins impacting
sphingolipid
signaling
pathway [30].
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Figure 2.11. Lipoprotein
lipase (LPL) gene is related
to ApoE gene which is
implicated in AD. Increased
levels of TG is associated
with LPL (circled in red) in
glycerolipid
metabolism
[30].
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2.5.

Conclusion
In our study, we detailed the workflow for UHPLC-QTOF-MS based lipidomics to

identify the lipid biomarkers in human plasma. We employed 12 lipid internal standards
representing major sub-classes of plasma lipidome for data normalization and semi

quantitation.

We found greater variation in the PL fraction between NCC and AD,

suggesting perturbations in phospho lipidome.

Our study showed 28 potential lipid

biomarkers related to phosphocholines, sphingomyelins, neutral glycosphingolipids, and

triacylglycerols. Lipid-gene centric pathway analysis suggested the implicated pathways
are either directly or indirectly related to AD.

Limitations to our study also warrant consideration. The small sample size limited
this study to account for the interference from systemic metabolism and the stage of disease
development. Further investigation is required to validate the results in a larger cohort of

samples. However, this pilot study was intended to investigate AD plasma lipidome and
stimulate further studies in AD.
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CHAPTER III

AN LC-MS/MS METHOD FOR DETERMINATION OF O6-BENZYLGUANINE AND

ITS METABOLITE O6-BENZYL-8-OXOGUANINE IN HUMAN PLASMA

3.1

Introduction
The resistance mechanisms developed by the tumor cells pose a major challenge in

the clinical treatment of various types of tumors such as malignant melanoma, malignant

glioma, and lymphomas [1,2]. The most important resistance mechanism is mediated by
the DNA-repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT) which plays an

important role in the protection of tumor cells from the cytotoxicity of alkylnitrosoureas
and methylating agents [3-6]. Increased AGT activity was reported in human solid tumors
such as colon cancer, melanoma, lung cancer, etc. Studies have shown that the inactivation

of AGT leads to the enhancement of the cytotoxic effects of chloroethyl nitrosoureas (e.g.,

carmustine) and methylating agents (e.g., dacarbazine and temozolomide) [7-9].
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O6-benzylguanine (O6BG) is known to irreversibly inhibit cellular AGT activity;

thus, it helps to increase the cytotoxic sensitivity of tumor cells to alkylating agents and
halts the repair of the damaged DNA bases as shown in Fig. 3.1A. In vivo, O6BG is rapidly
metabolized into O6-benzyl-8-oxoguanine (8-oxo-O6BG) (Fig. 3.1B) which is equally

potent inhibitors of AGT [10-14]. Therefore, to evaluate the efficacy of O6BG, both O6BG
and 8-oxo-O6BG must be measured simultaneously. Up to date, 34 clinical trials of O6BG

have been reported for various cancer treatments across the world at various phases of
studies

(https://clinicaltrials.gov/ct2/results?cond=&term=O6-

benzylguanine&cntry=&state=&city=&dist= , accessed 25 July 2019). The goal of this
work is to develop and validate an LC-MS/MS method for the measurement of O6BG and

8-oxo-O6BG in clinical samples. Although there were previously developed LC-DAD
methods available, these methods suffered interference from endogenous components and
other interfering drugs in plasma samples [15-17]. Furthermore, these LC-DAD methods
used 500 gL aliquot of plasma and required 12.5 times of pre-concentration prior to sample

analysis [15-17]. Since mass spectrometric detector possesses the unparalleled selectivity

and specificity over those of diode array detector, the aforementioned problems of LCDAD methods can be easily overcome.

In this work, we described the development and validation of a rapid and sensitive
LC-MS/MS method for the quantitation of O6BG and 8-oxo-O6BG in human plasma. It
uses 10.0 gL aliquot of human plasma, which is well-suited for pediatric studies with

compared to the previously reported studies where 500 gL of pediatric plasma were used
[18]. The developed method was applied for the measurement of O6BG and 8-oxo-O6BG
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in human plasma samples from the prior phase I clinical trial. This method is the first fully
validated LC-MS/MS method for the determination of O6BG and 8-oxo-O6BG.

3.2

Experimental

3.2.1. Chemicals and materials
The reference materials of O6BG and 8-oxo-O6BG in powder form were purchased

from Sigma-Aldrich (St. Louis, MO, USA) and Toronto Chemical Research (North York,
ON, Canada), respectively. O6-(p-chlorobenzyl)guanine (pCl-O6BG) used as internal

standard (IS) was supplied by Dr. Robert Moschel, Frederick Cancer Research, and
Development Center (Frederick, MD, USA). ACS-reagent-grade formic acid, sodium
hydroxide, and ethyl acetate were purchased from Sigma-Aldrich.

LC/MS-grade

acetonitrile and LC/MS-grade methanol were purchased from Fischer Scientific
(Pittsburgh, PA, USA). The pooled and six individual lots (Lot No.: 1M2070-02, 1M2070-

04, 1M2070-06, 1M2070-05, 1M2070-03, 1M2070-01) of blank human plasmas were
purchased from Innovative Research (Novi, MI, USA).
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Figure 3.1. (A) Inhibition of DNA repair enzyme O6-alkylguanine-DNA alkyltransferase
(AGT) by O6BG , and (B) metabolism of O6BG to 8-oxo-O6BG.
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3.2.2.

Solutions
The stock standard solutions of O6BG, 8-oxo-O6BG, and pCl-O6BG (IS) were

prepared at 1.00 mg/mL by dissolving the appropriate amount of each compound in a
known volume of methanol. The working stock standard solutions of O6BG, 8-oxo-O6BG,
and pCl-O6BG (IS) were prepared at the concentrations of 200, 250 and 10.0 |ig/mL
respectively by the serial dilution of each stock with methanol. All the stock and the

working stock standard solutions were stored at -70° C in glass vials before use.

The solvent-mixed working standard solutions containing O6BG/8-oxo-O6BG at
the concentrations of 4.00 x 104/1.60 x 105, 5.00 x 103/2.00 x 104, 3.75 x 103/1.50 x 104,

2.50 x 103/1.00 x 104, 1.25 x 103/5.00 x 103, 5.00 x 102/2.00 x 103, 250/1.00 x 103,
125/500, 75.0/300, 50.0/200, and 25.0/100 ng/mL were prepared by mixing the appropriate

volumes of the working stock solutions in a known volume of methanol. The IS working
solution of pCl-O6BG was prepared at a concentration of 2.00 x 103 ng/mL by diluting the

IS stock solution with a known volume of methanol. The mobile phase was prepared by

mixing 80% acetonitrile and 0.05% formic acid in water (v/v). The solvent-mixed QCs

(low, mid, high, and dilution) of O6BG/8-oxo-O6BG at the concentration of 3.75/15.0,
25.0/100, 188/750, 2.00 x 103/8.00 x 103 ng/mL were prepared at room temperature by

adding 5.00 uL each of the respective solvent-mixed working standard solution to 95.0 uL
of the mobile phase in individual borosilicate glass tubes (13.0 x 100 mm), then vortexed
for 5 s using MaxiMix II vortex mixer from Thermo Scientific.
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3.2.3.

Preparation of plasma calibrators and quality controls (QCs)

Plasma calibrators of O6BG/8-oxo-O6BG at the concentrations of 1.25/5.00,
2.50/10.0, 6.25/25.0, 12.5/50.0, 25.0/100, 62.5/250, 125/500, 250/1.00 x 103 ng/mL and
the plasma QCs (low, mid, high and dilution) at the concentrations of 3.75/15.0, 25.0/100,

188/750, 2.00 x 103/8.00 x 103 ng/mL were prepared at room temperature by adding 5.00

|iL each of the respective solvent-mixed working standard solution to 95.0 uf of the pooled
blank human plasma in individual borosilicate glass tubes (13.0 x 100 mm), then vortexed

for 5 s using MaxiMix II vortex mixer from Thermo Scientific. The calibrators and QCs
were stored at -70° C before use. It is worth noting that the solvent-mixed working standard
solutions for calibrators and QCs were prepared from two sets of independently prepared
stock solutions of O6BG and 8-oxo-O6BG.

3.2.4.

Sample preparation
Prior to extraction, patient samples, calibrators, and QCs stored at -70°C were

thawed unassisted on ice. After vortexing, 10.0 |iL aliquot of each patient plasma was

mixed with 90.0 |iL of the pooled human plasma to prepare 100 |iL of a diluted patient
sample in individual borosilicate glass tubes (13.0 x 100 mm). Then, 5.00 |iL of the IS
working solution was added to each 100 |iL aliquot of the diluted patient samples,

calibrators, and QCs in borosilicate glass tubes. All these glass tubes were vortexed for 5
s using a Multi-Tube Vortex Mixer from Troemner Precision Weights and Laboratory

Equipment (Thorofare, NJ, USA) followed by the addition of 50.0 |iL of 0.100 M sodium
hydroxide solution and vortexed for another 5 s. These samples were subjected to liquid
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liquid extraction with ethyl acetate (1.50 mL to each tube) and vortexing for 5 min,
followed by centrifugation at 1800 x g to facilitate phase separation. The top layer of
organic content was transferred to another borosilicate glass tube and dried under nitrogen

(15 psi) in a TurboVap LV evaporator from Caliper Life Sciences (Hopkinton, MA, USA)
at 30°C for 15 min. The residue was reconstituted in 100 |iL of the mobile phase and

subjected to LC-MS/MS analyses.

3.2.5.

LC-MS/MS system
The LC-MS system used for this work consisted of an LC-20AD HPLC unit with

SIL-20AC autosampler from Shimadzu Scientific Instruments (Columbia, MD, USA) in
conjunction with a Symmetry Shield RP18 column (2.1 mm x 100 mm, 3.5 |im) from
Waters Corporation (Milford, MA, USA), and an API 3200 turbo-ion-spray triple

quadrupole tandem mass spectrometer from AB Sciex (Foster City, CA, USA). The LCMS system was controlled by AB Sciex Analyst software (version 1.5.1) which was used

for both data acquisition and processing. The autosampler was maintained at 4°C with an

injection volume of 5.00 |1L of the reconstituted sample. Prior to sample analysis, the
column was equilibrated with the mobile phase at a flow rate of 0.600 mL/min for 10 min.

The analytes were then separated by the column and detected by the mass spectrometer
with a total run time of 5 min per sample.

The mass spectrometer was operated in the positive turbo-ion-spray ionization
mode. The molecular ions and its fragmentation pattern of O6BG, 8-oxo-O6BG and for

pCl-O6BG were determined using a solvent mixed standard solution at each concentration
of 500 ng/mL. Flow injection analysis was used for the optimization of the compound
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dependent (i.e., declustering potential, entrance potential, collision energy, collision exit
potential) and the source-dependent (i.e., curtain gas, collision assisted dissociation gas,

ionization voltage, source temperature, sheath gas, desolvation gas). The mass transitions
used for multiple-reaction-monitoring (MRM) mode were m/z 242.2 > 91.1 for O6BG, m/z

258.2 > 91.1 for 8-oxo-O6BG, and m/z 276.1 > 125.1 for pCl-O6BG. The optimized
parameters of the mass spectrometer were as follows: declustering potential at 50 V;
entrance potential at 10 V, collision energy at 30 psi, collision exit potential at 13 V, curtain

gas at 45 psi, collision assisted dissociation gas at 5 psi, ionization voltage at 5500 V,
source temperature at 600°C, sheath gas at 35 psi, desolvation gas at 45 psi, and the

quadrupole resolutions (Q1 and Q2) were set at unit. The LC column eluate was diverted
to waste at 3.20 min and returned to mass spectrometer at the beginning of each run using
a program-controlled switching valve of the instrument.

3.2.6.

Method validation

3.2.6.1. Selectivity and lower limits of quantitation (LLOQs)

The experiments were performed to determine the selectivity and LLOQs of the

method at the retention times and mass transitions of O6BG, 8-oxo-O6BG, and pCl-O6BG.
Six lots of blank human plasmas and corresponding plasma calibrators at LLOQ were used,
which were prepared by the sample extraction procedure described in Section 3.2.4 and

analyzed by five replicates per sample
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3.2.6.2. Recovery and matrix factor (MF)

The absolute recovery of O6BG or 8-oxo-O6BG (or the IS) was determined by the

mean peak area of O6BG or 8-oxo-O6BG (or the IS) at a specific concentration in human
plasma over the mean peak area of O6BG or 8-oxo-O6BG (or the IS) at the same
concentration in the extracted human plasma multiplying 100%.

The IS normalized

recovery was determined by the absolute recovery of O6BG or 8-oxo-O6BG over that of

the IS multiplying 100%. For this study, O6BG/8-oxo-O6BG QCs at three concentrations

(3.75/15.0, 25.0/100, 188/750 ng/mL) with a fixed concentration of the IS (100 ng/mL)

were prepared in the pooled blank human plasma and the corresponding matrices of
extracted pooled blank human plasma.

The absolute MF of O6BG or 8-oxo-O6BG (or the IS) was determined by the mean
peak area of O6BG or 8-oxo-O6BG (or the IS) at a specified concentration in the extracted
blank human plasma over that of O6BG or 8-oxo-O6BG (or the IS) at the same

concentration in the mobile phase. The IS normalized MF was determined by the absolute
MF of O6BG or 8-oxo-O6BG over that of the IS. For this study, O6BG/8-oxo-O6BG QCs
at three concentrations (3.75/15.0, 25.0/100, 188/750 ng/mL) with a fixed concentration of

the IS (100 ng/mL) were prepared in the six individual lots of blank human plasma and the

mobile phase.

3.2.6.3. Calibration curve

The calibration curves of O6BG and 8-oxo-O6BG were obtained using a double
blank human plasma (contains neither the analytes nor the IS), a single blank human plasma
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(contains only the IS) and eight non-zero human plasma calibrators (with the IS)
for O6BG/8-oxo-O6BG at the concentrations of 1.25/5.00, 2.50/10.0, 6.25/25.0, 12.5/50.0,
25.0/100, 62.5/250, 125/500, 250/1.00 x 103 ng/mL.

These calibration curves were

constructed by plotting the corresponding peak area ratios of O6BG or 8-oxo-O6BG to that

of the IS as y-axis versus the respective concentrations of O6BG or 8-oxo-O6BG as x-axis
by linear regression with 1/x2 weighting.

3.2.6.4. Accuracy, precision and dilution study
The intra-assay accuracy and precision were assessed by five replicate analyses

of each QC sample of O6BG/8-oxo-O6BG at three different concentrations (3.75/15.0,
25.0/100, 188/750 ng/mL) in the same validation batch. The inter-assay accuracy and
precision were evaluated by five parallel analyses of five identical QC samples of O6BG/8-

oxo-O6BG at the three QC concentrations over five validation batches. Accuracy and
precision were expressed as percent error (%RE) and coefficient of variation (CV). These

studies were also conducted on the dilution QCs (O6BG/8-oxo-O6BG; 2.00 x 103/8.00 x

103 ng/mL), where they were prepared after 10-fold dilution using the pooled blank human

plasma.

3.2.6.5. Stability studies
The stabilities of O6BG and 8-oxo-O6BG were investigated using the stock
standard solutions of O6BG and 8-oxo-O6BG (1.00 mg/mL each), and the low and high

plasma QCs of O6BG and 8-oxo-O6BG (3.75/15.0 and 188/750 ng/mL).

The stock

standard solutions were diluted according to the procedure described in Section 3.2.2 and
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used to prepare the low and high solvent-mixed QCs of O6BG/8-oxo-O6BG (3.75/15.0 and

188/750 ng/mL) in the mobile phase prior to the instrumental analyses.

The stabilities of the stock standard solutions and the plasma QCs were assessed
for short-term placement (6 and 24 h) on bench-top at 23°C and in the autosampler at 4°C

(post preparative); three freeze-thaw cycles (where the samples were frozen at -20°C for at
least 24 h and thawed at room temperature, 23°C, unassisted); and long-term storage (65

days) at -70°C. The stabilities of O6BG and 8-oxo-O6BG were determined with five

replicates by comparing the mean-peak-area ratios of analytes to IS in the test sample to
those of freshly prepared samples and expressed as percent recoveries.

3.2.7.

Method application

The method developed was tested using the leftover patient samples from a
previous phase I clinical trial of O6BG (Stefan et al., 1996, 1997). Based on the clinical
trial protocol, each patient received a 1-h bolus IV infusion of O6BG at a dose of 23.5
mg/m2. Blood samples were drawn from each patient prior to the infusion, and at intervals

of 15 min during the 1-h infusion; then, blood samples were drawn post-infusion at 5 min

intervals for 20 min, and at 30, 45, 60, 90 and 120 min, and subsequently at 4, 6, 8 12 and
24 h. Plasma samples were harvested from whole blood by a refrigerated centrifuge, and

then stored at -80°C until analysis.
In clinical sample analysis, patient samples together with 10 calibrators (i.e. double-

and single-blank, and eight nonzero) and a set of QCs at low, medium and high

concentrations were prepared according to the procedures described in the Section 3.2.4,
then analyzed by the procedure in the Section 3.2.5. The concentrations of patient samples
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were back-calculated based on the dilution factor applied to the samples which was 10 in
this work.

Results and Discussion

3.3

.

3.3.1.

Method development

3.3.1.1. Sample preparation and extraction
In this work, plasma samples were thawed on ice to maintain the endogenous

enzymatic activity at a minimal rate and to avoid interconversion between O6BG and 8oxo-O6BG. Due to the relatively high concentrations of O6BG and 8-oxo-O6BG in patient

samples in the O6BG clinical trial (Stefan et al., 1997), only 10 uL of patient plasma was
needed for instrumental analysis, which was subsequently diluted by 10 folds using the

pooled blank plasma. This feature of the method would be advantageous for pediatric
patients in comparison to the reported pediatric study of O6BG (Neville et al., 2004b),
where 500 |iL of each plasma sample was used.

Prior to extraction, alkalinization of the plasma sample in 0.100 M sodium

hydroxide was performed to deprotonate the analytes and to improve extraction efficiency.
Ethyl acetate was chosen as the organic solvent for extraction of O6BG, 8-oxo-O6BG, and

pCl-O6BG, which had been proven to be effective in the previous studies (Stefan et al.,
1996, 1997).
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3.3.1.2. Mass spectrometric detection
Since O6BG, 8-oxo-O6BG and pCl-O6BG can be protonated more easily than be
deprotonated in mass spectrometry under acidic condition; therefore, positive ionization

spectra were acquired in this work. As shown in Fig. 3.2 (A, C and E), the predominated

molecular ions of O6BG, 8-oxo-O6BG and pCl-O6BG were at m/z 242.2, m/z 258.2, m/z
276.1, respectively. These protonated molecular ions could be further fragmented in the

collision cell of the triple quadrupole mass spectrometer by nitrogen gas and produced the
predominant product ions at m/z 91.1 (tropylium cation, a fragment often found in aromatic

compounds containing a benzyl unit) for both O6BG and 8-oxo-O6BG, and m/z 125.1 for

pCl-O6BG (Fig. 3.2.B, D and F). Hence, the mass transitions at m/z 242.2 > 91.1 for O6BG,
m/z 258.2 > 91.1 for 8-oxo-O6BG, and m/z 276.1 > 125.1 for pCl-O6BG were used for

quantitation of O6BG and 8-oxo-O6BG using MRM mode
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Figure. 3.2. The representative MS and MS/MS spectra of O6BG (A and B), 8-oxo-O6BG
(C and D) and pCl-O6BG (E and F).
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3.3.1.3. Liquid chromatographic separation
To achieve baseline resolution of the analytes and IS, different column chemistries

and mobile phase compositions were investigated. Most of the columns tested resulted in

broad and tailing peaks. The desirable peak shape with baseline separation of O6BG, 8oxo-O6BG and pCl-O6BG were achieved by isocratic elution on Waters Symmetry Shield

RP18 column (2.1 mm x 100 mm, 3.5 |im) using the mobile phase consisting of 80%
acetonitrile and 0.05% formic acid in water. As shown in Fig. 3.3, the retention times of
the analytes (O6BG and 8-oxo-O6BG) were at 0.70 min, 2.60 min, and the IS (pCl-O6BG)

was at 1.80 min between the two analytes. In comparison to the previous method (Stefan
et al., 1997), the method developed not only achieved the baseline resolution of all analytes

with a much simpler elution profile, but also reduced the total run time from 11 min to 5
min.
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Figure. 3.3. The representative mass chromatograms of O6BG, 8-oxo-O6BG, and pCl-O6BG in the following
samples: double blank pooled human plasma (A, B and C); blank pooled human plasma (D, E and F); human plasma
at LLOQ (G, H and I); and a patient sample at 15-min time point (J, K and L).

3.3.2.

Method validation

3.3.2.1. Selectivity and LLOQs
The selectivity of the method developed as illustrated in Fig. 3.3A, B and C,

where there were no detectable interferences at the mass transitions and retention times of
O6BG, 8-oxo-O6BG and pCl-O6BG from the six individual lot blank plasmas and the
pooled blank plasma, as well as from patient plasma before infusion of O6BG.

Furthermore, there were no detectable interferences from pCl-O6BG at the mass transitions
and retention times of O6BG, 8-oxo-O6BG (Fig. 3.3D, E, and F).

The LLOQs of the method defined as the lowest concentrations of plasma

calibrators (Fig. 3.3G and H) were 1.25 ng/mL for O6BG and 5.00 ng/mL for 8-oxo-O6BG.
As shown in Table 3.1, the accuracy and precision of the method at LLOQs from six

individual lots of blank human plasma by five replicate measurements of each sample were
£

±2% and £ 6% for O6BG, and £ ±6% and £ 5% for 8-oxo-O6BG, respectively. These

numbers were smaller than those of the industry limits set by US Food and Drug
Administration (£ ±20 and £ 20%) and implied that the actual LLOQs of the method could

be lower if they were needed.
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Table 3.1. Accuracy and precision of O6BG and 8-Oxo-O6BG at LLOQ in six individual lots of human plasma (n = 5)

Plasma
matrix
Lot 1
Lot 2
Lot 3
Lot 4
Lot 5
Lot 6

[XN]a (ng/mL)
1.25
1.25
1.25
1.25
1.25
1.25

O6BG
[X]b ± SDc (ng/mL)
1.24 ± 0.05
1.22 ± 0.07
1.24 ± 0.02
1.23 ± 0.06
1.24 ± 0.08
1.24 ± 0.02

CVd (%)
4
6
2
5
6
2

REe (%)
-1
-2
-1
-2
-1
-1

[Xn] (ng/mL)
5.00
5.00
5.00
5.00
5.00
5.00

8-oxo-O6BG
[X] ± SD (ng/mL)
4.7 ± 0.2
5.1 ± 0.2
5.1 ± 0.2
5.2 ± 0.1
5.3 ± 0.1
5.1 ± 0.2
_— _

CV (%)
5
3
4
2
2
3
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a [XN] = nominal concentration of analyte in plasma calibrator; b[X] = mean measured concentration of analyte; cSD = standard
deviation of replicate measurements; dCV (%) = {SD/[X]} x 100%; eRE = {([X] - [Xn])/ [Xn]}x 100%.

RE(%)
-5
2
2
4
6
2

3.3.2.2. Recovery and matrix effect
Recovery is a measure of an extraction efficiency of an analytical method within

the limits of variability. The recoveries of O6BG and 8-oxo-O6BG at three different QC

concentrations in human plasma were summarized in Table 3.2. The absolute recoveries

of O6BG and 8-oxo-O6BG ranged 86-97% and 86-92%, respectively; whereas the IS

normalized recoveries of O6BG and 8-oxo-O6BG ranged 90-96% and 90-99%. These
results showed that ethyl acetate was a decent organic solvent for LLE for this work. The
recoveries of analytes were consistent across the QCs and the IS normalized recoveries

were closer to 100%.
Matrix effect is the effect of the coextracted matrix on the analytical signals which
could be either suppressed or enhanced. If it is not corrected, the matrix effect could result

in poor analytical accuracy, linearity, and reproducibility. The matrix effect in this work
was assessed by matrix factor (MF). As shown in Table 3.3, the absolute MFs of O6BG
and 8-oxo-O6BG ranged 0.96-1.02, and 0.93-1.05, respectively; whereas the IS normalized
MFs of O6BG and 8-oxo-O6BG ranged 0.95-1.06, and 0.91-1.06. These results indicated
the matrix effects on the analytical signals were negligible, which further proved the
sample extraction procedure was practically effective.
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Table 3.2. Recovery of O6BG and 8-oxo-O6BG in human pooled plasma (n = 5)

O6BG
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[Xn]
(ng/mL)
3.75
25.0
188

RecoveryXa ±
SD (%)
97 ± 2
86 ± 1
89 ± 3

RecoveryISb
± SD (%)
102 ± 4
96 ± 4
93 ± 3

8-oxo-O6BG

IS Normalized
Recovery0 ± SD (%)
95 ± 6
90 ± 5
96 ± 6

[Xn]
(ng/mL)
15.0
100
750

RecoveryX ± SD
(%)
92 ± 2
86 ± 2
92 ± 2

RecoveryIS ±
SD (%)
102 ± 4
96 ± 4
93 ± 3

IS Normalized
Recovery ± SD (%)
90 ± 5
90 ± 6
99 ± 5

= [(mean peak area of spiked analyte in human plasma)/(mean peak area of spiked analyte in extracted human plasma)] x
100%; bRecoveryis = [(mean peak area of spiked IS in human plasma)/(mean peak area of spiked IS in extracted human plasma)] x
100%; c IS Normalized Recovery = (RecoveryX/RecoveryIS) x 100%

aRecoveryx

Table 3.3. Matrix factors of O6BG and 8-oxo-O6BG in six individual lots of human plasma (n = 5)
8-oxo-O6BG

O6BG
Plasma
matrix

Lot 1

Lot 2
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Lot 3

Lot 4

Lot 5

Lot 6

[Xn]

(ng/mL)
3.75
25.0
188
3.75
25.0
188
3.75
25.0
188
3.75
25.0
188
3.75
25.0
188
3.75
25.0
188

MFXa ± SD

MFISb ± SD

IS Normalized MFc
± SD

(ng/mL)

0.96 ± 0.01
0.99 ± 0.01
0.99 ± 0.02
1.00 ± 0.03
0.99 ± 0.02
0.98 ± 0.02
0.99 ± 0.03
0.98 ± 0.01
1.02 ± 0.02
1.01 ± 0.02
0.98 ± 0.04
0.98 ± 0.03
0.97 ± 0.02
0.98 ± 0.03
0.99 ± 0.03
1.02 ± 0.01
0.99 ± 0.02
0.96 ± 0.03

0.94 ± 0.02
0.96 ± 0.03
1.00 ± 0.04
1.01 ± 0.02
0.96 ± 0.02
0.99 ± 0.03
1.01 ± 0.01
0.96 ± 0.02
0.96 ± 0.03
0.98 ± 0.04
1.02 ± 0.02
0.99 ± 0.01
0.98 ± 0.02
0.99 ± 0.01
0.94 ± 0.03
0.98 ± 0.03
1.02 ± 0.04
1.01 ± 0.03

1.02 ± 0.03
1.03 ± 0.04
0.99 ± 0.06
0.99 ± 0.05
1.03 ± 0.04
0.99 ± 0.05
0.98 ± 0.04
1.02 ± 0.03
1.06 ± 0.05
1.03 ± 0.06
0.96 ± 0.06
0.99 ± 0.04
0.99 ± 0.04
0.99 ± 0.04
1.05 ± 0.07
1.04 ± 0.04
0.97 ± 0.06
0.95 ± 0.06

15.0
100
750
15.0
100
750
15.0
100
750
15.0
100
750
15.0
100
750
15.0
100
750

[Xn]

MFX ± SD

MFIS ± SD

IS Normalized MF ±
SD

0.94 ± 0.05
0.94 ± 0.04
0.95 ± 0.06
0.95 ± 0.03
0.98 ± 0.01
1.05 ± 0.02
0.93 ± 0.03
0.94 ± 0.04
0.94 ± 0.03
1.04 ± 0.02
0.98 ± 0.04
1.01 ± 0.01
0.94 ± 0.04
0.99 ± 0.02
0.95 ± 0.04
0.94 ± 0.05
0.93 ± 0.05
0.95 ± 0.06

0.94 ± 0.02
0.96 ± 0.03
1.00 ± 0.04
1.01 ± 0.02
0.96 ± 0.02
0.99 ± 0.03
1.01 ± 0.01
0.96 ± 0.02
0.96 ± 0.03
0.98 ± 0.04
1.02 ± 0.02
0.99 ± 0.01
0.98 ± 0.02
0.99 ± 0.01
0.94 ± 0.03
0.98 ± 0.03
1.02 ± 0.04
1.01 ± 0.03

1.00 ± 0.07
0.98 ± 0.07
0.95 ± 0.10
0.94 ± 0.05
1.02 ± 0.03
1.06 ± 0.05
0.92 ± 0.04
0.98 ± 0.06
0.98 ± 0.06
1.06 ± 0.06
0.96 ± 0.06
1.02 ± 0.02
0.96 ± 0.06
1.00 ± 0.03
1.01 ± 0.07
0.96 ± 0.08
0.91 ± 0.08
0.94 ± 0.09

a MFX = (mean peak area of analyte in the extracted plasma)/(mean peak area of analyte in the mobile phase)
b MFIS = (mean peak area of IS in the extracted plasma)/(mean peak area of IS in the mobile phase)
c IS normalized MF = MFX/MFIS

3.3.2.3. Calibration curve

The calibration equations for O6BG and 8-oxo-O6BG derived from three batches

of calibrators in three validation days were y = 0.044 (±0.001)x + 0.069 (±0.003) with a
correlation coefficient of 0.999 for O6BG, and y = 0.186 (±0.005)x + 0.003 (±0.001) with
a correlation coefficient of 0.999 for 8-oxo-O6BG.

The accuracy and precision of

individual calibrators as shown in Table 3.4 were < ±4% and < 3% for O6BG, and < ±6%

and < 3% for 8-oxo-O6BG, respectively.

3.3.2.4. Accuracy, precision and dilution integrity

Accuracy of an analytical method is described as the closeness of the mean
measured obtained by the method to the nominal value (concentration) of an analyte, and
precision of an analytical method is described as the closeness of individual measurement

of an analyte when the method is repeatedly applied to a single sample. Dilution integrity

refers to the ability to dilute a sample with blank matrix prior to the analyses of analytes at

concentrations higher than those of the upper limits of quantitation (ULOQs) into the

calibration ranges of the analytes and obtain an accurate estimate of the concentrations
prior to dilution.
In this work, the accuracy, precision and dilution integrity of the method was

assessed using low, mid, high and dilution QC samples. As shown in Table 3.5, the intra
day accuracy and precision were < |2|% and < 3% for O6BG, and < |5|% and < 3% for 8-

oxo-O6BG; whereas the inter-day accuracy and precision were < |6|% and < 4% for O6BG,
and < |7|% and < 4% for 8-oxo-O6BG, respectively. These results indicated the method

developed was accurate and precise, and the integrity of the plasma sample was not affected
by sample dilution.
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Table 3.4. Accuracy and precision of O6BG and 8-Oxo-O6BG plasma calibrators in five validation batches
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[XN]a (ng/mL)
1.25
2.50
6.25
12.5
25.0
62.5
125
250

O6BG
[X]b± SDc (ng/mL)
1.27 ± 0.03
2.41 ± 0.07
6.25 ± 0.05
12.6± 0.2
25.3 ± 0.5
62 ± 1
124 ± 3
248 ± 7

CVd (%)
2
3
1
2
2
2
2
3

REe (%)
2
-4
0
1
1
0
-1
-1

[Xn] (ng/mL)
5.00
10.0
25.0
50.0
100
250
500
1.00 x 103

8-Oxo-O6BG
[X] ± SD (ng/mL)
5.14± 0.06
9.70 ± 0.04
24.3 ± 0.4
53 ± 1
102± 3
254 ± 5
501 ± 9
(1.02 ± 0.01) x 103
_— _

CV (%) RE (%)
1
3
1
-3
2
-3
2
6
3
2
2
2
2
0
1
2

a[XN] = nominal concentration of analyte in plasma calibrator; b[X] = mean measured concentration of analyte; cSD = standard deviation of
replicate measurements; dCV (%) = (SD/[X]) x 100%; eRE = {([X] - [XN])/ [XN]} x 100%

Table 3.5. Intra- and inter-assay accuracy and precision of O6BG and 8-oxo-O6BG in human pooled plasma (n = 5)

Intra-assaya

[Xn] (ng/mL)
1.25
3.75
25.0
188
2.00 x 103

O6BG
[X] ± SD (ng/mL)
1.24 ± 0.01
3.71 ± 0.01
24.6 ± 0.8
190 ± 2
(2.00 ± 0.02) x 103
_— _

CV (%)
0
0
3
1
1

RE (%)
-1
-1
-2
1
0

8-oxo-O6BG
[Xn] (ng/mL) [X] ± SD (ng/mL)
5.00
5.0 ± 0.3
15.0
14.3 ± 0.5
100
99 ± 1
750
745 ± 8
8.00 x 103
(7.99 ± 0.02) x103
_ _

CV (%)
6
3
1
1
0.3

RE (%)
1
-5
-1
-1
-0.1

8-oxo-O6BG
[X] ± SD (ng/mL)
CV (%)

RE (%)

5.1 ± 0.1
14.0 ± 0.5
96 ± 2
745 ± 10
(7.99 ± 0.02) x 103

3
-7
-4
-1
-0.1
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Inter-assayb

[Xn] (ng/mL)
1.25
3.75
25.0
188
2.00 x 103c

O6BG
[X] ± SD (ng/mL)

CV (%)

RE (%)

[Xn] (ng/mL)

1.23 ± 0.01
3.6 ± 0.1
23 ± 1
185 ± 4
(2.01 ± 0.01) x 103

1
3
4
2
0.5

2
-3
-6
-2
0.5

5.00
15.0
100
750
8.00 x 103c

_ _

_ _

1
4
2
1
0.3

a Measured by five replicate measurements of each QC sample within a validation batch.
b Measured by five parallel measurements of five identical QC samples at each concentration over five validation batches.
c Dilution QC was measured after 10x dilution with pooled blank human plasma.

3.3.2.5. Stability studies

The stability studies for O6BG and 8-oxo-O6BG were conducted, and the results

were summarized in Table 3.6. Our data showed that at room temperature on the benchtop, the stock solutions and plasma QCs were stable for at least 24 h and had the recoveries

of 95-98% and 93-100% for O6BG; and 99-101% and 95-99% for 8-oxo-O6BG. In the
autosampler (post-preparative) at 4°C, the plasma QCs were stable for at least 24 h and had
the recoveries of 92-99% for O6BG, and 92-102% for 8-oxo-O6BG. In the freeze-thawcycle study, the plasma QCs had the recoveries of 96-103% for O6BG, and 96-102% for 8-

oxo-O6BG. Furthermore, in the long-term storage (65 days at -70°C), the plasma QCs had

the recoveries of 95-99% for O6BG, and 95-97% for 8-oxo-O6BG. These data indicated

that O6BG and 8-oxo-O6BG were stable under all test conditions and showed no sign of
sample degradation.
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Table 3.6. Stabilities of O6BG and 8-oxo-O6BG under various test conditions (n = 5)

Recovery ± SD (%)

Condition

Temperature

Bench-top

23°C

Bench-top

23°C

Autosampler

4°C
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3 Freeze-thaw
cycles
Long-term storage
(65 days)

-70°C to 23°C
-80°C

Sample

Stock solutiona
Stock solutionb
Low QCc
High QCc
Low QC
High QC
Low QC
High QC
Low QC
High QC

O6BG

6h
95 ± 2
96 ± 2
100 ± 2
93 ± 1
99 ± 2
96 ± 3

24 h
98 ± 1
95 ± 2
98 ± 4
95 ± 3
92 ± 4
96 ± 2
102 ± 2
103 ± 4
95 ± 5
99 ± 4

8-oxo-O6BG
6h
24 h
101 ± 3
101 ± 2
99 ± 1
100 ± 3
96 ± 1
99 ± 2
95 ± 2
95 ± 2
102 ± 3
93 ± 2
99 ± 2
92 ± 1
96 ± 4
101 ± 3
95 ± 4
97 ± 2

a The concentrations of O6BG and 8-oxo-O6BG stock solutions were measured after serial dilution to prepare a mixed working standard solution at
concentrations of 3.75 ng/mL and 15.0 ng/mL for O6BG and 8-oxo-O6BG, respectively.
b The concentrations of O6BG and 8-oxo-O6BG stock solutions were measured after serial dilution to prepare a mixed working standard solution at
concentrations of 188 ng/mL and 750 ng/mL for O6BG and 8-oxo-O6BG, respectively.
cThe concentrations of low and high plasma QCs of O6BG/8-oxo-O6BG were 3.75/15.0 ng/mL and 188/750 ng/mL, respectively.

3.3.3

Method application

The applicability of method developed was tested by the measurement of O6BG
and 8-oxo-O6BG concentrations in patient plasma samples collected from a previous phase

I clinical trial of O6BG (Stefan et al., 1997). These samples were collected, prepared, and
analyzed as the procedures described in Section 3.2.7.

Fig. 3.4 showed the O6BG and 8-

oxo-O6BG concentration-time profiles in a patient by a 1-h bolus infusion of O6BG at a
dose of 23.5 mg/m2. Compared to the HPLC-DAD method developed in the previous work
(Stefan et al., 1997), the LC-MS/MS method implemented in this work not only could

produce comparable concentration-time profiles for O6BG and 8-oxo-O6BG in the patient,
but also required much less sample and analysis time, and showed no interference from co

eluted compounds in sample matrix. Therefore, the LC-MS/MS method developed is a

better method for the clinical study of O6BG, especially when the patient sample size is
small and analyte concentrations are low.
3.4 .

Conclusion

In this work, an LC-MS/MS method has been developed and validated for the
measurement of O6BG and its metabolite 8-oxo-O6BG in human plasma, which employs

LLE for sample extraction, reverse phase chromatography for analyte separation, and
tandem mass spectrometry for analyte detection and quantitation. This method is rapid,

sensitive and selective. It has linear calibration ranges of 1.25-250 ng/mL and 5.00-1.00 x

103 ng/mL for O6BG and 8-oxo-O6BG, respectively. The method uses only 10.0 |1L of

patient plasma sample per analysis and is well-suited for pediatric studies and clinical trials

where the sample volume is small and analyte concentrations are low. The method
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developed was tested using patient plasma samples from a prior phase I clinical trial and
the results were comparable with those obtained by the LC-DAD method.
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Figure. 3.4. The concentration-time profiles of O6BG and 8-oxo-O6BG in a patient who

received a 1-h bolus IV-infusion of O6BG at a dose of 23.5 mg/m2.
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CHAPTER IV
FUTURE DIRECTIONS

4.1.

In-Quest of biomarkers for Alzheimer’s Disease in Human Plasma using Liquid

Chromatography in tandem with High Resolution Mass Spectrometry (Quadrapole

Time-of-Flight(Q-TOF))

4.1.1

Bioanalytical

The work in this study had detailed the workflow for the untargeted discovery of
the probabilistic biomarkers in Alzheimer’s disease (AD) using the lipidomics approach

and bioinformatics tools [1,2]. This study was a pilot study to establish the probabilistic
biomarkers in AD that are Up- and Down-regulated. We found a total of 28 statistically

significant identified lipids, including LPC, PC, SM, and TG, and a total of 31 unidentified

features that were Up- and Down-regulated. Thought the study is warranted on the number
of study subjects in each condition (AD = 4 and NCC =3), a similar approach can be
employed to study in the larger cohort for the confirmation of these probabilistic
biomarkers of the AD disease. As well, this work can be extended by evaluating the
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usefulness of the reported potential biomarkers in predicting the early onset of AD. It can

be performed by the identification, quantitation, and validation of these plasma lipid
biomarkers in AD-P and MCI-AD stages using the methodology described in this work.
Longitudinal studies are to be performed to study the transitions and phenoconversion of these
biomarkers in the progression of the disease. Further, using the same sample sets, targeted

discovery experiments can be performed, and then targeted validation is to be performed on the

panel of probabilistic biomarkers [15]. Thus, the validated biomarkers can be used as a panel for

predicting the preclinical stage of the AD for the early intervention treatment. For further deeper
understanding at the pathway level, pathway analysis, and correlation of the enzymes responsible

for these aberrations at lipid levels are to be investigated in the AD disease models by performing
biological experiments.
In this study, we were able to identify, 148 and 108 lipid species in phospholipid fraction
(PL) and neutral lipid fraction (NL). Since lipids are complex molecules with fatty acids as side
chains, reverse phase chromatography employed in this study suffers from not able to separate the

isobaric peaks as it co-elutes the lipids of similar polarity. This issue can be addressed either by
employing the ion mobility as a front end to MS detection [3-5] or by using the normal phase
chromatography, HILIC chromatography [6-8], to fractionate each subclass of lipids then analyze

them using reverse phase chromatography. Co-elution of the isobaric peaks challenges the MS
detector to detect the low abundant oxidized species.
It is evident and established in the AD disease that neuroinflammation is the process that

begins earlier the disease diagnosis [9]. During the inflammatory process, lipids undergo oxidation
and form the oxidized lipids, which are indicators of the biological stress and serves as a biomarker
in many acute and chronic inflammation conditions [10]. Hence there is a vast scope for the

quantitation of these lipids and to compare the lipid profiles of oxidized products vs. their

precursors. The availability of the isotopes labeled lipid standards, and cost serves the major
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limitation for these types of studies. The current methodology fails to determine the location of the

double bonds in the fatty acyl chain and the position of the fatty acids attached to the glycerol

backbone in the complex lipid. Techniques like ozone induced dissociation of the double bonds

[11], Silver ion chromatography [12,13], and selective deuteration [14] that assist in the location of
the double bonds can be employed to address the unsaturation location in the lipids.

4.1.2

Molecular biology

By the action of the phospholipases enzymes as shown in Fig 4.1, phospholipids are
constantly being remodeled in terms of fatty acyl side chains, polar head groups and

generation of secondary messengers.

Phospholipase B (lysophospholipase) has
both PLA1 and PLA2 activity

Fig. 4.1. Phospholipase enzymes and site of action.
PLA1: Phospholipase A1, PLA2: Phospholipase A2, PLC: Phospholipase C, PLD:
Phospholipase D, R1 and R2: fatty acyl side chains, R3: phospholipid head group
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As shown in the Fig 2.5 and 2.6 , PLD, PLA and PLC genes/ enzymes play crucial role in

the AD.

Variants of PLD has been involved with APP and presenilin intracellular

trafficking (PLD1) and PLD2 has been involved with amyloid beta signaling. PLD

hydrolyses PC to produce choline and phosphatidic acid (PA) which acts as an effector for
clathrin mediated endocytosis [19] and have been implicated in AD pathogenesis. With

animal models to study PLD, the enzyme is emerging as a key player in regulating
phospholipids metabolism and is now a therapeutic target for several brain disorders,

including AD, due to its multiple role in signal transduction pathways [20, 21]. Recently
GWAS had reported the involvement of PLD3 in AD. Phospholipase C (PLC) cleaves
phospholipids before the phosphate group as shown in Fig 4.1 which generates

intermediate signaling molecules [22, 23]. As described in section 2.4.2.1, the role of
phospholipase A (PLA) variants in altering the composition of the phospholipids thus,

leading to increased concentration of certain lipid sub-classes and decreased concentration

of the other lipid sub-classes must be investigated by closely studying the ratio and
composition of the lipids changing in AD.

The results presented in chapter 2, in this thesis have also opened the area fir future
investigation which may contribute to the identification of a sensitive and specific plasma

lipid AD biomarker panel.

Such lipidomics studies will likely lead to a greater

understanding of the pathological processes involved in AD and may identify novel targets

for which therapeutic interventions are directed. The following summarizes suggested

areas for further investigation:
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1. Determination of PLC, PLD and PLA variants activity levels within the baseline cohort

is recommended. The levels of these enzymes are to be assessed longitudinally along with

the potential hall mark biomarkers of AD.
2. Assessing the levels of SMase in baseline cohort and in longitudinal studies to correlate

the sphingolipids and ceramides concentrations To improve the diagnostic sensitivity and

specificity of the existing lipid profiles, assessing ratios of lipid species may provide
additional information..

4.2.

Absolute Quantitation of O6-Benzyl Guanine and 8-oxo-O6-Benzyl guanine in
Human Plasma using Reverse Phase Liquid Chromatography-Triple Quadrapole
Mass Spectrometry (LC-MS/MS)

This work detailed the absolute quantitation of O6-Benzyl Guanine (O6BG) and 8oxo-O6-Benzyl guanine (8-oxo-O6BG) in the human plasma and its application to the
clinical study samples with 10.0 pL of patient sample volume diluted to 100 pL with pooled
human plasma blank matrix. Since the clinical dosing range of these analytes are high, and
the LC-MS/MS method is sensitive enough to go low, small sample volumes are required

for the bioanalysis of these analytes in the matrices. Therefore in the future, the method

could be validated using the Mitra® microsampling device (Neoteryx, LLC, CA), driven
by volumetric absorptive microsampling (VAMS®) technology [16,17]. Where patients

enrolled in clinical trial collects the small sample volumes in microliters (pL) from their
home and shipped to the analysis site as per directed procedure, making the clinical trial
process feasible and cheaper. Further, the method could be compared to using dried blood
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spot samples [18]. Validating the method with these sample collection techniques enables

accessible micro-sample collection for pediatric clinical studies of these analytes in the
future.
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